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ABSTRACT 
Kyle C. Arend: Regulation of Human Cytomegalovirus Major Immediate Early                      
Gene Expression During Lytic Replication  
(Under the direction of Nathaniel J. Moorman) 
 
Human cytomegalovirus (HCMV) is a significant cause of disease in immune-
compromised adults and immune naïve newborns. No vaccine exists to prevent HCMV 
infection, and current antiviral therapies have toxic side effects that limit the duration and 
intensity of their use.  Expression of the HCMV major immediate early (MIE) proteins, IE1 and 
IE2, is critical for the establishment of lytic infection and reactivation from viral latency. Defining 
the mechanisms controlling IE1 and IE2 expression is therefore important for understanding 
how HCMV regulates its replicative cycle. In Chapter 2 we identified several novel transcripts 
encoding full-length IE1 and IE2 proteins during HCMV lytic replication. While the canonical MIE 
mRNA was the most abundant transcript at immediate early times, the novel MIE transcripts 
accumulated to equivalent levels as the known MIE transcript later in infection and were found 
associated with polyribosomes. These results expand our understanding of the sequences 
controlling IE1 and IE2 expression by defining novel transcriptional units controlling the 
expression of full-length IE1 and IE2 proteins. Beyond transcriptional regulation, relatively little 
is known about the post-transcriptional mechanisms that control IE1 and IE2 protein synthesis. 
In Chapter 3 we found that the canonical MIE 5’ untranslated region (5’ UTR) has a positive role 
in translation control of reporter genes during transfection. We also found that the MIE 5’UTR 
was necessary for efficient IE1 and IE2 mRNA translation as well as viral replication during 
infection. These results demonstrate that the shared 5’ UTR of the IE1 and IE2 mRNA is a 
critical determinant of efficient HCMV replication.  Virus-induced changes in infected cells are 
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often driven by changes in cellular kinase activity. In Chapter 4 we applied a kinase capture 
technique, MIB-MS kinome profiling, to quantitatively measure perturbations in >240 cellular 
kinases simultaneously in cells infected with HCMV.  Based on the kinome data, we identified 
three compounds currently being studied in clinical trials that inhibited HCMV replication. These 
results show the utility of MIB-MS kinome profiling for identifying existing kinase inhibitors that 
can potentially be repurposed as novel antiviral drugs to limit the time and cost of new antiviral 
drug development. 
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Chapter 1: Introduction 
 
Herpesviridae Family 
The Herpesviridae family was originally classified based on their distinct viral particle 
morphology but in recent years have also been classified by specific genetic signatures. The 
original classification recognized four main components of herpesvirus virions including the 
core, capsid, tegument, and envelope. The envelope of the virion is comprised of a lipid bilayer 
of cellular membranes acquired by the virus as it transits from the nucleus to the cell surface. 
Viral glycoproteins protrude from the envelope and act as adaptors for virus binding to cellular 
receptors. A largely unstructured and asymmetric proteinaceous layer, called the tegument, lies 
between the envelope and the capsid. After virion endocytosis and dissolution of the virus 
envelope, tegument proteins are released into the cytoplasm where they assist in evading the 
host immune system, transporting the viral capsid to the nucleus, unpackaging the genome from 
the capsid at the nuclear membrane, and transactivating viral gene expression to initiate the 
lytic viral replication cycle. The capsid is an icosadeltahedral structure made of capsomere 
subunits that self-assemble and encase the DNA inside the core. The innermost layer of the 
virion, the virion core, consists of a single linear double-stranded DNA genome that varies in 
size based on the subclass of herpesvirus. Following capsid migration to the nuclear 
membrane, the viral genome enters the nucleus through nuclear pore complexes. Once inside 
the nucleus, viral genomes can either initiate a productive lytic replication cycle or establish a 
quiescent, latent state. During lytic replication, the majority of viral genes are expressed, driving 
the production of infectious progeny virus. Alternatively latent herpesvirus genomes express 
only a small subset of viral genes, called latency-associated transcripts, and do not produce 
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infectious virions. Latent genomes are maintained in reservoir cell populations throughout the 
host lifetime. Importantly, latent genomes can be reactivated by cellular or environmental stimuli 
to reinitiate the lytic replication cycle resulting in recurrent or potentially persistent cycles of 
herpesvirus infection.(1) 
Human Herpesviruses 
Herpesviruses are further distinguished into the three subclasses, alpha-herpesvirinae, 
beta-herpesvirinae, or gamma-herpesvirinae, according to genetic and biological parameters. 
To date, nine herpesviruses, spread amongst all three subclasses, have been identified that 
infect humans. Human alpha-herpesvirinae members (herpes-simplex virus 1 and 2[HSV-1/2] 
and varicella-zoster virus [VZV]) have a relatively rapid lytic replication cycle in host epithelial 
cells upon primary infection. Following primary infection, virions infect nearby sensory ganglia 
and are shuttled up the nerve axon by retrograde transport to the nucleus where they persist as 
a latent reservoir. In contrast, human gamma-herpesvirinae members (Epstein-Bar virus [EBV] 
and Kaposi’s sarcoma-associated virus [KSHV]) establish latent reservoirs in lymphoid tissues 
after primary lytic infection of epithelial cells or B cells and endothelial cells, epithelial cells, 
monocytes, or keratinocytes, respectively. Lastly, human beta-herpesvirinae members have a 
longer lytic replication cycle compared to other human herpesviruses.(1) In addition, human 
betaherpesviruses also have a broader range of cell-tropism for both initiating primary infections 
and establishing latent viral reservoirs. Human fibroblasts, epithelial cells, endothelial cells, 
dendritic cells, and smooth muscle cells can all be infected by betaherpesviruses, whereas 
latent virus has been found in monocytes and lymphocytes.(2-5) Human cytomegalovirus, 
formally classified as human herpesvirus 5 (HHV-5), as well as HHV-6a, HHV-6b and HHV-7 
are all members of the beta-herpesviridae subclass. Human cytomegalovirus (HCMV), the focus 
of this dissertation, is the prototypical betaherpesvirus and was the first and only member of this 
subclass for nearly three decades after its initial characterization in 1957. HCMV derives its 
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name “cytomegaly” meaning “abnormal enlargement of a cell” from the significant increase in 
cell size observed by microscopy during lytic replication in cell culture, which results from viral 
disruption of cytoskeletal structures.(6) 
HCMV Disease and Impact and on Human Health 
HCMV is serious health concern that draws relatively little public attention, though 
current estimates suggest nearly 70-100% of the world population is seropositive for HCMV.(7, 8) 
A potential reason for this lapse in public concern is that HCMV infections are usually 
asymptomatic or cause mild flu-like disease symptoms that resolve without treatment, in 
individuals with properly functioning immune systems.(9, 10) Yet, regardless of the appearance of 
clinical symptoms, HCMV-infected individuals produce high titers of virus that are shed through 
bodily fluids for days to weeks after the initial infection.(11, 12) The lack of clinical symptoms in 
HCMV-infected individuals combined with persistent virus shedding enables HCMV to transmit 
itself throughout the population in a seemingly “silent” manner.(13) While a competent immune 
system can limit active viral replication and mitigate disease symptoms, it cannot eradicate 
HCMV from the host. Instead, after primary infection, HCMV establishes a lifelong latent 
infection in CD14+ peripheral blood monocytes, CD34+ bone-marrow derived monocytes, and 
dendritic cells.(14-17) Latent infection of monocytes allows the virus to evade detection by the host 
immune system while also disseminating throughout the body as monocytes shuttle to different 
sites in response to immune stimuli. Although the exact mechanism of viral reactivation is 
unknown, it is clear that the transition of HCMV genomes from a latent to lytic viral replication 
cycle is closely correlated with monocyte differentiation.(17-23) The latent viral state and 
coordinated reactivation mechanism ensures the virus can stay hidden within the monocyte and 
yet arrive at target sites prepared to initiate new waves of lytic replication. Together the silent 
transmission mode and lifelong viral persistence/reactivation of HCMV within its host both 
contribute to the high prevalence of seropositivity in the human population.  
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Although HCMV infections are not of grave concern for healthy individuals, 
immunocompromised individuals experience significant rates of morbidity and mortality following 
HCMV primary infection or reactivation of latent infections.(16, 24) In particular, individuals who 
have received solid organ transplants, chemotherapy, or developed AIDS from a prior HIV 
infection are most severely at risk for life-threatening complications associated with HCMV 
disease.(10, 11, 25-29) HCMV not only presents a serious health risk for immunocompromised 
individuals but it is also a significant health concern for neonates, whom prior to birth, have not 
yet developed competent immune systems. Both primary HCMV infection of an HCMV-naïve 
mother and reactivation of latent HCMV during pregnancy can result in congenital infection of 
neonates. Statistically speaking, HCMV continues to be the leading cause of infectious 
congenital birth defects worldwide despite the fact that most congenital HCMV infections 
present as asymptomatic. Developmental disabilities such as blindness, deafness, and mental 
disability are most common among symptomatic HCMV-infected neonates, however death can 
also occur in severe cases.(12, 24, 30-34)  
To combat the disease burden of HCMV infection in immunocompromised patients, 
numerous drugs that inhibit HCMV lytic replication have been approved by the FDA, including 
gancyclovir, valganciclovir, acyclovir, foscarnet, and cidofovir.(11) Most of these compounds 
specifically target the viral DNA polymerase and limit viral DNA replication by either directly 
competing with deoxyguanosine triphosphate as a substrate for the viral DNA polymerase, or 
blocking cleavage steps required for DNA chain elongation.(35-37) Regardless of the specific 
mechanism of action, available drugs have significant issues that limit their use, such as limited 
bioavailability, low selective uptake by virally infected cells, and/or high levels of cellular toxicity 
that can further compromise the health of patients struggling with HCMV disease.(10, 11, 38) In 
addition, none of the current antiviral compounds are approved for use in either pregnant 
women to prevent congenital infections, or infants to treat congenital cases of HCMV infection 
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due to their toxicity issues. Lastly, nearly all approved HCMV antivirals target the viral DNA 
polymerase resulting in the emergence of HCMV strains with mutations in the viral DNA 
polymerase that confer resistance to the entire array of approved HCMV antivirals.(39) These 
issues associated with currently available HCMV antiviral drugs highlight the need for continued 
development of safer and more effective therapeutics. Furthermore, the development of 
antivirals that inhibit HCMV replication through novel mechanisms and/or targets is becoming 
increasingly important in order to counter the emergence of HCMV strains resistant to current 
antiviral drugs. 
Beyond antiviral compounds, the development of a prophylactic HCMV vaccine has 
great potential to address concerns associated with HCMV disease before they arise in 
susceptible populations. Results to date though have not been promising, as numerous 
candidate vaccines have proven non-efficacious in clinical trials. Nevertheless, several 
additional vaccine candidates are currently in various phases of clinical trials and may help to 
limit the incidence of HCMV disease in the near future.(40-44) Alternatively, researchers have 
found some therapeutic benefit with the administration of purified immunoglobulins directed 
against HCMV. Clinical evidence indicates that CMV-specific immunoglobulin treatment has 
fewer associated side effects than current antiviral drugs, particularly in regards to cellular 
toxicity, and therefore can safely be administered to both immunocompromised patients and 
pregnant women.(11, 45-47) At least one immunoglobulin treatment (Cytogam) has been approved 
by the FDA for treating HCMV disease.(48, 49) However, adoption of Cytogam as a first-line 
treatment has been limited, as Cytogam alone has limited efficacy. Instead Cytogam is most 
effective for treating HCMV disease when used in combination with ganciclovir.(50-52) The 
examples above highlight that alternative therapeutic approaches have thus far proven 
insufficient in alleviating HCMV disease, especially in cases of congenital infection. 
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HCMV Genetic Structure and Expression 
HCMV has the largest genome of any known human virus. The HCMV genome is a 
linear double-stranded DNA genome that ranges between 230-240 kilobase pairs (kbp) in size, 
depending on the specific virus strain. The genome consists of a long and short unique 
sequence each flanked by a set of inverted repeat sequences. The long and short unique 
regions encode the vast majority of proteins synthesized during infection and are fairly 
conserved between different virus strains. In contrast, the inverted tandem repeats are markedly 
different between patient isolates and tissue-culture adapted strains of HCMV. Furthermore the 
inverted repeat regions show very little protein coding capacity suggesting that their importance 
for viral replication in vivo is not reliant on the production of viral protein products. Their 
importance for HCMV replication remains poorly understood at this time.(1, 53)   
The HCMV genome was initially thought to encode about ~200 open reading frames 
(ORFs).(54) However recent technological advances have revealed that the protein coding 
capacity of the HCMV genome is much more extensive than previously appreciated. Most 
recently the use of ribosome profiling has shown that the HCMV genome encodes over 750 
peptide-coding regions during lytic viral replication.(55) While the function of the majority of the 
HCMV ORFs is unknown, the prevailing hypothesis is that the extensive viral protein repertoire 
facilitates HCMV replication in a wide range of cellular environments. HCMV infects fibroblasts, 
macrophages, as well as epithelial, endothelial, smooth muscle, neuronal, and glial cells that 
each have different gene expression profiles and pose unique challenges that HCMV must 
overcome to successfully replicate.(2-5, 56-59)  
Cascade of Viral Gene Expression during Lytic Replication 
During lytic replication, HCMV genes are expressed in a three-phase temporal cascade 
that is tightly regulated by a combination of host and viral factors. The three classes of viral 
genes are the immediately early (IE), early (E) and late (L) genes.(60) It is important to note 
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classification of genes into the IE, E, and L phases is not meant to indicate that their expression 
is limited only to that phase. Instead, IE genes continue to be expressed at E and L phases, and 
similarly that E genes continue to be expressed throughout the L phase of viral gene 
expression.(1, 61-63) 
The IE genes are expressed first, and are defined by their transcription in the absence of 
de novo protein synthesis.(64-67) Thus, IE genes do not require newly expressed viral proteins for 
their transcription. However, viral proteins in the tegument of incoming virions greatly facilitate 
IE transcription, particularly pp71.(68-70) HCMV IE genes are transcribed from only four regions of 
the genome that map to the UL122-123, UL36-37, IRS1/TRS1, and US3 regions of the HCMV 
genome. Collectively the IE proteins allow HCMV to evade detection by the host immune 
system, dysregulate the cell cycle, modulate cell metabolism, inhibit apoptosis, and trans-
activate transcription from a wide range of host and viral early promoters.(71) The most highly 
expressed IE proteins are encoded by the UL122-123 genomic region, otherwise referred to as 
the major immediate early (MIE) gene region. 
The promoters of viral E genes are trans-activated by viral IE proteins, and thus require 
prior IE gene expression.(64) E gene expression is much more widespread than IE genes, and E 
genes are dispersed across nearly the entire HCMV genome.(63) In general, viral E genes 
encode proteins that help produce a cellular environment conducive for viral DNA replication.(72) 
Furthermore, the machinery necessary for replicating the viral genome (e.g. the viral DNA 
polymerase encoded by UL54 and the polymerase processivity factors encoded by UL44) are 
expressed as E genes.(73-75) 
Viral L genes are transcribed after viral DNA replication. Therefore, prior expression of 
viral IE and E genes is required for late genes to be transcribed. Similar to E genes, L genes are 
dispersed throughout the viral genome. Late transcripts rapidly accumulate following DNA 
replication and continue to accumulate throughout the remainder of the HCMV replication 
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cycle.(63) Late genes typically encode proteins that are structural constituents of the virion and/or 
are responsible for orchestrating virion packaging and egress from the cell.(76) 
Major Immediate Early Protein Functions 
Robust MIE gene expression is required for expression of E viral genes suggesting that 
the MIE protein products play an important role in activating E promoters. The MIE gene 
contains a complex promoter-regulatory region, the major immediate early promoter (MIEP), five 
exons, and four introns.(77, 78) Transcription from the MIEP produces a 5.1kb MIE primary 
transcript that is alternatively spliced into at least four different mRNAs. The two predominant 
mRNAs are a 1.95kb IE1 mRNA (exon 1-2-3-4) and a 2.2kb IE2 mRNA (exons 1-2-3-5) that are 
translated into the IE1-72kDa and IE2-86kDa proteins, respectively.(78-83) Two additional low 
abundance mRNAs, a 0.65kb IE1 mRNA and a 1.7kb IE2 mRNA, arise from additional splicing 
events in either exon 4 or exon 5, respectively. These minor MIE mRNAs are translated into the 
IE1-38kDa and IE2-55kDa protein, but little is known about their role in HCMV replication.(81, 84)  
Due to their role in the establishment of lytic infection, the function(s) of the IE1-72kDa 
and IE2-86kDa proteins has garnered considerable interest over the years. While each protein 
plays an important role in HCMV lytic replication, only the IE2-86kDa protein is essential for 
virus replication.(85, 86) pIE1-72kDa is required for viral replication after infection at a low (<1) 
multiplicity of infection (MOI).(87) The MOI-dependent defect in the replication of recombinant 
viruses lacking IE1-72kDa expression suggests that viral tegument proteins, which are present 
at much higher amounts during high MOI infections, can compensate for the loss of the IE1-
72kDa protein.(88) The IE1-72kDa and IE2-86kDa proteins both localize to the nucleus(89), where 
they promote cell cycle progression to G1/S phase(90-92), inhibit cellular DNA synthesis(93), 
prevent apoptosis(92, 94), and autoregulate MIEP activity.(80, 82, 95, 96) In addition, the IE1-72kDa 
and IE2-86kDa proteins can independently transactivate a wide variety of cellular and viral 
promoters. While IE2-86kDa is a stronger transcriptional activator, IE1-72kDa and IE2-86kDa 
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typically activate promoters synergistically.(95, 97-101) IE1-72kDa mainly promotes transcription by 
antagonizing histone deacetylation that would otherwise silence viral gene expression.(102) IE1-
72kDa interacts with histone deacetylase 3 (HDAC3) and prevents HDAC3 from removing 
histone acetylation marks around target promoters. IE1-72kDa also disrupts nuclear domain 10 
(ND10) bodies during IE times of infection that would normally recruit HDACs and other 
chromatin remodeling enzymes to the viral genome, leading to suppressive nucleosome 
formation.(103-108) The ability of IE2-86kDa to transactivate promoters derives primarily from its 
interactions with components of the basal transcription machinery. IE2-86kDa binds to TATA 
binding protein (TBP) and transcription factor IIB (TFIIB), as well as numerous transcription 
factors including SP1, Tef-1, c-Jun, JunB, ATF-2, Egr-1, NF-kB, CBP, CHD-1, p300, and 
phosphorylated CREB.(98, 99, 109-118) 
Major Immediate Early Promoter-Regulatory Region 
The MIE genomic region is highly transcribed immediately after HCMV infection of 
permissive cells. As noted above, multiple alternatively spliced MIE mRNAs originate from a 
strong, constitutively active MIEP. The MIEP is regulated in part by a complex promoter-
regulatory region that contains multiple binding sites for cis-regulatory elements that recruit 
components of the transcription initiation complex (i.e. transcription factors) or stabilize complex 
formation to enhance transcription from the MIEP. Three regions of the MIEP were found to play 
important roles during lytic replication: the core promoter, the proximal enhancer and the distal 
enhancer.(119-121) The core promoter and proximal enhancer are essential for HCMV replication. 
The core promoter contains a prototypical TATA box that binds TBP and recruits the RNA 
polymerase II transcription initiation complex. The core promoter also contains a cis-repression 
sequence (crs) that overlaps the MIEP transcription start site.(122-125) The crs provides a 
mechanism for limiting MIEP transcription after the IE phase of lytic replication (discussed 
below). The proximal enhancer is also essential for HCMV replication. The proximal enhancer 
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contains several copies of repeat sequences with binding sites for several transcription factors 
including: NF-kB, CREB/ATF, AP-1, SP1, retinoic acid receptor, and NF-1.(126) Despite the 
requirement for the proximal enhancer for HCMV replication, the roles of the individual binding 
site(s) and cis-acting regulatory factor(s) are unknown. In contrast to the other two regions, the 
distal enhancer is only necessary for HCMV replication after low MOI infections. The distal 
enhancer includes binding sites for serum response factor, NF-kB, CREB/ATF, YY-1, and 
SP1.(127, 128) Removal of the distal enhancer delays viral replication due to decreased MIE gene 
expression and results in an aberrant small-plaque phenotype, even after high MOI infection. 
This suggests the redundancy of binding sites in the proximal and distal enhancers is required 
to promote robust MIE transcription and efficient HCMV replication.(129) Together, transcription 
factor binding sites in the core promoter, and proximal and distal enhancers endow the HCMV 
MIEP with the strongest known mammalian promoter activity. In addition, complex interplay 
between the cis-regulatory elements likely allows complex and dynamic regulation of MIE gene 
expression in specific settings.(130, 131) 
In addition to host transcription factors, HCMV proteins also regulate transcription from 
the MIEP. In particular, the viral tegument proteins pp71, pTRS1, and pUL69 enhance MIEP 
activity, and stimulate the initial burst of MIE gene expression.(69, 88, 132-134) The IE1-72kDa and 
IE2-86kDa proteins also autoregulate the MIEP.(71, 80, 82, 119) In contrast to their abilities to 
synergistically activate cellular and viral early promoters, the IE1-72kDa and IE2-86kDa proteins 
have opposing functions in MIEP regulation. The IE1-72kDa protein activates the MIEP similar 
to other viral promoters by antagonizing histone deacetylation, but can also directly bind the 
MIEP at NF-kB consensus binding sites to enhance transcription.(135) Conversely, the IE2-86kDa 
protein negatively regulates transcription from the MIEP by directly binding a 14bp cis-
repression sequence (crs) overlapping the MIEP transcription start site.(122, 124, 136, 137) Binding of 
IE2-86kDa protein to the crs inhibits assembly of the pre-initiation complex required for RNA 
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polymerase II recruitment and thus blocks transcription initiation from the MIEP.(138, 139) In 
summary, transcription from the MIEP is regulated at multiple levels including chromatin 
remodeling, recognition of cis-regulatory elements by cellular and viral factors, and 
autoregulation by IE1-72kDa and IE2-86kDa proteins.  
In Chapter 2, I describe the discovery of multiple novel MIE mRNAs that initiate 
transcription from regions of the MIE gene both 5’ and 3’ of the MIEP. In addition, I detail the 
role of two of the novel MIE promoters in HCMV lytic replication. Collectively, these experiments 
identify alternative promoter usage as an additional layer of transcriptional regulation for the MIE 
genomic region during HCMV lytic replication.  
Post-transcriptional Regulation of Major Immediate Early mRNAs 
While promoters regulate the transcription of an mRNA, 5’ and 3’ untranslated regions 
(5’UTRs and 3’UTRs, respectively) flanking the coding determinant sequence also influence 
protein levels by regulating mRNA translation.(140) The 5’ UTR is defined as the sequence that 
extends from the transcription start site to just before the translation initiation codon of a protein 
coding region. 5’UTRs play an especially important regulatory role, as they directly impact 
translation initiation, the rate limiting step in protein synthesis.(141) 5’UTRs can either enhance or 
repress translation of downstream coding regions. One general example of 5’ UTR positive 
regulation is the recruitment of eukaryotic translation initiation factors (eIF4E, eIF4G, and eIF4A) 
to the 5’-terminal 7-methylguanosine (m7G) mRNA cap. Together these initiation factors 
assemble into the eIF4F complex and enhance the efficiency of mRNA translation by facilitating 
ribosome recruitment to mRNAs containing pyrimidine-rich sequences proximal to the mRNA 
cap.(142) However 5’ UTRs can also inhibit mRNA translation efficiency as illustrated by the 
effect of short upstream open reading frames (uORFs) in 5’UTRs, which prevent ribosome 
scanning to the proper start codon of a downstream protein coding sequence.(143, 144) 
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Despite well-established roles for 5’ UTRs in regulating eukaryotic mRNA translation, 
relatively little is known about the importance of 5’ UTRs for the translation efficiency of HCMV 
mRNAs during lytic replication. HCMV mRNAs are entirely reliant on cellular ribosomes for the 
synthesis of viral polypeptides. However, HCMV-infected cells do not shut off cellular protein 
synthesis but instead globally upregulate the synthesis of translation initiation factors, the 
formation of polyribosomes, and the rate of protein synthesis compared to uninfected cells.(145-
147) The global increase in protein synthesis of HCMV-infected cells is facilitated by a wide-range 
of virus-induced cellular changes including increased ribosome biogenesis(148), accumulation of 
PABP and eIF4F complex subunits(147, 149, 150), and activation of cellular pathways that increase 
energy production and biosynthetic metabolites.(151-157) Nevertheless, by not antagonizing host 
protein synthesis viral mRNAs must compete with host mRNAs for access to ribosomes. The 
mechanisms that HCMV utilizes to ensure efficient translation of viral mRNAs at IE, E, and L 
stages of infection are still unknown. 
Although less-studied, post-transcriptional events are also thought to regulate the 
expression of MIE proteins. In particular, the rate of MIE protein synthesis and the association of 
MIE mRNAs with polyribosomes changes throughout infection despite fairly persistent 
transcription of the MIE gene after IE times of infection.(80, 158, 159) Furthermore, the IE1 mRNA 
was found to be post-transcriptional modified such that the 3’ UTR poly-A tail is shortened from 
its usual 200-250bp length down to 30bp at ~6.h.p.i.(158) The shortened poly-A tail was proposed 
to decrease the translation efficiency of IE1 mRNAs and account for the relative steady-state 
level of protein observed at E and L times of infection.(160-162) Viral proteins have been suggested 
to play a role in this process, as modification of IE1 poly(A) tail length requires the de novo 
expression of HCMV proteins. Besides these observations the factors and specific mechanisms 
that regulate IE1 and IE2 mRNA translation remain unknown  
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In Chapter 3, I show that the MIE 5’ UTR increases reporter gene expression in 
transfection assays, but not in a cell-free system. I also demonstrate that the MIE 5’ UTR 
increases reporter mRNA association with polyribosomes and enhances the translation 
efficiency of the mRNA compared to synthetic 5’ UTR sequences. In addition, I show that 
mutation of the canonical MIE 5’ UTR in recombinant viruses causes decreased viral infectivity, 
virion production, and expression of viral proteins compared to the wild-type virus. Furthermore, 
I demonstrate that the defects in recombinant viruses are caused by decreased translation 
efficiency of IE1 and IE2 mRNAs. These experiments identify the canonical MIE 5’ UTR 
sequence as a crucial component of the MIE mRNAs that post-transcriptionally regulates MIE 
protein expression. 
Virus-Induced Changes in Kinase Activity and Cell Signaling Pathways 
Kinases are cellular enzymes that phosphorylate targets to modulate their activity, 
localization, stability, and interaction with other cellular components. Kinase networks evolved to 
coordinate cellular processes and maintain homeostasis. Furthermore the arrangement of 
kinases in signaling cascades allows for rapid, exponential activation of cellular pathways in 
response to intracellular and extracellular signaling molecules.(163, 164)  
HCMV dysregulates cell signaling pathways involved in metabolism, protein synthesis, 
innate cellular defenses and cell cycle progression to facilitate viral replication.(148, 152, 165-169) 
Virus-host interactions modulate the activity of several host kinases that are essential for viral 
replication.(165, 166, 170-178) However the effect of HCMV infection on the activity of most kinases is 
unknown. This gap in our knowledge in part arises from the time and labor intensive process of 
studying individual kinases on a case by case basis. A more comprehensive understanding of 
the effect of infection on kinase activity is thus important to identify novel cellular signaling 
events that could potentially be targeted to limit virus replication.  
14 
 
In Chapter 4 we used kinome profiling, a mass spectrometry based technique that 
measures changes in the activity and/or abundance of hundreds of kinases simultaneously, to 
globally assess changes in kinase activity caused by HCMV infection.(179, 180) We used this 
information to identify novel cellular pathways altered by infection, thus providing the rationale 
for future studies to identify specific host-viral interactions that facilitate HCMV replication. We 
also developed a novel screening protocol to test compounds for antiviral activity, and identified 
several kinase inhibitors in clinical development that could potentially be repurposed as HCMV 
antivirals.  
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Chapter 2: Multiple Transcripts Encode Full-length Human Cytomegalovirus IE1 
and IE2 Proteins During Lytic Infection1 
 
Introduction 
The human cytomegalovirus (HCMV) IE1 and IE2 proteins are critical regulators of the 
viral replicative cycle. Both proteins are immediately expressed upon infection and together 
stimulate the expression of host and viral genes necessary for virus replication.(1) IE2 acts as a 
general transcription factor that broadly transactivates host genes and viral early and late genes 
to facilitate virus replication.(2-12) IE1 promotes transcription from the HCMV genome by 
inhibiting histone deactylases (HDACs), which otherwise limit virus transcription by forming 
inhibitory chromatin structures on the viral genome.(13-15) Re-expression of IE1 and IE2 is also 
thought to be critical for the reactivation of quiescent HCMV genomes from latent infection. 
Thus, understanding the regulatory mechanisms controlling IE1 and IE2 expression is important 
to understand how HCMV regulates its replicative cycle. 
The mRNAs encoding the 72kDa IE1 and 86kDa IE2 proteins are derived from a shared 
precursor RNA through alternative splicing.(16) The mature IE1 and IE2 transcripts share the 
same first three exons (exons 1 through 3), but differ in their final exon. Transcripts that include 
exon 4 encode the 72kDa IE1 protein, while transcripts that skip exon 4 and retain exon 5 
encode the 86kDa IE2 protein.(17) Several IE1 and IE2 splice variants have been identified. For 
example IE1 transcript variants arise from alternative splice donor and acceptor usage in exons 
1 This chapter appeared previously as an article in the Journal of Virology. The original citation is as 
follows:  Arend, K.C., Ziehr, B., Vincent, H.A., and Moorman, N.J. (2016) Multiple transcripts encode 
full-length human cytomegalovirus IE1 and IE2 proteins during lytic infection. J Virol 90, 8855-65. 
doi:10.1128/JVI.00741-16 
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3 and 4 respectively.(16-19) Similarly, IE2 transcript variants arise from alternative splicing within 
exon 5.(17) The proteins encoded by these alternatively spliced transcripts differ in function from 
full-length IE1 and IE2, highlighting the role of alternative splicing in expanding the functions of 
proteins encoded by the major immediate early (MIE) locus. 
In addition to alternative splicing, multiple promoters direct the transcription of several 
distinct RNAs from the MIE locus. The most studied promoter in this region is the major 
immediate early promoter (MIEP), whose activity is regulated by multiple cellular and viral 
factors such as CREB/ATF, NFB, SP1, pp71, pp65 and pTRS1.(20-32) In addition, the IE1 and 
IE2 proteins themselves regulate MIEP activity. While IE1 stimulates MIEP activity, IE2 binds a 
cis-repression sequence (crs) located adjacent to the MIEP transcription start site, inhibiting 
transcription initiation.(33-37) Alternative promoters in the MIE locus also control expression of IE1 
and IE2 transcript variants in specific contexts. A promoter proximal to the IE2-specific exon 5 
drives the expression of several truncated IE2 isoforms during the late stage of infection.(38-40) 
An additional promoter located 5’ of the MIEP is active in latently infected human monocytes, 
suggesting that MIE transcription may be driven by different promoters during lytic and latent 
infections.(41) 
In this study we identified several previously unrecognized MIE transcripts encoding full-
length IE1 and IE2 proteins that are expressed during HCMV lytic infection. The novel IE1 and 
IE2 transcripts differed from the known MIE transcript in their transcription start sites, and thus 
their 5’ untranslated regions (5’UTRs). Sequences surrounding each transcription start site 
possessed promoter activity that increased during HCMV infection. Each transcript was 
associated with polyribosomes (polysomes) in infected cells, suggesting that each contributes to 
IE1 and IE2 protein expression during infection. While the canonical MIE transcript is the most 
abundant transcript encoding IE1 or IE2 during the immediate early stage of infection, the novel 
MIE transcripts accumulated as infection progressed. Two of the newly identified transcripts 
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initiated in the first intron (intron A) of the known MIE transcript. Mutant viruses lacking intron A 
or the region surrounding one of the “intronic” promoters expressed lower levels of IE1 and IE2 
mRNA and protein, and replicated less efficiently than the parental virus. Together our data 
show that multiple transcripts encode full length IE1 and IE2 proteins during HCMV infection, 
and suggest that multiple transcription units act in concert to regulate IE1 and IE2 expression 
during lytic replication. 
Materials and Methods 
 
Cells and Viruses. Primary human foreskin fibroblasts (HFFs), MRC-5 fibroblasts and 
Hela cells were grown in DMEM with 10% FBS and penicillin and streptomycin. Unless 
otherwise indicated, BAC-derived HCMV AD169 strain containing a GFP reporter driven by the 
SV40 promoter was used for all infections.(42) Cell free virus was titered by the TCID50 method 
on MRC-5 fibroblasts.  
Construction of Recombinant Viruses. Recombinant viruses were constructed in the 
AD169 genomic background using bacterial artificial chromosome (BAC)-mediated 
recombineering, as previously described.(43-46) Briefly, the HCMV∆UTR378 BAC was 
constructed by amplifying a kanamycin cassette flanked by FRT sites with primers 
HCMV∆UTR378-FRTKanF (5'-TGGTGACGATACTTTCCATTACTAATCCATAACA 
TGGCTCTTTGCCACAAACCACGTCGTGGAATGCC-3') and HCMV∆UTR378-FRTKanR (5'-
ATCGTGCTGTGCCTAAGTCTGGCCTCCACTGTTAGGAGCAAGGAGCTGCCTCCCATGTGC
AGGTGCTG-3'), which contained 50 nucleotide homology arms flanking the desired insertion 
site in the HCMV genome. The PCR product was electroporated into the recombination-
competent EL250 E. coli strain, and recombinants were selected by growth on LB containing 
kanamycin and chloramphenicol. The kanamycin cassette was removed by induction of Flp 
recombinase with arabinose, leaving a 34bp FRT sequence in place of the 265 base pairs 
surrounding the UTR378 transcription start site (nucleotides 174085-174349 deleted, reference 
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genome FJ527563.1). The deletion of intron A was accomplished using a two-step 
recombination approach. In the first step the KanSacB gene was amplified with primers 
HCMV∆IntronA – KanSacBF (5'-GCGGCCGGGAACGGTGCATTGGAACGCGGA 
TTCCCCGTGCCAAGAGTGACAATTCGAGCTCGGTACCCGG-3') and HCMV∆IntronA – 
KanSacBR (5'-AGGGTCCATCTTTCTCTTGGCAGAGGACTCCATCGTGTCAAGGAC 
GGTGACATCCCGGGAAAAGTGCCACC-3'), which contained 50 nucleotide homology arms 
flanking intron A. Recombination with the AD169 genome resulted in the replacement of intron A 
with the KanSacB cassette. Recombinants were selected by growth on LB plates containing 
kanamycin and chloramphenicol. For the second step, the primers Exon1/2Fusion F/R (5'-
CGGCCGGGAACGGTGCATTGGAACGCGGATTCCCCGTGCCAAGAGTGACTCACCGTCCT
TGACACGATGGAGTCCTCTGCCAAGAGAAAGATGGACCCT-3' and 5'-AGGGTCCATC 
TTTCTCTTGGCAGAGGACTCCATCGTGTCAAGGACGGTGAGTCACTCTTGGCACGGGGAA
TCCGCGTTCCAATGCACCGTTCCCGGCCG-3', respectively) were used to amplify a region 
spanning the exon1/exon2 splice junction using IE2 cDNA as a template. The KanSacB 
cassette was then removed by a second round of recombineering using the PCR product 
above. The recombinants were grown on LB agar with chloramphenicol and 6% sucrose to 
select against colonies that retained the SacB gene. Sucrose-resistant colonies were then 
screened for kanamycin sensitivity to ensure loss of the kanamycin cassette. The resulting 
recombinant, HCMVIntronA contained a seamless fusion of exons 1 and 2. (nucleotides 
173738-174564 deleted, reference genome FJ527563.1) The absence of genomic 
rearrangements was confirmed by restriction digest of the recombinant BAC DNAs at each step. 
No errors were detected when the 500 base pairs on either side of each mutation were 
sequenced. To further confirm the absence of additional errors, the entire genome of the 
parental strain and both recombinants was sequenced. Next generation sequencing libraries 
were prepared from BAC DNA using the Nextera library preparation kit (Illumina), and the 
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libraries were sequenced on an Illumina MiSeq. No changes other than the intended mutations 
were detected in the recombinant genomes.  
Quantitative real-time PCR analysis. Total RNA was extracted using Trizol according 
to the manufacturer’s directions as described previously.(47, 48) Briefly, cell pellets were 
resuspended in Trizol, extracted with chloroform and RNA was precipitated with isopropanol. 
The RNA was resuspended in water and quantified on a NanoDrop spectrophotometer. For 
quantitative reverse transcriptase PCR (qRT-PCR), cDNA was generated from 0.5 µg total RNA 
using the High Capacity cDNA Reverse Transcription Kit (ThermoFisher) and random hexamer 
primers. The abundance of each transcript was determined using a real-time PCR machine 
(Biorad) and SYBR Select Master Mix (Roche). The abundance of each product was 
determined by comparison to a standard curve generated from qPCR analysis of tenfold serial 
dilutions of a DNA standard specific for each primer pair. For comparative analysis of MIE 
transcript abundance, each of the UTR-specific primer pairs were confirmed to i) only amplify 
the specific UTR sequence, and not amplify the other MIE UTRs or HCMV BAC DNA (data not 
shown) ii) have similar real time PCR efficiencies (>95% efficiency for each primer pair) and iii) 
have a similar linear range of detection of the appropriate DNA standard (linear between 108 
and 102 copies, R2 >.97 for all experiments included in this work). Where indicated 
phosphonoacetic acid (PAA; Sigma) was used at a final concentration of 200 µg/mL. Primer 
sequences used for qRT-PCR were: IE1 qPCR F/R (5’-CAAGTGACCGAGGATTGCAA-3’ and 
5’-CACCATGTCCACTCGAACCTT-3’), IE2 qPCR F/R (5’-TGACCGAGGATTGCAACGA-3’ and 
5’-CGGCATGATTGACAGCCTG-3’), GAPDH qPCR F/R (5’-CTGTTGCTGTAGCCAAATTCGT-
3’ & 5’-ACCCACTCCTCCACCTTTGAC-3’), UTR70 qPCR (5’-TAGCTGACAGACTAACAGAC-
3’), exon2-3 qPCR (5'-GGTCACGGGTGTCTCGGGCCGT-3'), UTR136 qPCR (5’-
TTGACCTCCATAGAAGACAC-3’), UTR378 qPCR (5’-CGCATTTGGAAGACTTAAGG-3’), 
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UTR136/378 qPCR Reverse (5’-CCTTGACACGATGGAGTCCT-3’), UTR487 qPCR F/R (5’-
GCATTATGCCCAGTACATGACC-3’ and 5’-GAAATCCCCGTGAGTCAAACC-3’). 
 For gene-specific reverse transcription reactions, primers specific for IE1 (exon 4) or IE2 
(exon 5) were used in the cDNA synthesis step: exon 4 RT (5’-TCCTTTTTAGCACGGGCCTT-
3’), exon 5 RT (5’-CGCATCCACCTCACTCTTCA-3’). The cDNA was then amplified by PCR 
using the following reaction conditions: 94oC for 5 minutes, thirty cycles of (94oC for 30 seconds, 
55oC for 30 seconds, 72oC for 5 minutes), followed by a 7 minute extension at 72oC. The 
following PCR primers were used: exon 4 Out (5’-TGAATTTCTCTTCCGTCTGG-3’); exon 4 In 
(5’-AACCTTAATCTGTTTGACGA -3’); exon 5 Out (5’-CTGCAAGAGTGGGTTGTCAG -3’); exon 
5 In (5’-CTGGGCGAGGATGTCACCGA -3’); UTR70 Out (5’-ACAGACTAACAGACTGTTCC -
3’); UTR70 In (5’-TCCATGGGTCTTTTCTGCAG -3’); UTR136 Out (5’-TGACCTCCATAGAAG 
ACACC -3’); UTR136 In (5’-TTCCCCGTGCCAAGAGTGAC -3’); UTR378 Out (5’-CGCTGAC 
GCATTTGGAAGAC -3’); UTR378 In (5’-TGTTCTGATAAGAGTCAGAG-3’); UTR487 Out (5’-
AAGTACGCCCCCTATTGACG -3’); UTR487 In (5’-CCCCTATTGACGTCAATGAC-3’). PCR 
products were analyzed on agarose gels and visualized with ethidium bromide on an imager 
(Biorad). PCR products were also sequenced to confirm the specificity of the PCR reaction.  
HCMV DNA was quantified essentially as described previously.(49) Briefly, infected cell 
pellets were lysed in DNA extraction buffer (400 mM NaCl, 10 mM Tris-HCl pH: 8.0, 10 mM 
EDTA) and digested with proteinase K (10 mg/mL) overnight at 37oC. The lysates were 
extracted with phenol-chloroform, digested with RNase A (10 mg/mL) for one hour at 37oC, and 
again extracted with phenol-chloroform. DNA was precipitated with isopropanol and 
resuspended in 10mM Tris-HCl pH 8.0. The number of HCMV genomes was determined by 
comparing the threshold values to a series of HCMV BAC DNA standards containing from 108 to 
101 HCMV genomes. Results were normalized to the total amount of DNA in the sample using 
qPCR primers specific for GAPDH. Primer sequences were: UL99 qPCR F/R (5'-
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GTGTCCCATTCCCGACTCG-3' and 5'-TTCACAACGTCCACCCACC-3'), and GAPDH qPCR 
F/R (listed above).  
Plasmid construction. To generate the promoter reporter constructs, the five hundred 
nucleotides from -450 to +50 bp flanking each transcription start site were amplified by PCR and 
cloned into the HindIII and NotI sites of the pGL3-Basic vector (Promega) using Gibson cloning 
(NEB). Primer sequences used were: pGL3 Basic UTR70 F/R (5'-
TCTTACGCGTGCTAGCCCGGCTATCGCCGATAGAGGCGACATCAAG-3' and 5'-
TACCAACAGTACCGGAATGCCAAGGCGGGCCATTTACCGTCATTG-3'); pGL3 Basic 
UTR136 F/R (5'-TCTACGCGTGCTAGCCCGGGCCGTATGTTCCCATAGTAACGCC-3' and 5'-
TACCAACAGTACCGGAATGCCAGTGTCTTCTATGGAGGTCAAAACAG-3'); pGL3 Basic 
UTR378 F/R (5'-TCTTACGCGTGCTAGCCCGGGCATCGCCTGGAGACGCCATCCAC-3' and 
5'-TACCAACAGTACGGAATGCCAATTCGCGTGGAGATCCCACGTTATG-3'); pGL3 Basic 
UTR487 F/R (5'-TCTTACGCGTGCTAGCCCGGGCACCACCGTCCCCAGTGCCCGCAG-3' and 
5'-TACCAACAGTACCGGAATGCCACAGAAAAGACCCATGGAAAGGAAC-3'). The inserted 
region was sequenced to confirm the absence of mutations.  To generate the plasmid 
pSVHMIEP, the nucleotides -94 to +64 relative to the canonical transcription start site in the 
MIEP were deleted from the pSVH vector ((50); generously provided by Q. Tang) using PCR-
mediated mutagenesis and Gibson cloning. Primers pSVHMIEP F/R (5'-
GGCACCAAAATCAACGGGACTTTCCATAGAAGACACCGGGACCGATCA-3' and 5'-
GGAAAGTCCCGTTGATTTTGGTGCC-3') were designed to i) flank the region to be deleted 
and ii) contain 20 nucleotides of sequence complementary to the other primer. The plasmid was 
amplified by PCR and the PCR product was circularized in a subsequent Gibson reaction. The 
clones were sequenced to confirm the absence of spurious mutations.  
Luciferase assays. Luciferase assays were performed as described previously.(51) 
Briefly, 200,000 Hela cells were transfected with the indicated plasmids using PEI as the 
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transfection reagent. Forty eight hours after transfection the cells were lysed in 150 µl of passive 
lysis buffer (Promega). 20 µl of lysate was mixed with 100 µl of luciferase reagent (Promega) 
and luciferase was measured on a luminometer (Molecular Devices). The luciferase results 
were normalized to the amount of protein in each sample as determined by the Bradford assay 
(VWR). Luciferase reactions were performed in duplicate, and the graphs show the mean of at 
least three biological replicates performed on different days. In experiments using primary 
fibroblasts, 4x106 cells were electroporated with the reporter constructs and replated into 6 well 
dishes two days prior to infection with HCMV. At the indicated time after infection cells were 
harvested and analyzed as above. 
Western blot. Western blots were performed essentially as described previously.(52) 
Briefly, cells were lysed in RIPA buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 
1% NP40, 1% sodium deoxycholate) with cOmplete protease inhibitors (Roche) on ice for 15 
minutes, and insoluble material was removed by centrifugation at 21,000 x g for ten minutes. 
Protein concentration was measured by the Bradford assay and equal amounts of protein (20 
µg) were loaded in each lane. Sample buffer (45 mM Tris-HCl, pH 6.8, 30% glycerol, 2% sodium 
dodecyl sulfate (SDS), 150 mM dithiothreitol (DTT), and 180 µM bromophenol blue) was added 
to each sample prior to boiling at 95oC for ten minutes. Insoluble material was removed by 
centrifugation for five minutes in a microcentrifuge at 21,000 x g and the samples were then 
resolved on polyacrylamide/SDS gels. Proteins were transferred to nitrocellulose membranes 
(Amersham) and blocked in TBST (20 mM Tris-HCl, pH 7.6, 140 mM NaCl, 0.1% Tween 20) 
with 5% nonfat milk for at least one hour at room temperature. For monoclonal antibodies, 
membranes were incubated with the indicated dilution of antibody in TBST with 1% bovine 
serum albumin (BSA) for one hour at room temperature. For polyclonal antibodies, membranes 
were incubated with the antibody in TBST with 5% BSA overnight at 4oC. Following incubation 
with primary antibody, membranes were washed thrice with TBST, and then incubated with 
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horseradish peroxidase coupled secondary antibodies for one hour at room temperature in 
TBST with 1% BSA. Membranes were then incubated with WesternBright ECL reagent 
(BioExpress) and imaged on a chemiluminesence detection system (Biorad). The following 
antibodies were used at the indicated dilution: ICP36 (UL44; Virusys, 1:1000), tubulin (Sigma, 
1:10,000), GFP (Roche, 1:2000). The IE1 ((53),1:100), IE2 ((54),1:100), and pp28 ((55),1:100) 
antibodies were a generous gift from the Shenk Lab.  
5’ Rapid amplification of cDNA ends (5’RACE). 5’ RACE was performed using the 
RLM-RACE (Ambion) kit according to the manufacturer’s protocol as previously described.(47)  
Briefly, total or polysome-associated RNA was treated with calf intestinal phosphatase (CIP) to 
dephosphorylate uncapped or degraded RNAs. The 5’ 7-methylguanosine cap was then 
removed by incubation with tobacco acid pyrophosphatase (TAP). An RNA linker was ligated to 
the newly exposed phosphate on the 5’ end of the RNA, and was then reverse transcribed with 
random hexamer primers. Nested PCR was performed using primers specific for the linker 
sequence ligated to the mRNA 5’ end and exon 2 of the MIE transcript. Primers used were: 5’ 
RACE Outer exon 2 5’-TTCGGCCAACTCTGGAAACAGC-3’; 5’ RACE Inner exon 2 5’-
ATCAGGGTCCATCTTTCTCTTGG-3’. PCR products were visualized by ethidium bromide 
staining on agarose gels, shotgun cloned into the pCR-Blunt vector (Invitrogen) and sequenced 
by Sanger sequencing at the UNC Genome Analysis Facility.  
Polysome Isolation. Polysomes and polysome-associated RNAs were isolated as 
described previously.(47, 48) Briefly, at the time of harvest, cells were incubated in normal growth 
media containing 0.1 mg/ml cycloheximide (CHX) for ten minutes. The cells were then washed 
three times with phosphate buffered saline (PBS) containing CHX, and lysed in 1 ml of 
polysome  buffer (20 mM Tris-HCl pH 7.4, 140 mM KCl, 5 mM MgCl2) containing 0.1% Triton X-
100, 10 mM dithiothreitol (DTT), and 100 µM CHX. The lysate was passed five times through a 
27 gauge needle to disrupt the cells, and nuclei were pelleted by centrifugation for five minutes 
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at 1150 x g. The cytoplasmic lysate was then centrifuged for ten minutes at 21,000 x g in a 
microcentrifuge to remove mitochondria and insoluble debris. The supernatant was layered onto 
a linear 10-50% sucrose gradients prepared in polysome buffer. The gradients were spun for 
two hours in an SW40 rotor at 32,000 rpm without brake, and the gradients were fractionated 
through a gradient fractionation system (Brandel) with continuous monitoring of OD254 (UA-6, 
Isco). Gradient fractions containing polysomes were extracted with Trizol, treated with Turbo 
DNase (Applied Biosystems), and the RNA converted to cDNA as described above.  
Results 
Multiple mRNAs with different transcription start sites encode full-length IE1 and 
IE2 proteins. In the course of identifying splice junctions in HCMV transcripts using next 
generation sequencing, we observed novel spliced transcripts in the major immediate early 
(MIE) locus encoded on the same strand as the IE1 and IE2 reading frames (data not shown). 
These results suggested the potential existence of undescribed IE1 and IE2 transcripts with 
alternative 5’ termini. We therefore performed 5’ rapid amplification of cDNA ends (5’ RACE) 
analysis to identify transcription start sites (TSSs) for mRNAs containing exon 2 of the MIE 
locus. To focus on transcripts that were translated during infection, we used polysome-
associated RNA in the 5’ RACE reactions. Cytoplasmic lysates of HCMV infected cells were 
resolved through 10-50% linear sucrose gradients, and RNA was extracted from fractions of the 
gradient containing polysomes. A representative absorbance profile showing the location of 
polysomes in the gradient is shown in Figure 1A. For 5’ RACE analysis we used the RLM-RACE 
procedure, wherein the mRNA cap is cleaved from mature transcripts by tobacco acid 
pyrophosphatase (TAP) and replaced with an RNA oligo containing a known sequence. 
Following random hexamer-primed reverse transcription, the cDNA was amplified using primers 
specific to the RNA oligo sequence and exon 2 of the MIE transcript. Multiple bands were 
present when the PCR products were visualized on agarose gels (Fig. 1B), demonstrating that 
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transcripts containing exon 2 are associated with multiple 5’ ends. No products were obtained in 
the absence of TAP, demonstrating the specificity of the PCR for mature, capped mRNAs. 
 
Figure 1 - Multiple transcription start sites give rise to mRNAs containing MIE exon 2. (A) HFFs 
were infected with HCMV (MOI=3) and harvested at 72 hours after infection. Cytoplasmic lysates were 
resolved through a 10-50% linear sucrose gradient to separate ribosomal subunits (40S, 60S), 
monosomes (80S) and polysomes. (B) 5’ RACE was performed on RNA extracted from gradient fractions 
containing polysomes in the presence or absence of tobacco acid pyrophosphatase (TAP). 5’ RACE PCR 
products were visualized on agarose gels, and cloned and sequenced (C) The cartoon shows the 
structure of the identified transcripts (not to scale). The number to the right of each transcript indicates the 
length of the 5’ untranslated region (UTR) of each transcript relative to the translation start site (AUG) 
located in exon 2. 
To identify the 5’ ends of the exon 2-containing transcripts, we cloned and sequenced 
the PCR products of the 5’ RACE reaction. Herein we refer to each MIE transcript by the length 
of their 5’ UTR. In addition to the previously identified MIE TSS (referred to as UTR136)(56), 
multiple clones containing additional 5’ ends were found (Fig. 1C). One of the novel transcription 
start sites (UTR487) was located 351 nucleotides 5’ of the start site of UTR136. Several clones 
identified a TSS previously observed in latently infected monocytes isolated from HCMV 
infected individuals (UTR406).(41) Transcripts initiating at this site have a 270 nucleotide 
extension of the 5’ end of exon 1 compared to the UTR136 start site. Two additional start sites, 
UTR232 and UTR200, were located between the UTR406 TSS and the UTR136 TSS. Each of 
the above transcripts used the previously described splice donor in exon 1 and splice acceptor 
in exon 2 of the MIE transcript. The directionality of the splice donor and acceptor sites 
confirmed that each transcript is encoded on the same strand of the viral genome as the IE1 
and IE2 open reading frames (ORFs). 
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We also identified two transcripts that initiated in intron A of the MIE locus. The first of 
these “intronic” transcripts, UTR378, initiated in the middle of intron A, 350 nucleotides 3’ of the 
canonical exon 1 splice donor site. This transcript used a unique splice donor site with a 
canonical splice donor sequence, and was spliced to the known splice acceptor in MIE exon 
2.(57) We also found several clones containing transcripts that initiated 54 nucleotides 5’ of the 
splice acceptor site of MIE exon 2 (UTR70). These results show that multiple transcription start 
sites give rise to a collection of transcripts containing MIE exon 2. The association of each 
transcript with polysomes suggests that the transcripts are both trafficked to the cytoplasm and 
translated into protein during HCMV infection. 
Each of the new MIE transcripts included exon 2, which contains the initiator methionine 
for both the IE1 and IE2 proteins.(16) To determine if the novel MIE transcripts encoded full-
length IE1 or IE2 proteins, we used RT-PCR to determine if IE1 or IE2 specific sequences (exon 
4 or exon 5, respectively) were found on mRNAs originating from each of the newly identified 
TSSs. We focused our analysis on four transcript isoforms: i) the longest transcript (UTR487), ii) 
the previously described MIE transcript (UTR136), and iii) the two transcripts initiating in intron A 
(UTR378 and UTR70). Total or polysome-associated RNA was extracted from HCMV infected 
cells and reverse transcribed using primers specific for either IE1 (exon 4) or IE2 (exon 5). The 
resulting cDNA was amplified using primers specific to exon 4 or 5 together with a primer 
recognizing the individual transcript isoforms. No PCR product was obtained from cDNA from 
uninfected cells or in the absence of reverse transcriptase, demonstrating the specificity of each 
reaction (Fig. 2A and 2B). In the presence of reverse transcriptase, PCR products were 
obtained from both polysome-associated (Fig. 2A) and total (Fig. 2B) cDNA for each 5’UTR 
linked to either IE1 or IE2-specific exons. Each MIE transcript was also detected in total RNA 
from cells infected with the HCMV TB40/E strain (Fig. 2C). Sequence analysis of the amplicons 
confirmed that each transcript contained exons 2 and 3, and was properly spliced to either exon 
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4 or exon 5 (data not shown). We conclude that transcripts arising from each MIE transcription 
start site give rise to mature cytoplasmic transcripts encoding full-length IE1 or IE2, and that 
each transcript has the potential to contribute to IE1 and IE2 protein expression during infection. 
 
Figure 2 - Transcripts originating from each MIE transcription start site give rise to mature IE1 and 
IE2 mRNAs. Mock infected (Mock) or HCMV infected MRC-5 fibroblasts were harvested at 72 hours after 
infection. (A) Polysome-associated RNA was extracted from AD169 infected cells and reverse transcribed 
using a primer specific for either exon 4 (IE1, top panel) or exon 5 (IE2, bottom panel). The resulting 
cDNA was amplified using a primer specific for either IE1 or IE2 together with a primer specific for each 
UTR, and the PCR products were visualized on agarose gels. Reverse transcriptase was omitted in a set 
of samples (-RT) to ensure the absence of contaminating DNA. (B) Total RNA was extracted and 
analyzed as in A. (C) As in B, except cells were infected with the HCMV TB40/E strain (MOI of 3). The 
PCR products in A, B and C were cloned and sequenced to ensure their specificity. 
 
To measure the temporal accumulation of each MIE transcript, we used quantitative 
reverse transcriptase PCR (qRT-PCR) to measure the abundance of each transcript at different 
times after infection. RNA was harvested at various times after infection, and the abundance of 
each MIE transcript was determined by comparison to a standard curve specific for each 
amplicon using qRT-PCR (Fig. 3A). Each primer pair had a similar range of detection, and 
amplified its target with similar efficiency. The abundance of the previously described MIE 
5’UTR (UTR136) decreased between 6 and 24 hours after infection (Fig. 3A).(16)  UTR136 
abundance did not return to initial levels until 96 hours after infection. The abundance of the 
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UTR378 transcript increased fivefold between 6 and 48 hours after infection, with a maximal 
increase at 96 hours.  The longest transcript, UTR487, displayed a similar trend, but was even 
more abundant at 96 hours as compared to the 6 hour time point.  
Temporal regulation of alternative MIE transcripts abundance and promoter 
activity. In comparing the abundance of the different transcripts, the known MIE transcript 
(UTR136) was by far the most abundant MIE transcript expressed at 6 hours after infection. 
However by 72 hours after infection the UTR378 and UTR487 transcripts were expressed to at 
least the same level as the UTR136 transcript. Thus the UTR136 transcript is the most 
abundant MIE transcript at immediate early times after infection. However the transcription of 
the novel MIE transcript isoforms increases as infection progresses, eventually rivaling the 
expression of the previously described MIE transcript, UTR136. Like the UTR136 transcript, 
UTR378 transcript abundance was increased in the presence of cycloheximide. In contrast, 
cycloheximide significantly reduced UTR487 abundance (Fig. 3B). To measure the role of viral 
DNA replication in the accumulation of each MIE transcript, we measured the effect of 
phosphonoacetic acid (PAA), an inhibitor of viral DNA replication, on MIE transcript abundance. 
PAA significantly inhibited the accumulation of the novel MIE transcripts, with a more 
pronounced effect on the accumulation of the UTR378 and UTR487 mRNAs (Fig. 3C). These 
data show that the newly identified MIE transcripts have a complex expression profile, which 
together with the UTR136 transcript allows for continued IE1/2 transcription throughout the 
HCMV lytic cycle.  
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Figure 3 - Temporal analysis of MIE transcript abundance. (A) Primary fibroblasts were infected with 
HCMV (MOI=3). The abundance of the indicated MIE transcript at each time point was measured by qRT-
PCR using the absolute abundance method as described in the Materials and Methods. (B) Cells were 
infected as in A in the absence (black bars) or presence of cycloheximide (grey bars). The relative 
abundance of the indicated transcript was measured by qRT-PCR at six hours after infection. Transcript 
abundance in untreated cells was set to one.  (C) Cells were infected as in A in the presence (open bars) 
or absence (black bars) of PAA. Transcript abundance was measured by qRT-PCR using the absolute 
abundance method. (* denotes p value < 0.001) (D) The reduction of UL99 mRNA expression in the 
presence of PAA is shown for comparison. 
 
Sequences surrounding transcription start sites act as promoters that recruit RNA 
polymerase to initiate transcription. To determine if the sequences surrounding the novel MIE 
transcription start sites possessed promoter activity, we cloned the region from -450 to +50 
base pairs flanking each transcription start site into a promoter-less luciferase reporter vector 
(Fig. 4A), and measured luciferase expression after transfection into Hela cells (Fig. 4B) or 
primary human fibroblasts (Fig 4C). Each promoter region increased the amount of luciferase 
activity in both cell types as compared to the empty luciferase vector lacking a promoter, 
although to varying degrees. The reporter containing the MIEP was the most active promoter, 
increasing luciferase expression by >49,000 fold compared to the empty vector (Fig 4B). The 
least active promoter segment was the region surrounding the UTR378 TSS, which resulted in a 
modest but consistent >3 fold increase in luciferase activity. The regions surrounding the 
UTR487 and UTR70 transcription start sites had greater activity, increasing luciferase activity by 
28 and 51 fold, respectively, compared to the empty vector. We next measured the effect of 
HCMV infection on the activity of each promoter. Fibroblasts were electroporated with the 
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reporter constructs, infected with HCMV, and luciferase activity was measured over a time 
course of infection (Fig. 4D). Infection had minimal effect on the activity of the UTR136 
promoter, increasing its activity by 2-fold throughout infection. Consistent with our qRT-PCR 
analysis, each of the novel promoters was induced by HCMV infection. Compared to uninfected 
cells, the UTR70 promoter was induced 25, 58, and 50-fold at 24, 48 or 72 hours after infection, 
respectively. The UTR378 promoter was similarly induced 130, 435, 470-fold after infection, and 
UTR487 was induced 5, 20, 20-fold (Fig. 4D). We conclude the regions surrounding the novel 
MIE transcription start sites have promoter activity that is induced during HCMV infection. 
Figure 4 - DNA sequences surrounding the novel MIE transcription start sites have promoter 
activity. (A) Cartoon showing the location of the regions tested for promoter activity. (B) Hela cells were 
transfected with the indicated reporter plasmids, and luciferase activity was measured at 24 hours after 
transfection. The graph shows the fold change in luciferase activity relative to cells transfected with the 
empty pGL3 Basic vector, which lacks a promoter for the luciferase gene. (C) The indicated reporters 
were electroporated into MRC-5 fibroblasts, and luciferase activity was measured at 24 hours after 
electroporation. (D) MRC-5 fibroblasts were electroporated with the indicated reporters and then infected 
with HCMV (MOI=3). Luciferase activity was measured at the indicated times after HCMV infection. The 
graph shows the fold change in luciferase activity relative to the activity of each reporter at 6 hours after 
infection. 
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The core promoter region of the MIEP is not necessary for IE1 and IE2 expression 
outside the context of HCMV infection. We next investigated if the novel MIE promoters were 
active outside of infection in the context of the MIE genomic locus. The plasmid pSVH contains 
the region of the HCMV genome from 840 nucleotides upstream of the MIEP transcription start 
site to 1,413 nucleotides downstream of the polyadenylation signal following exon 5.(17) 5’ RACE 
analysis of polysome-associated RNA from pSVH transfected Hela cells using a gene-specific 
primer recognizing MIE exon 2 produced a single prominent band (Fig. 5D). When the PCR 
product was sequenced it was found to correspond to the previously defined MIEP transcription 
start site, UTR136. Thus the UTR136 transcript is the predominant MIE transcript expressed 
from MIE locus in uninfected cells.  
Previous studies found that the highly active MIEP can suppress the activity of weaker 
promoters by competing for RNA polymerase II recruitment.(58, 59) To determine if promoter 
competition might explain our failure to observe transcripts arising from the alternative 
promoters in pSVH-transfected cells, we generated a mutated version of the pSVH plasmid 
(pSVHMIEP) in which the core promoter region of the MIEP (nucleotides -94 to +64 bp 
surrounding the transcription start site) was deleted (Fig. 5A). Both IE1 and IE2 protein and 
mRNA were expressed following pSVHMIEP transfection, albeit at significantly reduced levels 
compared to pSVH-transfected cells (Fig. 5B and 5C, respectively). This could reflect increased 
alternative promoter activity driven by a change in proximity to the MIE enhancer. In any case, 
these data show that the core promoter region of the MIEP is not required for IE1 and IE2 
expression from the MIE genomic locus outside the context of infection.  
5’ RACE analysis of polysome-associated RNAs from pSVHMIEP transfected cells 
generated two PCR products, neither of which matched the size of the UTR136 5’ UTR found in 
cells transfected with wild type pSVH.  When the PCR products were cloned and sequenced, 
they were found to correspond to the UTR378 and UTR70 transcription start sites in intron A 
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(Fig. 5D). Thus the regions flanking the alternative transcription start sites in intron A have 
promoter activity that is sufficient to drive IE1 and IE2 expression in the context of the MIE 
genomic locus in the absence of the MIEP. These data also suggest that promoter suppression 
by the MIEP limits the activity of the intronic MIE promoters.  
Figure 5 - The core promoter region of the MIEP is not necessary for IE1 and IE2 expression 
outside the context of HCMV infection. (A) Cartoon showing a portion of the MIE locus in pSVH. The 
numbers show the location of the MIE transcription start sites for the indicated MIE transcripts described 
in Figure 1. pSVH∆MIEP was created by removing a 158bp region containing the MIEP core promoter (-
94 to +64 relative to the transcription start site). (B) Hela cells were left untransfected ((-) control), or 
transfected with pSVH or pSVH∆MIEP (∆MIEP). IE1 and IE2 protein levels were measured by Western 
blot at 24 hours after transfection. (C) Hela cells were transfected and harvested as in B. The relative 
abundance of the IE1 and IE2 mRNAs in pSVH∆MIEP transfected cells as compared to pSVH transfected 
cells was determined by qRT-PCR using the ∆∆Ct method. IE1 and IE2 abundance in pSVH transfected 
cells is set to one. (D) Hela cells were transfected as in B. 5’ RACE analysis of polysome-associated RNA 
was performed using gene specific primers located in exon 2. 5’ RACE PCR products were visualized on 
agarose gels and subsequently cloned and sequenced. No PCR products were obtained in cells where 
tobacco acid pyrophosphatase (TAP) was omitted, demonstrating that the PCR products were derived 
from mRNAs containing a 5’ m7G cap.  
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Intron A of the MIE locus is important for efficient IE1 and IE2 expression and 
HCMV replication. Our results suggested that sequences in intron A contributed to the 
expression of IE1 and IE2. We therefore constructed an HCMV recombinant, HCMVIntronA, 
wherein the entirety of intron A was deleted, leaving a seamless fusion of exon 1 to exon 2 of 
the canonical MIE transcript. We also constructed a second recombinant, HCMV∆UTR378, 
lacking the 250 nucleotides surrounding the transcription start site for the UTR378 transcript 
(Fig. 6A). The entire genome of each recombinant and the parental virus was resequenced to 
confirm the absence of spurious mutations. Infectious virus was recovered following 
electroporation of the recombinant genomes into MRC-5 fibroblasts, demonstrating that neither 
intron A nor the sequences surrounding the UTR378 promoter are essential for virus replication 
(Fig. 6B).    
To measure the effect of each mutation on virus replication, we compared the replication 
kinetics of the wild type and recombinant viruses. Cells were infected at a multiplicity of infection 
(MOI) of 0.5 or 3, and the accumulation of cell-free virus was measured over a single round of 
virus replication. We observed reduced accumulation of cell-free virus with both mutants at 72 
and 96 hours after infection at either multiplicity of infection, though the effect was more 
pronounced at the lower multiplicity (Fig. 6B and 6C). In addition, both recombinants viruses 
had a modest, but reproducible, reduction in the accumulation of viral DNA (Fig. 6D). Thus 
deletion of intron A or the region surrounding the UTR378 promoter resulted in delayed 
replication kinetics compared to wild type virus. 
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Figure 6 - Removal of MIE intron A delays HCMV replication. (A) Diagram depicting the genomic 
regions removed from each recombinant HCMV BAC. (B) MRC-5 fibroblasts were infected with wild type 
(WT) HCMV, HCMV∆Intron A (∆Intron A) of HCMV∆UTR378 (∆UTR378) (MOI=0.5). Cell free virus was 
quantified at the indicated times after infection by the TCID50 assay. (C) Fibroblasts were infected with 
HCMV (MOI=3) and cell free virus quantified as in B. (* = p < 0.05) (D) Fibroblasts were infected as in B, 
and the relative abundance of viral DNA was quantified by real-time PCR at 72 hours after infection. The 
amount of viral DNA in cells infected with wild type virus was set to one. (* = p value < 0.001) 
 
To better define the defect in viral replication after low multiplicity infection, we measured 
the accumulation of representative immediate early, early and late proteins after infection with 
the recombinant viruses. Both recombinants expressed decreased levels of the IE1 and E2 
proteins as compared to the wild type virus. In addition, the levels of the early protein pUL44 
and the late protein pp28 were expressed with delayed kinetics and to reduced levels (Fig. 7A). 
The delayed replication of the HCMVIntron A and HCMVUTR378 viruses thus correlated with 
decreased IE1 and IE2 protein expression. 
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Figure 7 - Deletion of intron A results in decreased IE1 and IE2 mRNA and protein expression.    
(A) MRC-5 fibroblasts were infected with the indicated strains of HCMV (MOI=0.5). The expression of 
representative HCMV immediate early (IE1 and IE2), early (UL44), and late (pp28) proteins was 
measured by Western blot. (B) Fibroblasts were as in A. DNA was extracted from infected cells at two 
hours after infection, and HCMV genome abundance was measured by qPCR. (C) MRC-5 fibroblasts 
were infected as in A. The relative abundance of IE1 (left), IE2 (middle), and UTR136 (right) mRNAs in 
cells infected with each recombinant virus was measured by qRT-PCR  and compared to the levels in 
cells infected with wild type HCMV, which was set to one. (* = p < 0.05) 
 
To determine if the reduction in IE1 and IE2 protein levels were the result of decreased 
IE1 and IE2 transcript levels, we measured the accumulation of IE1 and IE2 transcripts after 
infection with each recombinant virus. Despite the presence of equivalent numbers of viral 
genomes (Fig. 7B), IE1 and IE2 mRNA levels were reduced in cells infected with the 
recombinants as compared to cells infected with the wild type virus at early times of infection 
(Fig. 7C). At late times after infection both recombinants expressed reduced levels of IE2 
mRNA, but IE1 mRNA levels were similar to those in cells infected with the wild type virus (Fig. 
7C). Expression of the UTR136 transcript closely mirrored IE1 expression; less UTR136 mRNA 
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was present early after infection with either mutant, but its expression reached the same levels 
as in wild type infected cells by 72 hours. Thus the defect in IE1 and IE2 mRNA levels 
correlated with a decrease in IE1 and IE2 protein expression. We conclude that sequences in 
intron A, and the sequences surrounding the UTR378 TSS in intron A, are important for 
maximal expression of IE1 and IE2 and efficient HCMV replication. 
Discussion 
Proper regulation of IE1 and IE2 expression is critical for both lytic and latent HCMV 
infection. In this study we describe novel IE1 and IE2 transcript isoforms arising from alternative 
transcription start site usage. The novel transcripts encode full-length IE1 and IE2 proteins, but 
differ from the previously described MIE transcript in their 5’ UTRs (Fig. 2). Several of the new 
transcript isoforms extended exon 1 of the previously described MIE transcript, while two of the 
novel transcripts initiated within intron A (Fig. 1). The DNA sequences surrounding the new 
transcription start sites had promoter activity (Fig. 4B and 4C) that was induced upon HCMV 
infection (Fig. 4D), consistent with the accumulation of the novel transcript isoforms as infection 
progressed (Fig. 3A). Deletion of MIE intron A or the region surrounding the UTR378 TSS in 
intron A delayed the production of cell-free virus (Fig. 6B and 6C) and decreased IE1 and IE2 
mRNA and protein accumulation (Fig. 7). Together these results suggest that multiple 
transcription units within the MIE region control the expression of full-length IE1 and IE2 
proteins during lytic virus replication. 
Several spliced and alternatively spliced transcripts are transcribed from the MIE    
locus.(16-19) Many of the alternative IE1 and IE2 mRNAs encode truncated versions of the IE1 
and IE2 proteins that have distinct roles in regulating HCMV gene expression.(18, 19) Our results 
suggest that in addition, the MIE locus gives rise to multiple transcripts encoding full-length IE1 
and IE2 proteins. RT-PCR analysis of infected cell RNA demonstrated that each of the MIE 
transcription start sites was linked to both exons 2 and 3, as well as the IE1- or IE2-specific 
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exons (exon 4 or 5, respectively, Fig. 2A). The alternative transcripts were expressed from both 
laboratory (AD169) and clinical (TB40/E) HCMV strains (Fig. 2B and 2C) and thus likely are not 
the result of adaption of the virus to in vitro passage. Each MIE transcript was associated with 
polysomes in HCMV-infected cells, suggesting that these transcripts contribute to IE1 and IE2 
protein expression (Fig. 2A). In addition our results show that the upstream MIE transcription 
start site previously found in latently infected monocytes (UTR406; (41)) is also utilized during 
lytic infection (Fig. 1). Thus multiple transcription units contribute to the expression of full-length 
IE1 and IE2 during lytic HCMV infection. 
We also found that deleting either intron A of the MIE locus or a portion of intron A 
containing one of the novel MIE promoters decreased IE1 and IE2 mRNA and protein levels 
(Fig. 7), and delayed virus replication (Fig. 6B and 6C) without affecting viral entry (Fig. 6D). 
These results are consistent with a role for the MIE transcripts that initiate in intron A in the 
expression of IE1 and IE2 during infection. We obtained similar results with the smaller deletion 
of sequences surrounding the UTR378 start site. Interestingly, while IE1 and UTR136 mRNA 
levels were similar at late times after infection with the wild type and deletion viruses, IE2 
expression remained reduced at all time points (Fig. 7). This may suggest that the alternative 
MIE transcripts are more important for IE2 expression, particularly during the late stage of 
infection. However it is important to note that other undefined regulatory elements could also be 
affected by these mutations, and thus could contribute to the observed decrease in IE1 and IE2 
expression, as suggested by the decreased expression of the UTR136 transcript at early times 
after infection when intron A was deleted. Detailed mapping of transcription factor binding sites 
and regulatory sequences controlling the intronic promoters together with a series of subtle viral 
mutants will be needed to better define the factors that regulate intronic promoter activity.  
Our results suggest that the transcriptional regulation of full-length IE1 and IE2 is more 
complex than previously appreciated. We found that the MIE locus contains multiple promoters, 
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including two promoters located in intron A of the previously described MIE transcript. This 
could explain results showing that the presence of intron A modestly enhances the expression 
of downstream reporter genes.(60-62) Perhaps this reflects a contribution of the UTR378 and 
UTR70 promoters to transgene expression. Our data also suggests that the coordinated 
regulation of the MIE promoters allows for appropriate levels of IE1 and IE2 expression 
throughout infection. The MIEP suppressed the weaker alternative MIE promoters in the context 
of the MIE locus (Fig. 5), which correlates with the accumulation of the alternative MIE 
transcripts later in infection when increased IE2 protein levels should limit MIEP            
activity.(32, 35, 37, 63) We also find that the UTR378 transcript can be transcribed in the presence 
cycloheximide, suggesting a potential role in the immediate early expression of IE1 and IE2 as 
well. However the contribution of this transcript to IE1 and IE2 expression at IE times is likely to 
be minor, as it is approximately tenfold less abundant than the UTR136 transcript at this time.  
We also found that maximal accumulation of the alternative MIE transcripts required viral 
DNA replication (Fig. 3B). The promoters of herpesvirus late genes contain TATT motifs, which 
are recognized by a complex of viral proteins that facilitate RNA polymerase II recruitment.(64, 65) 
Interestingly, TATT elements are found approximately 30 nucleotides upstream of several of the 
alternative MIE transcription start sites (UTR487, UTR406, and UTR378; our unpublished 
observations), suggesting a role for HCMV proteins in regulating the accumulation of the 
alternative MIE transcripts. Thus the specific sequence elements in the alternative MIE 
promoters may allow for the temporal or context-specific regulation of IE1 and IE2 transcription. 
Together our data suggest a model for the regulation of IE1 and IE2 expression during 
HCMV infection. During the immediate early stage of infection IE1 and IE2 transcription is 
controlled primarily by the MIEP. As IE2 accumulates it binds the crs sequence in the MIEP and 
represses MIEP promoter activity. Suppression of the MIEP by IE2 allows the weaker promoters 
controlling expression of the UTR70 and UTR378 transcripts to become active, which together 
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account for the majority of the IE1 and IE2 transcripts made during the later stages of infection. 
The combined action of the multiple MIE promoters thus allows for continued transcription of IE1 
and IE2 despite the accumulation of IE2 protein as infection progresses.  
An interesting hypothesis arising from these results is that the existence of multiple 
regulatory regions controlling IE1 and IE2 transcription might also contribute to cell-type or 
context dependent expression. While our data suggests a role for the alternative MIE promoters 
in fibroblasts, perhaps the alternative MIE transcription units play a more pronounced role in 
controlling IE1 and IE2 expression in monocytes or macrophages where MIEP activity is limited. 
The alternative promoters could also respond to distinct environmental cues, similar to the 
situation for ORF50 of the gammaherpesviruses. The gammaherpesvirus Rta protein is 
functionally analogous to IE2, transactivating viral gene expression to drive lytic replication and 
reactivate from latency.(66-68) Multiple transcripts arising from at least three distinct promoters 
regulate ORF50 expression in both KSHV and MHV68 (69), and each ORF50 promoter responds 
uniquely to temporal and cell-specific cues.(70, 71) Together with our data, these results suggest 
that the use of alternative promoters may be a common herpesvirus strategy to allow for the 
precise regulation of herpesvirus IE gene expression. Future experiments will focus on 
identifying the role of specific sequence elements that regulate the alternative MIE promoters, 
and their roles, in other cell types and during latent infection. 
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Chapter 3: The 5’ Untranslated Region of the Major Immediate Early mRNA is 
Necessary for Efficient Human Cytomegalovirus Replication1 
 
Introduction  
Human cytomegalovirus (HCMV) is a betaherpesvirus that establishes mainly 
asymptomatic lifelong infection in healthy individuals. However HCMV is a significant cause of 
disease in newborns and immune compromised adults. Primary infection of immune naïve 
newborns causes over 5,000 cases of long-term birth defect each year in the US alone, 
including deafness, microcephaly, mental defect and in some cases death. Reactivation of 
latent HCMV infection in immune compromised adults, typically after transplant, can lead to 
severe complications including organ failure, neutropenia and death. Thus HCMV is a significant 
human pathogen that causes disease in multiple patient populations. 
 Two critical regulators of the HCMV replication cycle are the major immediate early 
proteins IE1 and IE2.(1) Both IE1 and IE2 are immediate early genes and expressed to high 
levels within hours after virus entry. In addition their re-expression is thought to be critical for 
HCMV reactivation. IE1 helps establish lytic infection by preventing the deposition of 
suppressive chromatin marks on viral genomes, and also inhibits the type I interferon response 
by binding to the STAT1 transcription factor.(2-4) IE2 is a broadly acting transcriptional activator, 
which stimulates the expression of host genes(5-9) and HCMV early genes needed for viral DNA 
replication.(10-17) Viruses lacking IE1 are viable, but replicate poorly after low multiplicity 
1 This chapter has been submitted to the Journal of Virology and is currently under review.           
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infections(18, 19), while deletion of IE2 completely blocks virus replication.(20, 21) The regulation of 
IE1 and IE2 expression is thus a central event in the HCMV life cycle.  
 Given the important role of IE1 and IE2 in HCMV replication, much work has been done 
to understand the factors controlling their expression. The mature IE1 and IE2 transcripts arise 
from a common precursor RNA by alternative splicing.(22) Mature mRNAs containing exons 1-4 
encode the IE1 protein. An exon-skipping event gives rise to the mature IE2 mRNA, composed 
of exons 1-3 and exon 5.(10, 23-26) Early in infection the HCMV major immediate early promoter 
(MIEP) drives robust expression of the IE1/2 precursor RNA. Multiple factors regulate MIEP 
activity including the cellular transcription factors AP1, SP1, NFB, and MEF2D.(27-33) In addition 
viral proteins including pTRS1, pUL83, pp71, and the IE1 and IE2 proteins themselves modulate 
MIEP activity.(34-39) Later in infection IE2 binds a cis-repression sequence (crs) in the MIEP and 
represses its activity(40-44) and alternative MIE promoters become active(45), allowing for 
continuous, but dynamic, IE1 and IE2 expression throughout infection.  
 While less studied, post-transcriptional regulatory events also control IE1 and IE2 
expression. For example, cellular factors regulate IE1/IE2 alternative splicing.(23-26) In addition 
the rate of synthesis of the IE1 and IE2 proteins changes throughout infection(46), potentially due 
to the effects of cellular microRNAs.(47) Consistent with this, the amount of mature IE1 and IE2 
mRNAs associating with polyribosomes, or polysomes, changes as infection progresses.(48, 49) 
However little is known of the factors controlling IE1 and IE2 mRNA translation, and how these 
mechanisms might contribute to HCMV replication.  
 An important factor regulating mRNA translation is the 5’ untranslated region (5’UTR) 
preceding the mRNA coding region.(50) Though sometimes viewed exclusively as translational 
enhancers, 5’UTRs can either enhance or repress mRNA translation. RNA binding proteins 
(RBPs) can recognize specific sequences in the 5’UTR and facilitate ribosome recruitment to 
enhance translation.(51) Alternatively, RNA structure in the 5’UTR can impede ribosomal subunit 
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scanning or translation start site recognition(52-56), or serve as binding sites for RBPs that 
suppress translation.(50, 57-59) Experimentally determining the impact of a 5’UTR on mRNA 
translation is therefore critical for understanding the regulation of protein expression.  
 To better understand the post-transcriptional regulation of IE1 and IE2 protein expression, we 
investigated the role of the shared 5’UTR of the IE1 and IE2 mRNAs (MIE 5’UTR) in the control 
of mRNA translation and virus replication. Using a combination of biochemical approaches and 
recombinant viruses we found that the sequence of the MIE 5’UTR is an important determinant 
of IE1 and IE2 mRNA translation efficiency. In a cell-free system the MIE 5’UTR repressed 
translation. In contrast, in transfected cells the MIE 5’UTR enhanced the expression of a 
reporter gene, and increased its association with polysomes. During HCMV infection, 
replacement of the majority of the MIE 5’UTR with an unstructured sequence of equal length led 
to a defect in IE1 and IE2 mRNA association with polysomes, decreased IE1 and IE2 protein 
expression and diminished HCMV replication. These studies show that the MIE 5’UTR is 
necessary for efficient IE1 and IE2 protein expression, and identify the MIE 5’UTR as a critical 
determinant of HCMV replication. 
Materials and Methods  
 
Cells and viruses. HeLa cells and MRC5 primary fibroblasts were cultured in DMEM 
(Sigma) containing 10% fetal bovine serum (Gibco) and penicillin and streptomycin (Sigma). 
Virus stocks were grown on MRC5 fibroblasts, and titered using the tissue culture infectious 
dose 50 (TCID50) assay, unless otherwise noted. In all experiments ADinGFP was used as the 
wild type HCMV strain.(60)  
Recombinant viruses were made using a two-step recombination process as described 
previously.(37, 45, 61, 62) Briefly, SW105 E. coli containing the ADinGFP bacterial artificial 
chromosome (BAC) were induced to be recombination competent by incubation at 42oC for 15 
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minutes. The bacteria were then electroporated with a kanamycin/levansucrase (KanSacB) 
expression cassette containing 50 nucleotides of sequence flanking the desired insertion site to 
guide recombination into the HCMV genome. The KanSacB recombination template was 
generated by PCR using the primers IE UTR del KS F and IE UTR del KS R listed in Table 1. 
After recombination, bacteria were selected for growth on kanamycin, and the lack of gross 
recombination was confirmed by restriction digest. Correct insertion of the KanSacB cassette 
was determined by PCR amplification of the region containing the KanSacB cassette followed 
by sequencing of the amplicon. Correct insertants were subjected to a second round of 
recombination to replace the KanSacB cassette with the intended mutation. To generate the Full 
CAA recombinant genome, the oligos Full CAA oligo F and Full CAA oligo R were annealed, 
and then amplified using primers IE UTR CAA F and IE UTR CAA R. The PCR product was 
then electroporated into bacteria containing the KanSacB insertion, and recombinants were 
selected for by growth on LB agar containing 6% sucrose, which is toxic in the presence of the 
SacB gene. Replica plating was used to confirm the absence of the kanamycin cassette prior to 
restriction digest to monitor genomic integrity. To generate the +10 CAA recombinant genome 
the oligos +10 CAA F and +10 CAA R were annealed and amplified with primers IE UTR CAA F 
and IE UTR CAA R prior to recombination and selection as above. The region from +500 to -
500 nucleotides surrounding the recombination site was PCR amplified and sequenced to 
confirm the absence of unintended mutations. For recombinants with the correct genotype, BAC 
DNA was purified (Nucleobond) and electroporated into MRC5 fibroblasts to generate infectious 
virus. Two independent isolates of each recombinant virus were generated from the wild type 
BAC; both isolates were characterized. Primer and oligo sequences are listed in Table 1. 
Plasmids. The luciferase reporter vectors were made by cloning the indicated 5’UTR 
sequence into the HindIII and NcoI sites of pGL3-Control (Promega) using Gibson assembly 
(NEB). To generate the wild type MIE 5’UTR reporter, the MIE 5’UTR was PCR amplified using 
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primers MIE UTR-pGL3 F and MIE UTR-pGL3 R using cDNA from HCMV infected cells as a 
template. To generate the Full CAA reporter, the Full CAA ultramer was PCR amplified using 
primers MIE UTR-pGL3 F and MIE UTR-pGL3 R. The PCR products were cloned into pGL3 
control using Gibson assembly. Primer and ultramer sequences are listed in Table 1. 
Luciferase assays. Luciferase assays were performed essentially as described 
previously.(63) Hela cells were transfected with 0.5 µg of each plasmid using polyethylenimine 
(PEI; Sigma) as the transfection reagent. Twenty-four hours after transfection the cells were 
lysed in 1X Passive Lysis Buffer (Promega) for 10 minutes at room temperature. Eight 
microliters (µL) of lysate were mixed with 40 µL luciferase reagent (Promega) and luciferase 
activity was measured using a luminometer (Molecular Devices LSII Max). The amount of 
luciferase activity was normalized to the protein content of each sample as determined by the 
Bradford assay. All transfection data is the mean of at least three independent experiments 
performed on multiple days. For in vitro translation reactions, the indicated 5’UTR-luciferase 
reporter fusion was PCR amplified with a 5’ primer containing a T7 promoter, and a reverse 
primer that added a poly(A) tail to the end of the luciferase ORF. The sequences of the primers 
used for PCR are listed in Table 1. The PCR product was then used as template in an in vitro 
transcription reaction (mMessageMachine T7 In Vitro Transcription kit; Ambion) containing 7-
methylguanosine, resulting in capped, polyadenylated reporter mRNA. Rabbit reticulocyte 
lysates (RRLs; Promega) were programmed with 1 µg mRNA, and the in vitro translation 
reaction was allowed to proceed for 90 minutes at 30oC. Luciferase activity was determined 
using a luminometer as above. Each in vitro translation assay was performed a minimum of 
three times. 
Analysis of nucleic acid abundance. Analysis of RNA abundance was performed 
essentially as described previously.(45, 64) Briefly, cells or frozen cell pellets were resuspended in 
1 milliliter (mL) of Trizol. 200 µL of chloroform was added, and the samples were vortexed and 
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spun for 10 minutes at 15,000 x g. An equal volume of isopropanol was added to the aqueous 
layer, and the RNA was pelleted by centrifugation at 15,000 x g for 30 minutes. The RNA was 
resuspended in 1X DNAse buffer containing 20U DNase (Turbo DNase free kit; Ambion) and 
incubated for 30 minutes at 37oC. The DNase was inactivated per the manufacturer’s protocol, 
and the RNA was quantified using a spectrophotometer (NanoDrop). An equal mass of RNA 
from each sample, typically 0.5 µg, was added to 1X reverse transcription reaction mix (High 
Capacity cDNA Reverse Transcription Kit; ThermoFisher) together with random hexamer 
primers. The reaction was incubated at 25oC for 10 minutes, 37oC for 120 minutes and 85oC for 
5 minutes. For real time PCR reactions, 2 µL of the reverse transcription reaction were mixed 
with 1X SYBR Green Master Mix and 0.5 µM gene specific primers (Table 1), and subjected to 
PCR under the following conditions: 95oC for 5 minutes, 40 cycles of 95oC for 10 seconds and 
55oC for 30 seconds, 72oC for 7 minutes. The absolute quantification method was used to 
determine transcript abundance by comparing the abundance of each PCR product to a 
standard curve generated from tenfold serial dilutions of a DNA standard specific for each 
primer pair. 
 HCMV DNA was quantified essentially as described previously.(45, 62, 64, 65) Briefly, 
samples were incubated in DNA extraction buffer (400 mM NaCl, 10 mM Tris-HCl pH: 8.0, 10 
mM EDTA) containing proteinase K (10 mg/mL) overnight at 37oC. The samples were extracted 
with phenol-chloroform, digested with RNase A (10 mg/mL) for 1 hour at 37oC, extracted again 
with phenol-chloroform, and the DNA was precipitated with isopropanol and resuspended in 
10mM Tris-HCl pH 8.0. qPCR with primers specific to the UL99 gene (UL99F and UL99R, Table 
1) were used to determine the number of HCMV genomes by comparing the threshold values to 
a series of HCMV BAC DNA standards containing from 108 to 101 HCMV genomes.   
Analysis of protein expression. Western blot analysis was performed as described 
before.(66) Briefly, cells were scraped and stored as dry frozen pellets at -80oC until analysis. 
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Cell pellets were resuspended in RIPA buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM 
EDTA, 1% NP40, 1% sodium deoxycholate) containing 1X cOmplete protease inhibitor cocktail 
(Roche) and the protein concentration was determined by the Bradford assay. Equal amounts of 
protein were resolved on SDS-PAGE gels and then transferred to nitrocellulose membranes 
(Amerhsam). The membranes were blocked in TBS-T (20 mM Tris-HCl, pH 7.6, 140 mM NaCl, 
0.1% Tween 20) containing 5% non-fat milk for at least 1 hour prior to incubation with primary 
antibody. Mouse monoclonal antibodies were diluted in 1% bovine serum albumin (BSA) in 
TBS-T and incubated with the membrane for 1 hour at room temperature. Rabbit polyclonal 
antibodies were diluted in 5% BSA in TBS-T and incubated overnight at 4oC. Membranes were 
washed with TBS-T, incubated with HRP-conjugated secondary antibody, and then visualized 
by chemiluminescence using a digital imager (Biorad). Antibodies specific for the following 
proteins were used: IE1 (1:100; (67)), UL44 (1:1000; Virusys), pp28 (1:100; (68)), tubulin 
(1:10,000; Sigma). All experiments were performed a minimum of three times, and 
representative results from a single experiments are shown. 
Viral growth analysis. Cells were infected with HCMV at the indicated multiplicity of 
infection in a minimum volume of complete growth media. Virus was incubated with cells for 1 
hour at 37oC with rocking every 15 minutes, after which time the inoculum was removed and 
replaced with fresh media. The amount of virus in cell free supernatants was quantified using 
either the TCID50 method to measure infectious units, or qPCR as above to enumerate HCMV 
genomes as previously described.(37, 69) For single step growth analysis, cells were infected at a 
multiplicity of three, or the equivalent number of viral genomes, as described in the text. 
Supernatants were harvested at 24 hour intervals and stored at -80oC until use.   
Results  
The MIE 5’UTR enhances mRNA translation in vitro. 5’UTRs can either enhance or 
inhibit translation depending on their length, sequence composition, the presence of RNA 
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structure, and the cellular milieu. To understand how the MIE 5’UTR affects mRNA translation, 
we measured the effect of the MIE 5’UTR on the expression of a luciferase reporter gene. 
Comparing the MIE 5’UTR sequence from multiple clinical and laboratory isolates (AD169, 
Towne, Toledo, Merlin, HAN20, and TB40/E) revealed that the MIE 5’UTR was 100% conserved 
across multiple strains, suggesting a critical role in regulating IE1 and IE2 mRNA translation. 
We cloned the 136 nucleotides of the MIE 5’UTR upstream of a luciferase reporter gene (Fig. 
1A), in vitro transcribed the 5’UTR-luciferase fusion, and measured luciferase activity in rabbit 
reticulocyte lysates (RRLs). We compared the results to the empty vector, where the 5’UTR 
consists of 32 nucleotides derived from the multi-cloning site. To control for the effect of the 
additional length of the MIE 5’UTR on luciferase expression, we also compared our results to a 
reporter where the 5’UTR consisted of 136 nucleotides composed of CAA trinucleotide repeats. 
Translation efficiency is inversely correlated with 5’UTR length and RNA secondary structure. 
CAA repeat sequences contain no RNA secondary structure, therefore comparing the effects of 
the MIE 5’UTR to a CAA repeat sequence of the same length allows us to control for the effects 
of 5’UTR length on translation, and suggests that any observed phenotypes result from changes 
to either RNA structure and/or the removal of specific RBP binding sites.(70) Compared to the 
CAA control, the MIE 5’UTR repressed reporter expression in RRLs (Fig. 1A). We performed 
similar experiments in cells transfected with the above luciferase reporters, and observed 
different results (Fig. 1B). In transfected cells the MIE 5’UTR luciferase construct was the most 
active while the empty vector control was the least active. Luciferase RNA levels were 
approximately the same between the constructs (Fig. 1C), indicating that the change in 
luciferase activity is due to a change in luciferase protein expression rather than increased 
luciferase transcription. 
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Figure 1 - The MIE 5’UTR increases reporter gene expression outside the context of infection.    
(A) In vitro transcribed, capped, and polyadenylated luciferase reporter mRNAs were translated in rabbit 
reticulocyte lysates (RRLs), and luciferase activity was measured. Data show the relative luciferase 
activity of the MIE 5’ UTR (WT) and CAA 5’ UTR (Full CAA) compared to the pGL3-Control reporter, 
which was set to 100%. (B & C) The luciferase reporter constructs were transfected into Hela cells, and 
luciferase activity (B) and RNA levels (C) were measured 24 hours after transfection. Changes in 
luciferase activity and RNA abundance are relative to pGL3-Control, which was set to one. (* p<0.05; ** 
p<0.005; *** p<0.001) 
 To more directly measure the effect of the MIE 5’UTR on translation efficiency, we 
measured the association of the different reporter mRNAs with polysomes in transfected cells.  
Cytoplasmic lysates were resolved through linear sucrose gradients to separate 
ribonucleoprotein complexes, ribosomal subunits, monosomes and polysomes. Importantly this 
assay compares the distribution of RNA throughout the gradient, and thus measures mRNA 
translation efficiency independent of RNA abundance.  
Transfection of the reporters did not affect overall levels of translation as judged by the 
similar abundance of polysomes in each sample (Fig. 2, top panels), and the similar distribution 
of the GAPDH RNA across the gradient (data not shown). The empty vector (Fig. 2A) and CAA 
(Fig. 2C) 5’UTR mRNAs showed a similar distribution across the gradients, with the majority of 
the mRNA concentrated in fractions containing light polysomes (<3 ribosomes). In contrast, the 
MIE 5’UTR mRNA was more abundant in fractions containing heavier polysomes (Fig. 2B), 
consistent with more efficient translation as compared to the two control transcripts. We 
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quantified the translation efficiency (TE) of each reporter by calculating the ratio of mRNA in 
fractions containing polysomes versus the total amount of mRNA in the entire gradient. The TE 
of the mRNA containing the MIE 5’UTR was increased 3.95 fold relative to the empty vector 
control (Fig. 2D), while the TE of the CAA 5’UTR reporter was not statistically different from the 
control. Thus while the MIE 5’UTR repressed translation compared to the CAA reporter in a cell-
free system, it enhanced translation in intact cells. We conclude that the MIE 5’UTR enhances 
translation outside the context of infection.  
The MIE 5’UTR is a critical determinant of HCMV replication. We next determined 
the role of the MIE 5’UTR on IE1 and IE2 protein expression during HCMV infection. To do so, 
we constructed and analyzed two recombinant viruses with mutations in the MIE 5’UTR (Fig. 
3A). In the first recombinant (Full CAA) we replaced nucleotides +1 to +110 of the MIE 5’UTR 
with CAA trinucleotide repeats, as in our luciferase reporters. The 10 nucleotides 5’ of the splice 
Figure 2 - The MIE 5’UTR increases the translation of a luciferase reporter gene. The pGL3 Control, 
MIE 5’ UTR (WT), and CAA 5’ UTR (Full CAA) luciferase reporter constructs were transfected into Hela 
cells, and cytoplasmic lysates were resolved through 10-50% linear sucrose gradients to separate 
ribosomal subunits, individual ribosomes (80S) and polysomes (A, B, C; top panels). Representative 
OD254 absorbance profiles for cytoplasmic lysates are shown. (A, B, C; bottom panels) qRT-PCR 
analysis was performed to determine the percent of the cytoplasmic RNA in each gradient fraction. For A, 
B, and C, the results of one representative experiment of three total are shown. (D) The translation 
efficiency (TE) for each reporter was determined by dividing the amount of the RNA in polysomes by the 
total amount of RNA in the gradient. The graph shows the mean and standard error of the mean of three 
independent experiments. (* p ≤0.05; NS = not significant). 
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donor site in exon 1 and the 17 nucleotides of the MIE 5’UTR in exon 2 were left unchanged to 
limit potential effects on exon 1/2 splicing and the context of the translation site. The second 
recombinant (+10 CAA) was identical to the Full CAA recombinant, except that the first 10 
nucleotides of the wild type 5’UTR were left unchanged to avoid potential effects on the crs site 
in the MIEP(71), which is critical for repression of MIEP activity by IE2 binding.(42, 44, 72) Two 
independent isolates of each recombinant were analyzed. Virus was recovered after 
transfection of either recombinant genome into fibroblasts, indicating that neither mutation 
resulted in a complete block to HCMV replication. 
 Using the TCID50 method to quantify virus stocks, we consistently obtained low titer 
stocks with either recombinant virus. However fibroblasts infected with the recombinant viruses 
showed greater cytopathic effect than wild type virus after high multiplicity (MOI of 3) infection 
(data not shown). The increase in cytopathic effect with the recombinant viruses suggested that 
the TCID50 assay did not accurately measure the levels of infectious virus present in the stocks. 
Figure 3 - Mutations in the MIE 5’UTR decrease HCMV infectivity. (A) Cartoon showing the mutations 
in the IE 5’UTR for the Full CAA and +10 CAA viruses (B) Primary fibroblasts were infected with an equal 
number of TCID50 units (MOI of 3), or an equivalent number of viral genomes of wild type (WT, black 
bars), Full CAA (white bars), or +10 CAA (gray bars) HCMV. The amount of intracellular HCMV genomes 
was quantified by real-time PCR at 6 hours after infection. (C) The number of HCMV genomes in virus 
stocks was measured by real-time PCR, and divided by the number of TCID50 units to obtain the 
genome/TCID50 ratio. The results are the mean of two independent experiments. (*p ≤0.05; NS = not 
significant) 
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Consistent with this idea, 6 hours after infection with an equal number of TCID50 units, cells 
infected with the recombinant viruses contained more intracellular genomes as compared to the 
wild type virus (Fig. 3B). Quantitative PCR analysis of virus stocks revealed that the 
recombinant virus stocks had approximately 50 fold more genomes per infectious unit than the 
wild type virus (Fig. 3C). Thus both recombinant viruses had a decrease in the particle to 
infectious unit ratio compared to wild type HCMV. 
 To determine if replacement of the MIE 5’UTR affected HCMV replication, we performed 
single step growth analysis on the wild type, Full CAA and +10 CAA viruses. The amount of cell-
free virus was measured over a time course of infection using both the TCID50 assay and qPCR. 
Fewer infectious virions (Fig. 4A) and HCMV genomes (Fig. 4B) accumulated after infection with 
the Full CAA and +10 CAA viruses as compared to the wild type virus. Similar results were 
obtained with an independent isolate of each virus. Thus the wild type sequence of the MIE 
5’UTR is necessary for efficient HCMV replication. 
 
Figure 4 - Mutations in the MIE 5’UTR decrease HCMV replication. Fibroblasts were infected with an 
equivalent number of genomes of wild type (black bars), Full CAA (white bars), or +10 CAA (gray bars) 
HCMV. The number of genomes was equivalent to a multiplicity of three TCID50 units per cell of wild type 
virus. Cell-free virus in the supernatant was quantified using either (A) the TCID50 method or (B) real-time 
PCR analysis of viral genomes. The graphs show the average and standard deviation of three 
independent experiments.  The dashed line indicates the limit of detection (* p ≤ 0.05; ** p ≤ 0.005). 
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The MIE 5’UTR is necessary for efficient IE1 and IE2 protein expression during 
HCMV infection. We next determined how the replacement of the MIE 5’UTR affected HCMV 
protein expression. Cells were infected with an equivalent number of genomes of each virus, 
and the levels of the IE1 and IE2 protein and RNA were measured at 6 hours after infection. 
Both IE1 and IE2 protein levels were reduced in the Full CAA and +10 CAA viruses as 
compared to wild type virus (Fig. 5A) though there was no statistically significant difference in 
IE1 or IE2 mRNA levels (Fig. 5B). 5’RACE confirmed that the mutations did not alter the 
transcription start site of the MIE mRNA, and RT-PCR showed that neither mutation affected 
splicing of exon 1 to exon 2 (data not shown). We also measured viral protein expression 
throughout a single round of virus replication (Fig. 5C). Both recombinants expressed less IE2 
protein than wild type virus at each time after infection. IE1 levels were also decreased, though 
the effect was more pronounced with the Full CAA virus. The defect in IE1 expression 
decreased over time, likely due to accumulation of the long-lived IE1 protein over the course of 
the lytic cycle. The early protein UL44 and the late pp28 protein were also expressed to reduced 
levels and with delayed kinetics, consistent with the defect in HCMV replication. To better 
understand the defect in IE1 and IE2 expression, we measured IE1 and IE2 mRNA levels. IE1 
and IE2 mRNAs levels were similar following infection with wild type virus and either 
recombinant (Fig. 5D, E). We conclude that the MIE 5’UTR is necessary for efficient IE1 and IE2 
protein expression and the subsequent expression of early and late proteins needed for HCMV 
replication.  
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The discrepancy between IE1 and IE2 protein and mRNA levels suggested that the MIE 
5’UTR regulates IE1 and IE2 mRNA translation during infection. We therefore measured the TE 
of the IE1 and IE2 mRNAs at 24 hours after infection with the wild type or recombinant viruses 
sing sucrose density gradient centrifugation. The overall levels of polysomes were similar in 
cells infected with each virus, indicating that each virus had the same effect on overall levels of 
translation (Fig. 6, left panels). In cells infected with wild type virus, more IE1 and IE2 mRNA 
was present in fractions containing polysomes than in those containing monosomes, consistent 
with efficient IE1 and IE2 translation early in infection (Fig 6A). Both IE1 and IE2 were less 
efficiently translated after infection with the +10 CAA virus as evidenced by the decrease in 
mRNA abundance in fractions containing heavy polysomes (Fig. 6C). A more pronounced 
Figure 5 - The MIE 5’UTR is required for efficient IE1 and IE2 protein accumulation during 
infection. (A) Fibroblasts were infected with an equivalent number of genome of wild type HCMV (WT) or 
the indicated recombinants. Western blot showing IE1 and IE2 protein levels at 6 hours after infection. (B) 
Cells were infected as in A, and the abundance of the IE1 (black bars) and IE2 (white bars) mRNAs at 6 
hours after infection was determined by qRT-PCR. (C) Cells were infected as in A, and viral protein 
expression was measured by Western blot over a time course of infection. (D & E) Cells were infected as 
A, and qRT-PCR was used to quantify the abundance of the IE1 (D) or IE2 (E) mRNAs over a time 
course of infection. There was no statistical difference in IE1 and IE2 RNA levels between wild type virus 
and the recombinants. 
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decrease in IE1 and IE2 TE was seen during infection with the Full CAA virus; compared to wild 
type virus less IE1 and IE2 mRNAs were found in the fractions containing polysomes (fractions 
9-12), and more of each mRNA was present in fractions containing ribosomal subunits and 
monosomes (fractions 3-7; Fig. 6B). In contrast, the cellular GAPDH mRNA had the same 
distribution throughout the gradient after infection with each virus, demonstrating that the MIE 
5’UTR mutations specifically impact translation of the IE1 and IE2 mRNAs. 
 To quantify the differences in IE1 and IE2 mRNA translation, we calculated the TE for 
IE1 and IE2 after infection with each virus (Fig. 7). We found that the IE1 mRNA is translated 
almost twice as efficiently as the IE2 mRNA at 24 hours after infection (TE of 2.28 and 1.20, 
Figure 6 - The MIE 5’UTR is necessary for efficient association of the IE1 and IE2 mRNAs with 
polysomes. Fibroblasts were infected with an equal number of genomes of WT (A), Full CAA (B), or +10 
CAA (C) viruses. The number of genomes used was equivalent to a multiplicity of three TCID50 units per 
cell with wild type virus. At 24 hours after infection cytoplasmic lysates were resolved through 10-50% 
linear sucrose gradients, and the abundance of polysomes in each sample was determined by continuous 
OD254 absorbance monitoring during fractionation of the gradient. A representative experiment of three 
total is shown in the left column. The percent of the IE1, IE2 or GAPDH RNAs in each fraction of the 
gradient was determined by qRT-PCR. The graphs show the mean and standard deviation of three 
independent experiments. 
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respectively), which closely agrees with previous measurements of IE1 and IE2 translation 
efficiency at this time point.(73) After infection with the +10 CAA virus, the TE of the IE1 mRNA 
was decreased by 2.15 fold. IE2 mRNA translation was reduced to a similar extent (2.8 fold). 
The reduction in TE was even greater after infection with the Full CAA virus, and affected IE1 
and IE2 to a similar degree (7.6 and 10 fold, respectively). We conclude that the defect in IE1 
and IE2 protein expression with the Full CAA and +10 CAA viruses results from decreased IE1 
and IE2 mRNA translation. Together with the data above, these results identify the 5’UTR of the 
IE1/2 mRNA is a critical regulatory element controlling IE1 and IE2 protein expression and 
HCMV replication.  
Discussion  
  5’UTRs play important roles in regulating mRNA translation, and can either enhance or 
repress protein synthesis. Our results show that in the context of HCMV infection, the MIE 
5’UTR serves to enhance translation, and thus demonstrates the importance of post-
transcriptional regulatory mechanisms in regulating IE1 and IE2 protein expression. We found 
that the MIE 5’UTR enhances translation outside the context of infection, and is necessary for 
efficient IE1 and IE2 mRNA translation in HCMV infected cells. Replacement of the MIE 5’UTR 
with a synthetic sequence of the same length decreased the particle to infectious unit ratio, but 
did not affect HCMV entry. Rather replacement of the MIE 5’UTR resulted in decreased IE1 and 
Figure 7 - The MIE 5’UTR is necessary for 
efficient IE1 and IE2 translation during HCMV 
infection. The translation efficiency of the IE1 
(black bars), IE2 (white bars) and GAPDH (gray 
bars) mRNAs in cells infected with wild type 
(WT), Full CAA, or +10 CAA viruses at 24 hours 
after infection was calculated using the data in 
Figure 6. The translation efficiency is the amount 
of RNA in polysomes (fractions 9-12) divided by 
the amount of RNA in monosomes (fractions 3-
7). (NS = not significant; * = p < 0.05; ** = p value 
< 0.01 *** = p < 0.005) 
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IE2 protein expression, delayed and reduced early and late protein expression, and decreased 
virus replication. Together these data identify the MIE 5’UTR as a critical determinant of HCMV 
replication. 
 The replication defect of viruses lacking the MIE 5’UTR likely arises from decreased IE1 
and IE2 protein levels, which our data suggests is due to a defect in IE1 and IE2 mRNA 
translation. The fact that more IE1 and IE2 RNA is found in gradient fractions containing 
ribosomal subunits and monosomes after infection with the Full CAA and +10 CAA viruses 
indicates that the defect lies in translation initiation. This suggests that the MIE 5’UTR helps 
recruit factors that facilitate ribosome recruitment. RBPs serve as bridges between specific 
5’UTR sequences and 43S preinitiation complexes.(50) Perhaps specific RBPs recognize 
sequences and/or RNA secondary structures in the MIE 5’UTR during HCMV infection to 
facilitate 43S recruitment. At least some of these factors are likely cellular, as the MIE 5’UTR 
also enhanced translation of a reporter gene in transfected cells. However HCMV encodes 
multiple RBPs that could also bind the MIE 5’UTR to influence IE1 and IE2 mRNA translation.(74) 
Future experiments to define specific MIE 5’UTR sequences needed to enhance translation, 
and the associated host and/or viral factors, will likely provide further insight into translational 
control of IE1 and IE2 protein expression.  
Collectively these data expand our understanding of the regulatory mechanisms controlling 
IE1 and IE2 protein expression by showing that proper regulation of IE1 and IE2 mRNA 
translation is important for efficient HCMV replication. Interestingly, these data also suggest that 
transcriptional and translational control of IE1 and IE2 expression could be linked. We recently 
found that later in infection multiple transcription start sites generate a series of mRNAs 
encoding full-length IE1 and IE2 proteins.(45) These mRNAs differ only in their 5’UTR sequence, 
and thus would be predicted to translate with different efficiencies. This could explain previous 
studies showing temporal regulation of the association of the IE1 and IE2 mRNAs with 
74 
 
polysomes throughout the HCMV lytic cycle.(46, 49) While our data shows an enhancing role for 
the MIE 5’UTR during lytic infection in fibroblasts, it is also possible that the MIE 5’UTR has 
different effects in different settings and cell types. For example, regulated IE1 and IE2 mRNA 
translation could potentially serve to dampen the effects of spurious IE1 and IE2 transcription 
during latency. These studies thus provide the rationale for future work to define the role of the 
MIE 5’UTR in other infection settings.  
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 Table 1. Primers and oligonucleotide sequences 
Primer Name Sequence (5' -> 3') 
qRT-PCR GAPDH F CTGTTGCTGTAGCCAAATTCGT 
qRT-PCR GAPDH R ACCCACTCCTCCACCTTTGAC 
qRT-PCR IE1  F CAAGTGACCGAGGATTGCAA 
qRT-PCR IE1 R CACCATGTCCACTCGAACCTT 
qRT-PCR IE2 F TGACCGAGGATTGCAACGA 
qRT-PCR IE2 R CGGCATGATTGACAGCCTG 
UL99 F GTGTCCCATTCCCGACTCG 
UL99 R TTCACAACGTCCACCCACC 
qRT-PCR Fluc F ACAAAGGCTATCAGGTGGCT 
qRT-PCR Fluc R CGTGCTCCAAAACAACAACG 
MIE UTR-pGL3 F GAGGCCTAGGCTTTTGCAAAACAGATCGCCTGGAGACGCCATCCAC  
MIE UTR-pGL3 R TATGTTTTTGGCGTCTTCCATCGTGTCAAGGACGGTGAGTCACTCT  
Full CAA Ultramer-
pGL3 
GAGGCCTAGGCTTTTGCAAAACAACAACAACAACAACAACAACAACAACA
ACAACAACAACAACAACAACAACAACAACAACAACAACAACAACAACAACA
ACAACAACAACAACAACAACAACAACAACACAAGAGTGACTCACCGTCCT
TGACACGATGGAAGACGCCAAAAACATA 
IE UTR del KS R 
AGGCGTGTACGGTGGAGGTCTATATAAGCAGAGCTCGTTTAGTGAACCG
GAATTCGAGCTCGGTACCCGG 
IE UTR del KS R 
AGCCAAGGGGGTGGGCCTATAGACTCTATAGGCGGTACTTACGTCACTC
TTGATCCCGGGAAAAGTGCCACC 
T7 Primer WT UTR F CATCAAGCTTTAATACGACTCACTATATCAGATCGCCTGGAGACGCCATC 
T7 Primer Full CAA F GCTTTAATACGACTCACTATAGCAACAACAACAACAACAAC 
T7 pGL3 F GCTTTAATACGACTCACTATAGGGCATTCCGGTACTGTTG 
luc pA R TTTTTTTTTTTTTTTTTTTTTTTTTTTACACGGCGATCTTTCCGCCCTTC 
Full CAA oligo F 
AGGCGTGTACGGTGGGAGGTCTATATAAGCAGAGCTCGTTTAGTGAACC
GCAACAACAACAACAACAACAACAACAACAACAACAACAACAACAACAAC
AACAACAACAACAACAACAACAACAACAACAACAACAACAACAACAACAAC
AACAACAACAACCAAGAGTGACG 
Full CAA oligo R 
CCAAGGGGGTGGGCCTATAGACTCTATAGGCGGTACTTACGTCACTCTTG
GTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTG
TTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGT
TGTTGTTGCGGTTCACTAAAC 
+10 CAA oligo F 
AGGCGTGTACGGTGGGAGGTCTATATAAGCAGAGCTCGTTTAGTGAACC
GTCAGATCGCCCAACAACAACAACAACAACAACAACAACAACAACAACAA
CAACAACAACAACAACAACAACAACAACAACAACAACAACAACAACAACAA
CAACAACAACAACAACAACAACCAAGAGTGACG 
+10 CAA oligo R 
CCAAGGGGGTGGGCCTATAGACTCTATAGGCGGTACTTACGTCACTCTTG
GTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTG
TTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGT
TGTTGTTGGGCGATCTGAC 
IE UTR CAA F AGGCGTGTACGGTGGGAGGTCTAT 
IE UTR CAA R CCAAGGGGGTGGGCCTATAGAC 
  
76 
 
REFERENCES 
1.   Stinski, M. F., Thomsen, D. R., Stenberg, R. M., and Goldstein, L. C. (1983) Organization and 
expression of the immediate early genes of human cytomegalovirus. J Virol 46, 1-14 
 
2.   Nevels, M., Paulus, C., and Shenk, T. (2004) Human cytomegalovirus immediate-early 1 protein 
facilitates viral replication by antagonizing histone deacetylation. Proc Natl Acad Sci U S A 101, 
17234-9 
 
3.   Zalckvar, E., Paulus, C., Tillo, D., et al. (2013) Nucleosome maps of the human cytomegalovirus 
genome reveal a temporal switch in chromatin organization linked to a major IE protein. Proc Natl 
Acad Sci U S A 110, 13126-31 
 
4.   Saffert, R. T., Penkert, R. R., and Kalejta, R. F. (2010) Cellular and viral control over the initial 
events of human cytomegalovirus experimental latency in CD34+ cells. J Virol 84, 5594-604 
 
5.   Caswell, R., Bryant, L., and Sinclair, J. (1996) Human cytomegalovirus immediate-early 2 (IE2) 
protein can transactivate the human hsp70 promoter by alleviation of dr1-mediated repression. J 
Virol 70, 4028-37 
 
6.   Caswell, R., Hagemeier, C., Chiou, C. J., et al. (1993) The human cytomegalovirus 86k immediate 
early (IE) 2 protein requires the basic region of the tata-box binding protein (TBP) for binding, and 
interacts with TBP and transcription factor TFIIB via regions of IE2 required for transcriptional 
regulation. J Gen Virol 74 ( Pt 12), 2691-8 
 
7.   Yurochko, A. D., Huong, S. M., and Huang, E. S. (1999) Identification of human cytomegalovirus 
target sequences in the human immunodeficiency virus long terminal repeat. Potential role of IE2-
86 binding to sequences between -120 and -20 in promoter transactivation. J Hum Virol 2, 81-90 
 
8.   Lukac, D. M., Harel, N. Y., Tanese, N., and Alwine, J. C. (1997) Taf-like functions of human 
cytomegalovirus immediate-early proteins. J Virol 71, 7227-39 
 
9.   Petrik, D. T., Schmitt, K. P., and Stinski, M. F. (2007) The autoregulatory and transactivating 
functions of the human cytomegalovirus IE86 protein use independent mechanisms for promoter 
binding. J Virol 81, 5807-18 
 
10.   Hermiston, T. W., Malone, C. L., Witte, P. R., and Stinski, M. F. (1987) Identification and 
characterization of the human cytomegalovirus immediate-early region 2 gene that stimulates 
gene expression from an inducible promoter. J Virol 61, 3214-21 
 
11.   Iwamoto, G. K., Monick, M. M., Clark, B. D., et al. (1990) Modulation of interleukin 1 beta gene 
expression by the immediate early genes of human cytomegalovirus. J Clin Invest 85, 1853-7 
 
12.   Geist, L. J., Monick, M. M., Stinski, M. F., and Hunninghake, G. W. (1991) The immediate early 
genes of human cytomegalovirus upregulate expression of the interleukin-2 and interleukin-2 
receptor genes. Am J Respir Cell Mol Biol 5, 292-6 
 
13.   Crump, J. W., Geist, L. J., Auron, P. E., et al. (1992) The immediate early genes of human 
cytomegalovirus require only proximal promoter elements to upregulate expression of interleukin-
1 beta. Am J Respir Cell Mol Biol 6, 674-7 
 
14.   Geist, L. J., Monick, M. M., Stinski, M. F., and Hunninghake, G. W. (1992) Cytomegalovirus 
immediate early genes prevent the inhibitory effect of cyclosporin a on interleukin 2 gene 
transcription. J Clin Invest 90, 2136-40 
 
77 
 
15.   Monick, M. M., Geist, L. J., Stinski, M. F., and Hunninghake, G. W. (1992) The immediate early 
genes of human cytomegalovirus upregulate expression of the cellular genes myc and fos. Am J 
Respir Cell Mol Biol 7, 251-6 
 
16.   Geist, L. J., Monick, M. M., Stinski, M. F., and Hunninghake, G. W. (1994) The immediate early 
genes of human cytomegalovirus upregulate tumor necrosis factor-alpha gene expression. J Clin 
Invest 93, 474-8 
 
17.   Kline, J. N., Geist, L. J., Monick, M. M., et al. (1994) Regulation of expression of the IL-1 receptor 
antagonist (IL-1ra) gene by products of the human cytomegalovirus immediate early genes. J 
Immunol 152, 2351-7 
 
18.   Greaves, R. F., and Mocarski, E. S. (1998) Defective growth correlates with reduced accumulation 
of a viral DNA replication protein after low-multiplicity infection by a human cytomegalovirus IE1 
mutant. J Virol 72, 366-79 
 
19.   Mocarski, E. S., Kemble, G. W., Lyle, J. M., and Greaves, R. F. (1996) A deletion mutant in the 
human cytomegalovirus gene encoding ie1(491aa) is replication defective due to a failure in 
autoregulation. Proc Natl Acad Sci U S A 93, 11321-6 
 
20.   Marchini, A., Liu, H., and Zhu, H. (2001) Human cytomegalovirus with IE-2 (UL122) deleted fails to 
express early lytic genes. J Virol 75, 1870-8 
 
21.   Yu, D., Silva, M. C., and Shenk, T. (2003) Functional map of human cytomegalovirus ad169 defined 
by global mutational analysis. Proc Natl Acad Sci U S A 100, 12396-401 
 
22.   Stenberg, R. M., Witte, P. R., and Stinski, M. F. (1985) Multiple spliced and unspliced transcripts 
from human cytomegalovirus immediate-early region 2 and evidence for a common initiation site 
within immediate-early region 1. J Virol 56, 665-75 
 
23.   Awasthi, S., Isler, J. A., and Alwine, J. C. (2004) Analysis of splice variants of the immediate-early 
1 region of human cytomegalovirus. J Virol 78, 8191-200 
 
24.   Du, G., Dutta, N., Lashmit, P., and Stinski, M. F. (2011) Alternative splicing of the human 
cytomegalovirus major immediate-early genes affects infectious-virus replication and control of 
cellular cyclin-dependent kinase. J Virol 85, 804-17 
 
25.   Hou, W., Torres, L., Cruz-Cosme, R., et al. (2016) Two polypyrimidine tracts in intron 4 of the 
major immediate early gene are critical for gene expression switching from IE1 to IE2 and for 
replication of human cytomegalovirus. J Virol 90, 7339-49 
 
26.   Martinez, F. P., Cruz, R., Lu, F., et al. (2014) CTCF binding to the first intron of the major 
immediate early (MIE) gene of human cytomegalovirus (HCMV) negatively regulates MIE gene 
expression and HCMV replication. J Virol 88, 7389-401 
 
27.   Meier, J. L., Keller, M. J., and McCoy, J. J. (2002) Requirement of multiple cis-acting elements in 
the human cytomegalovirus major immediate-early distal enhancer for viral gene expression and 
replication. J Virol 76, 313-26 
 
28.   Hunninghake, G. W., Monick, M. M., Liu, B., and Stinski, M. F. (1989) The promoter-regulatory 
region of the major immediate-early gene of human cytomegalovirus responds to t-lymphocyte 
stimulation and contains functional cyclic amp-response elements. J Virol 63, 3026-33 
 
29.   Isomura, H., Tsurumi, T., and Stinski, M. F. (2004) Role of the proximal enhancer of the major 
immediate-early promoter in human cytomegalovirus replication. J Virol 78, 12788-99 
 
78 
 
30.   Lashmit, P., Wang, S., Li, H., et al. (2009) The CREB site in the proximal enhancer is critical for 
cooperative interaction with the other transcription factor binding sites to enhance transcription of 
the major intermediate-early genes in human cytomegalovirus-infected cells. J Virol 83, 8893-904 
 
31.   Lashmit, P. E., Lundquist, C. A., Meier, J. L., and Stinski, M. F. (2004) Cellular repressor inhibits 
human cytomegalovirus transcription from the ul127 promoter. J Virol 78, 5113-23 
 
32.   Macias, M. P., Huang, L., Lashmit, P. E., and Stinski, M. F. (1996) Cellular or viral protein binding 
to a cytomegalovirus promoter transcription initiation site: Effects on transcription. J Virol 70, 
3628-35 
 
33.   Hennighausen, L., and Fleckenstein, B. (1986) Nuclear factor 1 interacts with five DNA elements 
in the promoter region of the human cytomegalovirus major immediate early gene. EMBO J 5, 
1367-71 
 
34.   Bresnahan, W. A., and Shenk, T. E. (2000) Ul82 virion protein activates expression of immediate 
early viral genes in human cytomegalovirus-infected cells. Proc Natl Acad Sci U S A 97, 14506-
11 
 
35.   Cantrell, S. R., and Bresnahan, W. A. (2005) Interaction between the human cytomegalovirus 
UL82 gene product (pp71) and hdaxx regulates immediate-early gene expression and viral 
replication. J Virol 79, 7792-802 
 
36.   Cantrell, S. R., and Bresnahan, W. A. (2006) Human cytomegalovirus (HCMV) UL82 gene product 
(pp71) relieves hdaxx-mediated repression of hcmv replication. J Virol 80, 6188-91 
 
37.   Cristea, I. M., Moorman, N. J., Terhune, S. S., et al. (2010) Human cytomegalovirus pUL83 
stimulates activity of the viral immediate-early promoter through its interaction with the cellular 
IFI16 protein. J Virol 84, 7803-14 
 
38.   Romanowski, M. J., Garrido-Guerrero, E., and Shenk, T. (1997) pIRS1 and pTRS1 are present in 
human cytomegalovirus virions. J Virol 71, 5703-5 
 
39.   Romanowski, M. J., and Shenk, T. (1997) Characterization of the human cytomegalovirus IRS1 
and TRS1 genes: A second immediate-early transcription unit within IRS1 whose product 
antagonizes transcriptional activation. J Virol 71, 1485-96 
 
40.   Liu, B., Hermiston, T. W., and Stinski, M. F. (1991) A cis-acting element in the major immediate-
early (IE) promoter of human cytomegalovirus is required for negative regulation by IE2. J Virol 
65, 897-903 
 
41.   Pizzorno, M. C., and Hayward, G. S. (1990) The IE2 gene products of human cytomegalovirus 
specifically down-regulate expression from the major immediate-early promoter through a target 
sequence located near the cap site. J Virol 64, 6154-65 
 
42.   Cherrington, J. M., Khoury, E. L., and Mocarski, E. S. (1991) Human cytomegalovirus IE2 
negatively regulates alpha gene expression via a short target sequence near the transcription 
start site. J Virol 65, 887-96 
 
43.   Macias, M. P., and Stinski, M. F. (1993) An in vitro system for human cytomegalovirus immediate 
early 2 protein (IE2)-mediated site-dependent repression of transcription and direct binding of IE2 
to the major immediate early promoter. Proc Natl Acad Sci U S A 90, 707-11 
 
44.   Reeves, M., Murphy, J., Greaves, R., et al. (2006) Autorepression of the human cytomegalovirus 
major immediate-early promoter/enhancer at late times of infection is mediated by the recruitment 
of chromatin remodeling enzymes by IE86. J Virol 80, 9998-10009 
79 
 
 
45.   Arend, K. C., Ziehr, B., Vincent, H. A., and Moorman, N. J. (2016) Multiple transcripts encode full-
length human cytomegalovirus IE1 and IE2 proteins during lytic infection. J Virol 90, 8855-65 
 
46.   Stenberg, R. M., Depto, A. S., Fortney, J., and Nelson, J. A. (1989) Regulated expression of early 
and late RNAs and proteins from the human cytomegalovirus immediate-early gene region. J 
Virol 63, 2699-708 
 
47.   Murphy, E., Vanicek, J., Robins, H., et al. (2008) Suppression of immediate-early viral gene 
expression by herpesvirus-coded micrornas: Implications for latency. Proc Natl Acad Sci U S A 
105, 5453-8 
 
48.   Stenberg, R. M., Thomsen, D. R., and Stinski, M. F. (1984) Structural analysis of the major 
immediate early gene of human cytomegalovirus. J Virol 49, 190-9 
 
49.   Stamminger, T., Puchtler, E., and Fleckenstein, B. (1991) Discordant expression of the 
immediate-early 1 and 2 gene regions of human cytomegalovirus at early times after infection 
involves posttranscriptional processing events. J Virol 65, 2273-82 
 
50.   Hinnebusch, A. G., Ivanov, I. P., and Sonenberg, N. (2016) Translational control by 5'-
untranslated regions of eukaryotic mRNAs. Science 352, 1413-6 
 
51.   Hinnebusch, A. G. (2014) The scanning mechanism of eukaryotic translation initiation. Annu Rev 
Biochem 83, 779-812 
 
52.   Gray, N. K., and Hentze, M. W. (1994) Regulation of protein synthesis by mRNA structure. Mol Biol 
Rep 19, 195-200 
 
53.   Arribere, J. A., and Gilbert, W. V. (2013) Roles for transcript leaders in translation and mrna decay 
revealed by transcript leader sequencing. Genome Res 23, 977-87 
 
54.   Pickering, B. M., and Willis, A. E. (2005) The implications of structured 5' untranslated regions on 
translation and disease. Semin Cell Dev Biol 16, 39-47 
 
55.   Boeras, I., Seufzer, B., Brady, S., et al. (2017) The basal translation rate of authentic HIV-1 RNA is 
regulated by 5'UTR nt-pairings at junction of r and u5. Sci Rep 7, 6902 
 
56.   Sobczak, K., and Krzyzosiak, W. J. (2002) Structural determinants of brca1 translational 
regulation. J Biol Chem 277, 17349-58 
 
57.   Romeo, D. S., Park, K., Roberts, A. B., et al. (1993) An element of the transforming growth factor-
beta 1 5'-untranslated region represses translation and specifically binds a cytosolic factor. Mol 
Endocrinol 7, 759-66 
 
58.   Zhang, D. L., Hughes, R. M., Ollivierre-Wilson, H., et al. (2009) A ferroportin transcript that lacks 
an iron-responsive element enables duodenal and erythroid precursor cells to evade translational 
repression. Cell Metab 9, 461-73 
 
59.   Iakova, P., Wang, G. L., Timchenko, L., et al. (2004) Competition of cugbp1 and calreticulin for the 
regulation of p21 translation determines cell fate. EMBO J 23, 406-17 
 
60.   Wang, D., Bresnahan, W., and Shenk, T. (2004) Human cytomegalovirus encodes a highly specific 
rantes decoy receptor. Proc Natl Acad Sci U S A 101, 16642-7 
 
80 
 
61.   Moorman, N. J., Sharon-Friling, R., Shenk, T., and Cristea, I. M. (2010) A targeted spatial-
temporal proteomics approach implicates multiple cellular trafficking pathways in human 
cytomegalovirus virion maturation. Mol Cell Proteomics 9, 851-60 
 
62.   Ziehr, B., Vincent, H. A., and Moorman, N. J. (2016) Human cytomegalovirus pTRS1 and pIRS1 
antagonize pkr to facilitate virus replication. J Virol 
 
63.   Ziehr, B., Lenarcic, E., Vincent, H. A., et al. (2015) Human cytomegalovirus TRS1 protein 
associates with the 7-methylguanosine mRNA cap and facilitates translation. Proteomics 15, 
1983-94 
 
64.   Lenarcic, E. M., Ziehr, B., De Leon, G., et al. (2014) Differential role for host translation factors in 
host and viral protein synthesis during human cytomegalovirus infection. J Virol 88, 1473-83 
 
65.   Ziehr, B., Lenarcic, E., Cecil, C., and Moorman, N. J. (2016) The eIF4AIII RNA helicase is a 
critical determinant of human cytomegalovirus replication. Virology 489, 194-201 
 
66.   Vincent, H. A., Ziehr, B., and Moorman, N. J. (2016) Human cytomegalovirus strategies to 
maintain and promote mRNA translation. Viruses 8, 97 
 
67.   Zhu, H., Shen, Y., and Shenk, T. (1995) Human cytomegalovirus IE1 and IE2 proteins block 
apoptosis. J Virol 69, 7960-70 
 
68.   Silva, M. C., Yu, Q. C., Enquist, L., and Shenk, T. (2003) Human cytomegalovirus ul99-encoded 
pp28 is required for the cytoplasmic envelopment of tegument-associated capsids. J Virol 77, 
10594-605 
 
69.   Arend, K. C., Lenarcic, E. M., Vincent, H. A., et al. (2017) Kinome profiling identifies druggable 
targets for novel HCMV antivirals. Mol Cell Proteomics 16, S263-276 
 
70.   Babendure, J. R., Babendure, J. L., Ding, J. H., and Tsien, R. Y. (2006) Control of mammalian 
translation by mRNA structure near caps. RNA 12, 851-61 
 
71.   Lashmit, P. E., Stinski, M. F., Murphy, E. A., and Bullock, G. C. (1998) A cis repression sequence 
adjacent to the transcription start site of the human cytomegalovirus US3 gene is required to 
down regulate gene expression at early and late times after infection. J Virol 72, 9575-84 
 
72.   Lang, D., and Stamminger, T. (1993) The 86-kilodalton IE-2 protein of human cytomegalovirus is a 
sequence-specific DNA-binding protein that interacts directly with the negative autoregulatory 
response element located near the cap site of the IE-1/2 enhancer-promoter. J Virol 67, 323-31 
 
73.   Tirosh, O., Cohen, Y., Shitrit, A., et al. (2015) The transcription and translation landscapes during 
human cytomegalovirus infection reveal novel host-pathogen interactions. PLoS Pathog 11, 
e1005288 
 
74.   Lenarcic, E. M., Ziehr, B. J., and Moorman, N. J. (2015) An unbiased proteomics approach to 
identify human cytomegalovirus RNA-associated proteins. Virology 481, 13-23 
  
81 
 
 
 
 
Chapter 4: Kinome Profiling Identifies Druggable Targets for Novel Human 
Cytomegalovirus (HCMV) Antivirals1
 
Introduction 
Developing a new antiviral drug can take over a decade and cost more than a billion 
dollars before approval for use in patients.(1) Even then, the majority of drugs in development will 
not meet the criteria for FDA approval. This arduous development process delays new 
treatments from reaching the clinic and greatly increases healthcare costs. Repurposing of 
existing drugs for use as antivirals provides an alternative to the traditional drug development 
process and leverages the fact that viruses manipulate many of the same cellular pathways 
dysregulated in other diseases states. Drugs targeting these mutual signaling events may have 
unintended uses as novel antiviral therapies. There are currently thousands of FDA-approved 
drugs whose effect on virus replication has not been examined. As these drugs have already 
been tested for safety and bioavailability in humans, they could be rapidly repurposed for clinical 
use.(2) Thus repurposing of FDA-approved drugs as antivirals is a rapid, cost-effective means to 
identify new treatments for viral infections.  
Human cytomegalovirus (HCMV) is a pervasive public health issue.(3) Primary infection 
during pregnancy is the leading cause of congenital birth defects, and reactivation of latent 
infection during immunosuppression can lead to significant morbidity and mortality.(4) The few 
1 This chapter appeared previously as an article in the journal Molecular and Cellular Proteomics. The 
original citation is as follows: Arend, K.C., Lenarcic, E.M., Vincent, H.A., Rashid, N., Lazear, E., 
McDonald, I.M., Gilbert, T.S., East, M.P., Herring, L.E., Johnson, G.L., Graves, L.M., and 
Moorman, N.J. (2017) Kinome profiling identifies druggable targets for novel human cytomegalovirus 
(HCMV) antivirals. Mol Cell Proteomics 16, S263-S276. doi 10.1074/ mcp.M116.065375. 
Supplemental data available online. 
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drugs available to treat HCMV infection are associated with severe side effects, and no 
vaccines for HCMV currently exist.(5) In addition, the emergence of drug-resistant HCMV strains 
has become increasingly common.(6) Thus new antiviral drugs are greatly needed to curtail 
HCMV disease.  
 The extensive manipulation of cellular signaling pathways by HCMV suggests that drug 
repurposing may be an especially useful approach to identify new antiviral drugs. HCMV has a 
prolonged replication cycle that is tightly integrated into the state of the infected cell. Thus 
HCMV actively manipulates a multitude of cellular signaling pathways to facilitate virus 
replication, including inhibition of cellular intrinsic defenses and activation of pathways that 
control protein synthesis and metabolism.(7-14) These changes generate a cellular environment 
conducive for virus replication and serve as potential targets to limit HCMV disease.  Recent 
studies have taken advantage of high throughput screening opportunities to search for protein 
kinase inhibitors(15, 16) or other compounds that may block HCMV replication.(17) 
Manipulation of host kinase activity accounts for many of the changes in cellular 
signaling observed during HCMV infection. HCMV inhibits several cellular kinases critical for the 
innate immune response such as protein kinase R (PKR), which potently suppresses HCMV 
replication when activated.(13) The HCMV TRS1 and IRS1 proteins antagonize PKR activation, 
ensuring continued synthesis of viral proteins and limited expression of interferon-dependent 
genes.(18) Conversely, infection also activates cellular kinases that drive signaling pathways that 
promote virus replication. Specifically, HCMV activates the AMPK and mTOR kinases to 
increase glycolysis and fatty acid synthesis to generate anabolic metabolites required for the 
production of infectious virus.(19-22) Inhibiting AMPK or mTOR activity dramatically decreases 
virus replication.(21, 23) Thus the coordinated activation and inhibition of cellular kinases is a 
critical aspect of HCMV replication.  
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Dysregulated kinase activity underlies multiple disease states such as cancer, 
autoimmunity and diabetes. As a result, kinase inhibitors are a promising class of drugs for 
treatment of a wide range of diseases, and could potentially be repurposed for use as HCMV 
antivirals.(24, 25) For instance, multiple cancer cell types show increased mTOR activity and an 
ATP-competitive mTOR kinase inhibitor Torin1 was developed as an effective cancer treatment. 
Based on the increase in mTOR activity during HCMV infection, we previously found that a 
specific mTOR inhibitor, Torin1, inhibited lytic replication of representative alpha-, beta-, and 
gammaherpesvirus.(23) Further, transplant recipients treated with the mTOR inhibitor rapamycin 
showed decreased incidence and severity of HCMV disease.(26)  These examples highlight the 
clinical utility of repurposing existing kinase inhibitors targeting HCMV-induced kinases as novel 
antiviral therapeutics. 
 While the above examples demonstrate the importance of a small subset of cellular 
kinases in HCMV replication, the full complement of virus-induced changes to the host kinome 
are unknown. The sheer number of human kinases (~500) presents a significant hurdle to 
measuring each kinase during infection using standard approaches, particularly those where 
antibodies or other reagents are unavailable.  Kinome profiling was developed to facilitate the 
quantitative measurement of changes in hundreds of kinases from a single sample.(27) 
Multiplexed kinase inhibitor beads coupled with mass spectrometry (MIB-MS), is an adaption of 
the original KinoBead method described by Daub, Kuster and others.(28-33)   Using immobilized 
pan kinase inhibitors for kinase capture, MIB-MS can be used to quantify differences in kinase 
expression/ abundance and in some instances, kinase activity between samples.(34-36)  Similar 
examples of immobilized kinase inhibitor capture have proven the utility of this methodology to 
study the kinome (For review see (29)).  Coupled with quantitative mass spectrometry (MS), the 
difference in the amount of captured kinase from each sample provides a global and unbiased 
view of kinome perturbations between samples.  Additionally, methods such as KinActiv(37), and 
84 
 
targeted MRM-based approaches(38) can be applied to profile changes in the activation state of 
the kinome. 
Our research group and others have applied MIB-MS kinome profiling to define kinome 
adaptations to select kinase inhibitors, to acquired drug resistance and to epigenetic 
inhibitors.(27, 35, 39, 40) MIB-MS proteomics has also been used to characterize the kinome of 
model organisms.(41)  In infectious disease, kinome profiling provided an in-depth picture of how 
Ebola virus infection altered liver cell signaling networks, and identified new host targets for 
novel antiviral drugs.(42, 43) These examples demonstrate the utility of kinome profiling for 
identifying changes in kinase activity associated with multiple disease states. 
The objective of this study was to use MIB-MS kinome profiling to identify temporal 
alterations in the host kinome induced by HCMV infection. Our ultimate goal was to elucidate 
virus-induced changes to the host kinome that could be targeted with existing kinase inhibitors 
to limit HCMV replication. Using two different HCMV strains, we compared the 
abundance/activity of >240 kinases in uninfected and infected cells over a time course of 
infection. Both lab-adapted AD169 strain and the TB40/E clinical strain induced remarkably 
consistent kinome changes, which were predicted to affect multiple signaling pathways and a 
wide variety of cellular processes. Our MIB-MS results directed our efforts to test a number of 
kinase inhibitors for their anti-viral effects.  Using a simple assay to quantify the effects of these 
inhibitors on HCMV replication, we identified three kinase inhibitors currently in clinical 
development or use that significantly decreased HCMV replication. One such compound, 
OTSSP167, potently inhibited HCMV replication at nanomolar concentrations not toxic to 
uninfected cells. These data demonstrate the utility of MIB-MS kinome profiling for defining 
novel virus-induced kinome changes and for identifying host pathways that can be targeted by 
existing or emerging drugs to limit virus replication. 
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Materials and Methods 
Cells and Viruses. Primary human MRC-5 fibroblasts were obtained from the ATCC 
and cultured in DMEM containing 10% fetal bovine serum and penicillin/streptomycin. In all 
experiments, cells were used between passage 7 and 21. The HCMV AD169inGFP strain, 
which contains a GFP expression cassette inserted in the UL21.5 locus(44), was used as the wild 
type HCMV strain. The pp28-GFP virus has been described previously.(45) This virus expresses 
the HCMV pp28 protein as a GFP fusion protein from its native location in the HCMV genome 
under the control of its endogenous promoter, and replicates with similar kinetics and efficiency 
as wild type HCMV. Unless otherwise noted. Infections were performed at a multiplicity of 
infection (MOI) of one. Cell free HCMV was quantified using the TCID50 method on primary 
human fibroblasts as previously described.(46)  
 For TGF treatment, MRC-5 fibroblasts were serum-starved for 24 hours. Cells were 
infected with HCMV AD169inGFP at an MOI of 3. Forty-eight hours after infection cells were 
treated with 4 µg of human TGF-β1 (Cell Signaling Technology; #5154) for 4 hours prior to 
harvest. 
MIB-MS Kinome Profiling. Cell pellets were lysed in MIB-MS lysis buffer (50 mM 
HEPES, pH 7.5, 150 mM NaCl, 0.5% Triton X-100, 1 mM EDTA, 1 mM EGTA, 10 mM NaF, 2.5 
mM NaV04 plus Protease Inhibitor Cocktail (Roche) and Phosphatase Inhibitor Cocktail 2 
(Sigma P5726) and 3 (Sigma P0044).   Samples were sonicated and clarified by centrifugation 
at 14,000 x g and supernatants filtered through a 0.2 µm filter (Corning 431219). Protein 
amounts were quantified by Bradford protein assay and the concentration of protein was 
normalized across samples prior to adjusting salt concentration to 1M NaCl. MIB-MS columns 
composed of 4 immobilized kinase inhibitors (PP58, Purvalanol B, VI16832, and UNC21474), 
were prepared by mixing equal proportions of immobilized kinase inhibitors in a final volume of 
200 µL settled beads. Columns were equilibrated with MIB-MS high salt buffer (50 mM HEPES, 
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pH 7.5, 1 M NaCl, 0.5% Triton X-100, 1 mM EDTA, and 1 mM EGTA) prior to passing samples 
over MIBs columns by gravity flow.  MIB columns were sequentially washed with MIB-MS high 
salt buffer, MIB-MS low salt buffer (50 mM HEPES, pH 7.5, 150 mM NaCl, 0.5% Triton X-100, 1 
mM EDTA, and 1 mM EGTA), and SDS wash buffer (50 mM HEPES, pH 7.5, 150 mM NaCl, 
0.5% Triton X-100, 0.1% SDS, 1 mM EDTA, and 1 mM EGTA).  Proteins were eluted from MIB 
columns by boiling for 15 minutes in elution buffer (100 mM Tris-HCl, pH 6.8, 0.5% SDS, 1% β-
mercaptoethanol) twice.  DL-DTT was added to a final concentration of 5 mM and samples were 
incubated at 60°C for 25 minutes.  Samples were cooled to room temperature on ice and 
iodoacetamide was added to a final concentration of 20 mM.  Samples were incubated for 30 
minutes at room temperature in the dark. DL-DTT was added to bring the final concentration to 
10 mM and samples were incubated at room temperature for five minutes in the dark.  Samples 
were then concentrated to a final volume of ~100 µL in 10K Amicon Ultra centrifugal 
concentrators and proteins purified by methanol chloroform extraction.  Samples were re-
suspended in 50 mM HEPES, pH 8.0, and digested with sequencing grade porcine trypsin 
(Promega) overnight at 37°C.  Samples were extracted with ethyl acetate 3 times to remove 
residual detergent and desalted using Pierce C-18 spin columns according to the 
manufacturer’s protocol. 
LC/MS/MS analysis. The peptide samples were analyzed by LC/MS/MS using an Easy 
nLC 1000 coupled to a QExactive HF mass spectrometer (Thermo Scientific). Samples were 
injected onto an Easy Spray PepMap C18 column (75 μm id × 25 cm, 2 μm particle size) 
(Thermo Scientific) and separated over a 2 hour method. The gradient for separation consisted 
of 5–32% mobile phase B at a 250 nl/min flow rate, where mobile phase A was 0.1% formic acid 
in water and mobile phase B consisted of 0.1% formic acid in ACN. The QExactive HF was 
operated in data-dependent mode where the 15 most intense precursors were selected for 
subsequent fragmentation. Resolution for the precursor scan (m/z 400–1600) was set to 
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120,000 with a target value of 3 × 106 ions. MS/MS scans resolution was set to 15,000 with a 
target value of 2 × 104 ions. The normalized collision energy was set to 27% for HCD. Peptide 
match was set to preferred, and precursors with unknown charge or a charge state of 1 and ≥ 8 
were excluded. 
Data analysis. Raw data files were processed using MaxQuant version 1.5.3.17 and 
searched against the reviewed Uniprot human database (containing 20,203 entries, downloaded 
Aug 2015), appended with a Uniprot HCMV AD169 or TB40/E database and contaminants 
database, using Andromeda within MaxQuant. Enzyme specificity was set to trypsin, up to two 
missed cleavage sites were allowed, carbamidomethylation of C was set as a fixed modification 
and deamidation of N,Q, oxidation of M, phospho of S,T,Y and acetyl of N-terminus were set as 
variable modifications. The mass tolerance for precursor (main search) and product ions was 
set to 6 ppm and 20 ppm, respectively. A 1% FDR was used to filter all data. Match between 
runs was enabled, and a minimum of two unique peptides was required for label-free 
quantitation (LFQ) using the LFQ intensities. Data are available via ProteomeXchange with 
identifier PXD005276. 
Experimental design and statistical rationale. Two biological replicates for each time 
point after infection with HCMV AD169 and two biological replicates for each time point after 
HCMV TB40/E infection (0, 24, 48, 72 hr) were used for MIB-MS experiments, in sum providing 
four independent replicates for each time point. Assessment of individual MaxQuant analyses 
conducted for both strain and replicate showed consistent results between strains and replicates; 
therefore, the datasets from both strains and replicates were merged to provide a more robust 
analysis. We selected a set of 25 proteins in an unbiased manner by ranking them in terms of 
their variability across all samples from largest to smallest based upon median absolute deviation, 
a robust measure of variability.  We then performed hierarchical clustering of the log transformed 
protein intensities from each of these 25 most variable proteins using 1 - the Spearman’s 
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correlation as the distance metric.  The clustering profile indicates that samples cluster strongly 
together by time point rather than virus type, indicating similar temporal patterns of change.    
   Statistical testing based upon these samples was performed to identify those kinases 
whose patterns showed strong temporal changes in expression that were consistent across all 
replicates.  Statistical analyses were performed in the R statistical programming language 
version 3.3.1.  Biological duplicates from each strain were searched separately in MaxQuant, 
and LFQ values from all four MaxQuant runs were merged into a single dataset consisting of n 
= 16 samples (four time points per run). To reduce our dataset to a subset of consistently 
observed kinases, we removed those kinases that were found to have less than or equal to two 
peptides in all four MaxQuant runs, in addition to kinases that had greater than 35% missing 
values (LFQ value of 0) across samples in the merged dataset.   
 To determine which kinases showed consistent temporal trends in expression, we 
utilized linear mixed models(47, 48) to model the log LFQ for each particular kinase with respect to 
time, accounting for correlation between samples within each run as well potential inter-run 
heterogeneity in kinase trends.  Specifically, we utilized a linear mixed model with a run-level 
random intercept and a run-level random slope with respect to time, treating time as a 
continuous variable. Similar to previous studies, Log LFQ values were assumed to be 
approximately normally distributed.(49)  Mock samples were treated as a zero hour time point. P-
values for the significance of the estimated time trend coefficient were computed using the 
summary function from the lmerTest(50) package on the fitted model, testing the null hypothesis 
that the slope of the time trend is equal to zero.  P-values from each kinase were corrected for 
multiple testing using the Benjamini-Hochberg procedure(51) kinases with adjusted p-values less 
than 0.05 were considered to have a significant trend in expression over time.  Hierarchical 
clustering was utilized to display changes in observed log LFQ intensity with respect to the set 
of kinases showing such significant time trend (1 – Spearman Correlation distance metric).     
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Pairwise changes between a single time point and the mock sample were similarly computed 
using linear mixed models, testing the null hypothesis that the difference in log LFQ between a 
given time point and the mock sample is 0, where within-run correlation is accounted for with a 
run-level random intercept.  Raw and adjusted p-values were reported for each kinase, as well 
as model estimates for time (log LFQ scale) for the trend analysis or difference in log LFQ for 
the pairwise analyses.  Prior to statistical analysis, missing kinases were imputed by first 
calculating the covariance matrix between samples using only pairwise complete observations.  
Then, for each kinase with missing values, a single sample was randomly drawn from a 
multivariate normal distribution with the calculated covariance matrix and mean predicted from 
the trend between time and the non-missing LFQ values for that kinase (linear mixed model). 
Missing values in the given kinase were replaced with the corresponding elements from this 
random sample.      
Analysis of protein expression. Analysis of protein levels by Western blot was 
performed essentially as described previously.(52) Briefly, infected cells were pelleted and stored 
at -80oC until use. Cell lysates were prepared by resuspending cell pellets in RIPA buffer (50 
mM Tris-HCl pH 7.4, 1% NP-40, 0.25% sodium deoxycholate, 150 mM NaCl, 1 mM EDTA, and 
complete protease inhibitor (Roche)) and incubation on ice for 15 minutes.  Cellular debris was 
removed by centrifugation at 21,000 x g for 10 min. Total protein concentration was determined 
by Bradford assay. Equal amounts of protein were separated on SDS-PAGE gels and 
transferred to nitrocellulose or PVDF membranes. Membranes were blocked in Tris-buffered 
saline containing 0.1% Tween (TBS-T) and 5% non-fat milk or 5% bovine serum albumin (BSA) 
for phosphoblots for 1 hour at room temperature.  Blots were then incubated overnight with the 
indicated antibodies. Rabbit polyclonal antibodies were diluted in TBS-T containing 5% BSA and 
incubated with membranes at 4oC overnight. Mouse monoclonal antibodies were diluted in TBS-
T containing 1% BSA and incubated with membranes for at least one hour at room temperature. 
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After washing with TBS-T, membranes were incubated with HRP-conjugated anti-rabbit or anti-
mouse secondary antibodies and visualized by enhanced chemiluminesence (ECL) using the 
BioRad ChemiDoc system. The following commercial antibodies were used in this study: MELK 
(#2274, Cell Signaling Technologies); eIF4B (#3592, Cell Signaling Technologies) 
phospho-eIF4B Ser406; (#5399, Cell Signaling Technologies); -actin (sc-47778, Santa Cruz 
Biotechnology); ICP36 (UL44; 10D8, Virusys), tubulin (DM1A, Sigma), TGFBR2 (#A304-414A, 
Bethyl), Ephrin A2 (#6997, Cell Signaling Technology), Ephrin B4 (#14960, Cell Signaling 
Technology), phosphorylated Smad 2/3 (#8828, Cell Signaling Technology), total Smad 2/3 
(#3122, Cell Signaling Technology), IE1(53), TRS1(54) and pp28(55) were kindly provided by Dr. 
Tom Shenk (Princeton University). 
Quantification of viral DNA. Viral DNA was quantified by real time PCR (qPCR) 
previously described.(56) Briefly, MRC5 fibroblasts were infected with HCMV at an MOI of 0.05 
and harvested by scraping. The cell pellet was resuspended in lysis buffer (400 nM NaCl, 10 
mM Tris-HCl pH 8.0 and 10 mM EDTA). Proteinase K (40 µg/mL) and SDS (final concentration 
0.16%) was then added and the cells were incubated at 37°C overnight. The lysates were 
extracted with phenol followed by incubation with 40 µg/mL RNase A at 37°C for one hour. The 
lysate was again extracted with phenol followed by a chloroform extraction. The DNA was 
precipitated with ethanol and resuspended in 10 mM Tris-HCl, pH 8.0. Quantitative PCR was 
performed using primers specific for the HCMV UL99 gene (UL99F 5’ 
GTGTCCCATTCCCGACTCG 3’, UL99R 5’ TTCACAACGTCCACCCACC 3’) and GAPDH 
(GAPDHF 5’ CTGTTGCTGTAGCCAAATTCGT, GAPDHR 5’ ACCCACTCCTCCACCTTTGAC 
3’). Viral DNA abundance was determined using the absolute abundance method by 
comparison to a standard curve of AD169 BAC DNA ranging from 101 to 109 copies. GAPDH 
copy number was quantified using the same approach with a standard curve consisting of the 
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same dilution series of the GAPDH amplicon. Viral DNA abundance in each sample was 
normalized to the abundance of GAPDH to control for variation in loading. 
Quantification of mRNA. Viral or cellular mRNA levels were quantified by reverse 
transcriptase real time PCR (qRT-PCR) as described before.(57) Briefly, cell pellets were 
resuspended in 1 mL of Trizol (Thermo Fisher Scientific). Total RNA was purified according to 
the manufacturer’s specifications (with the exception of a >1 hr incubation of isopropanol at -20° 
C.). Contaminating DNA was removed using the Turbo DNAse kit according to the manufacturer 
directions (Thermo Fisher Scientific). One microgram of DNAse-treated RNA was reverse 
transcribed using High-Capacity cDNA Reverse Transcription Kit (Thermo Fisher Scientific). 
Quantitative reverse transcriptase real time PCR (qRT-PCR) was performed using SYBR green 
master mix (Thermo Fisher Scientific) and the following primers: IE1F 5’ 
CAAGTGACCGAGGATTGCAA 3’, IE1R 5’ CACCATGTCCACTCGAACCTT 3’; UL44F 5’ 
GCGTGCAAGTCTCGACTAAGGAGC 3’, UL44R 5’ AAGTACTGTGCCTCTTAGTCGGGGG 3’; 
UL99F 5’ GTGTCCCATTCCCGACTCG 3’, UL99R 5’ TTCACAACGTCCACCCACC 3’; HO1F 5’ 
CGTGCAGAGAATTCTGAGTTC 3’, HO1R 5’ AGACGCTTTACGTAGTGCTG 3’). The 
abundance of each transcript was determined using the absolute abundance method and a 
standard curve consisting of tenfold serial dilutions of the specific amplicon cloned into the 
pCRBlunt vector (Invitrogen). Serial dilutions from 108 to 101 were used for each gene, and the 
R2 value of each standard curve was > 0.98. The relative increase in HO1 mRNA levels after 
TGF treatment was determined using the ΔΔCt method, with uninfected, untreated cells 
serving as the reference sample. 
Antiviral Drug Screen. MRC-5 fibroblasts were seeded into 96-well plates. At 
confluency the media was replaced with serum-free DMEM for 24h. Cells were infected with 
HCMV-pp28GFP at an MOI of 1 for one hour, and drugs diluted in serum-free media were 
added to the cells at the time the inoculum was removed. Compounds were purchased from 
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Selleckchem, and included: Alisertib (S1133), PF 03814735 (S2725), LY2603618 (S2626), 
OTSSP167 (S7159), SBI-0206965 (S7885), TG003 (S7320), Tivatinib (S2753(, MRT67307 
(S7948), Saracatinib (S1006), Sotrastaurin (S2791), BMS-777607 (S1561), OTX015 (S7360), 
Dinaciclib (S2768). At 96 hours after infection the cells were washed with PBS, trypsinized, and 
transferred to a round bottom plate. Cells were fixed in 4% paraformaldehyde for 10 minutes at 
room temperature, washed twice with PBS, and then resuspended in 200 µL of FACS buffer. A 
Guava EasyCyte HT flow cytometer (EMD Millipore) was used to determine the number of GFP 
positive cells. The GFP-positive gate was set so that less than 1% of uninfected cells crossed 
the threshold. Drug treated wells were normalized to vehicle treated wells for each appropriate 
dilution. IC50 values were calculated using GraphPad Prism software. 
Cellular toxicity assay. Lactate dehydrogenase release was used to assess drug 
toxicity to uninfected cells as per the manufacturer’s directions (Sigma).  For the initial screen of 
kinase inhibitors, MRC-5 cells were serum starved overnight before addition of the drugs. 96 
hours after addition of the drugs, LDH activity in the supernatant was measured by absorbance 
at 450nm and normalized to the activity in untreated media. 
Results 
MIB-MS kinome profiling identifies host signaling pathways altered by HCMV 
infection. We utilized MIB/MS profiling to identify time-dependent changes in the human 
kinome throughout HCMV infection using the laboratory strain, AD169, and the clinical strain 
TB40/E.(58) Our MIB-MS columns were composed of a four inhibitor (PP58, Purvalanol B, 
VI16832, and UNC21474) bead mix that was optimized for kinome capture as previously 
reported ((27) (East, unpublished observations). A schematic of the kinome profiling workflow is 
shown in Figure 1. Primary human fibroblasts were serum-starved prior to infection to decrease 
basal signaling and allow for better quantification of virus-induced changes in the kinome. 
Infected cell lysates were harvested at 24, 48 or 72 hours after infection, and kinases were 
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enriched from cell lysates with MIB columns as described above. The captured kinases were 
digested and identified by LC-MS/MS and the expression/abundance of each kinase relative to 
the uninfected control at each time point after infection was determined using label-free 
quantification (MaxQuant-see Methods).  
 
Figure 1 - Cartoon showing 
workflow of kinome profiling of 
HCMV infected cells. Primary 
human fibroblasts were infected with 
HCMV at a multiplicity of 3, or left 
uninfected for 24, 48, or 72 hours. 
Lysates were passed over 
multiplexed inhibitor beads to enrich 
for kinases. The recovered kinases 
were digested with trypsin, and the 
tryptic peptides were analyzed by 
LC/MS/MS.  Label-free quantification 
was used to determine the 
abundance of each recovered 
kinase. Kinome dynamics resulting 
from HCMV were determined by 
comparing the abundance of each 
kinase in infected samples relative to 
uninfected control.  *Kinome tree 
illustration reproduced courtesy of 
Cell Signaling Technology, Inc. 
(www.cellsignal.com). 
 
 
In addition to identifying changes in the kinome in response to HCMV infection, this 
approach allowed us to directly compare HCMV strains associated with clinical infections to 
their lab-adapted counterparts. Infection with either HCMV strain significantly altered the 
abundance/activity of multiple cellular kinases as identified by MIB-MS, and these changes were 
observed to be highly consistent between both strains. These strains were first analyzed 
individually, and the datasets from both strains combined to provide a more robust analysis. The 
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full list kinases quantified during infection is shown in Tables S1 and S2.  244 kinases were 
present in all samples, and only these kinases were included in the subsequent analyses. To 
generate a high confidence list of kinases whose recovery with MIB-MS was changed by 
infection, we used linear mixed models (See Statistical Analysis in Methods) to identify kinases 
consistently altered at multiple times after infection. The graphs showing the linear mixed model 
analysis for each quantified kinase are shown in Figure S1. Using this conservative analysis, we 
found 53 kinases that were more abundantly recovered after MIB-MS from infected lysates at all 
times after infection (Fig. 2A). Significant among these included the cyclin-dependent kinases 
(CDK 1, 7, 9, 10), receptor and non-receptor tyrosine kinases (INS, MET, MERTK, HCK, LYN), 
and lipid kinases (PIP4K2C, PIP4K2B, PIK3C3, PI4K2B, PIK3R4).  We also identified 51 
kinases that were consistently recovered at reduced levels from infected cell lysates (Fig. 
2A,Table S3).  This group included PDGFR A/B), FGF (1/2), TGF-β (1/2) and other receptor 
tyrosine kinases (e.g. Ephrin RTKs). 
The graphs showing the fold change for each kinase during infection compared to 
uninfected cells are shown in Figures S2 and S3. Some kinases were consistently altered at all 
times after infection (Table S3), while others were significantly changed only at discreet times 
after infection (Tables S4). Several of these kinase changes, such as increased AMPK and p70 
S6 kinase (p70S6K), have been previously observed during HCMV infection (21, 22).  At 24 hours 
after infection, 64 kinases were significantly altered compared to uninfected cells (Fig. 2B).  The 
percentage of kinases changed during infection at each time point is shown in Figure 2C. 
Overall, more kinases were affected at 48 and 72 hours, with 138 and 139 kinases showing 
quantitative differences in capture by MIB-MS, respectively. Together these data show that 
HCMV infection significantly changes the abundance/activity of multiple cellular kinases in a 
temporal manner. 
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Figure 2 - Host kinome changes quantified over a time course of HCMV infection. (A) Heat map 
showing the quantified kinases significantly altered during HCMV infection. Fibroblasts were infected with 
AD169 or TB40E at a multiplicity of one, and cellular kinases were identified and quantified by MIB-MS 
kinome profiling. The heat map shows the change in kinase quantification for kinases significantly altered 
at multiple times after infection. (B) Graph showing the number of cellular kinases significantly changed at 
each time after HCMV infection as quantified by MIBS-MS as compared to the uninfected sample. (C) 
Percentage of kinases (of 244 total) at each time point with a significant increase, decrease, or no change 
in recovery with MIB-MS after HCMV infection. 
To identify signaling pathways altered by HCMV infection, we performed bioinformatics 
analysis to identify signaling networks significantly altered in our kinome data. We found that 
infection increased or decreased signaling through multiple biological pathways and processes. 
Kinases that were detected in greater abundance by MIB-MS after infection were associated 
with multiple signaling pathways, including the AMPK, mTOR and ERK/MAPK signaling 
networks (Table S5). This data was consistent with previous studies showing that HCMV 
infection induces the AMPK, mTOR and ERK kinases. Similarly, multiple pathways were 
negatively impacted by infection (Table S6), such as the NFkB and PDGFR pathways, in line 
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with the previously reported inhibition of NFkB and PDGFR signaling pathways by HCMV. Thus 
MIB-MS kinome profiling accurately identified known HCMV-induced changes in cellular 
signaling pathways important for HCMV replication. 
Novel cellular pathways affected by HCMV infection. Our kinome profiling data 
identified multiple signaling pathways affected by HCMV infection. For instance, the ephrin 
(Eph) receptor kinases are a large family of tyrosine kinases that play important roles in cell-to-
cell communication, gene expression, and cell growth (59). HCMV infection significantly 
decreased the amount of EphA4, EphB2, EphB3 and EphB4 quantified by MIB-MS at 24 hours 
after infection (Fig. 3A). In contrast, we found that EphA2 was slightly elevated at 24 hours after 
infection and slowly decreased at 48 and 72 hours. To determine if the changes in Eph receptor 
capture by MIBs were due to changes in Eph kinase activity or Eph receptor abundance, we 
measured the expression of EphA2 and EphB4 by Western blot analysis. Infected cells 
expressed less EphB4 protein (Fig. 3B) compared to uninfected controls, while EphA2 levels 
initially increased, before declining to levels seen in uninfected cells by 72 hours after infection. 
The change in EphA2 and EphB4 protein levels detected by Western blots after infection closely 
matched the changes in EphA2 and EphB4 quantified by MIB-MS kinome profiling. Interestingly, 
the decrease in EphB4 protein abundance was not reflected in EphB4 transcript abundance 
(Fig. 3C), suggesting that post-transcriptional regulatory events limit EphB4 abundance in 
HCMV infected cells.  
97 
 
Figure 3 - HCMV infection alters multiple novel signaling pathways. (A) Fold change in the amount of 
ephrin (Eph) kinases recovered with MIBs over a time course of HCMV infection relative to uninfected cells. 
Primary human fibroblasts were infected with either AD169 or TB40E as in Figure 1. The results are the 
average from all infections combined. (B) MRC-5s were serum-starved for 24 hours before infection with 
AD169 at a multiplicity of three. The levels of the Ephrin A2 (EPHA2), Ephrin B4 (EPHB4) and IE1 proteins 
were measured by Western blot over a time course of infection. The levels of tubulin were measured as a 
loading control. (C) As in (B), levels of EphB4 mRNA levels were measured by qRT-PCR. (D) Same as in 
(A). (E) MRC-5s were infected with AD169 at a MOI of 3 for 48 hours. Cells were then treated with 4 µg of 
TGF-β1 for 4 hours. Levels of Smad2/3-P, Smad2, TGF-β receptor II, and pTRS1 were determined by 
Western blot. (F) MRC-5s were infected as in (D). Cells were then treated with 4 µg of TGF-β1 for 24 hours. 
Levels of HO1 mRNA (a Smad2/3-responsive transcript) were measured by qRT-PCR. (G) Fold change in 
MELK kinase as in A. (H) Western blot of MELK expression as in B. (I) Western blot results for 
phosphorylation of the MELK substrate eIF4B (Ser406) and total eIF4B. 
Interestingly, we observed a decrease in the amount of TGF receptor subunits TGFRI 
and TGFRII quantified by MIB-MS from infected cell lysates (Fig. 3D). Binding of TGF to the 
TGF receptor results in phosphorylation of SMAD family transcription factors (60). To determine 
if HCMV infection inhibited TGF receptor signaling, we measured SMAD phosphorylation in 
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response to TGF treatment in mock and HCMV infected cells (Fig. 3E). As expected, TGF 
treatment induced SMAD phosphorylation in uninfected cells. However, no SMAD 
phosphorylation was observed in response to TGF treatment of HCMV infected cells, despite 
the maintained or slightly elevated levels of TGFR2. In addition we found that HCMV infection 
prevented the TGF-dependent increase in the HO1 mRNA observed in uninfected cells (Fig. 
3F).  Taken together, these results suggest that HCMV infection inhibits TGF signaling. 
We also observed an increase in the serine/threonine kinase MELK after infection. 
MELK is an AMPK family member involved in the regulation of replication stress and cell 
proliferative responses (61, 62).  MELK activity increases in proportion to MELK expression (52), 
and MELK has been reported to phosphorylate multiple proteins involved in cell cycle, 
transcriptional and translational regulation (63-65). MIB-MS analysis identified increased MELK at 
24-48 hours, which decreased after 72 hours of infection (Fig. 3G).  To confirm the changes in 
MELK expression, we performed Western blots on lysates after infection (Fig. 3H). As 
determined by Western blotting, MELK protein levels followed the MIB-MS pattern, with the 
highest levels observed at 24-48 hours compared to uninfected cells.  Recently MELK was 
shown to phosphorylate eIF4B on Ser406 (64).  Using a phosphospecific antibody to this site 
(Ser406), we found increased eIF4B Ser406 phosphorylation after infection that mirrored the 
changes in MELK and eIF4B protein expression (Fig. 3H).  These data identify two previously 
unreported effects of HCMV infection on host signaling pathways, demonstrating the utility of 
MIB-MS kinome profiling for identifying cellular signaling pathways altered by HCMV infection.  
Development of a novel assay to test HCMV antiviral efficacy.  Based on our MIB-
MS kinome profile data, we identified several drugs currently in clinical use or development that 
could be used to target HCMV-induced kinases. We therefore developed a rapid assay to 
assess the ability of these drugs as inhibitors of HCMV replication (Fig. 4A). Our assay utilizes a 
recombinant virus (pp28-GFP) expressing the HCMV pp28 protein fused to the green 
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fluorescent protein (GFP) on its carboxyl terminus (45). The pp28-GFP fusion protein is 
expressed from its native location in the HCMV genome under the control of its endogenous 
promoter. While pp28 expression is essential for HCMV replication, we previously showed that 
the pp28-GFP virus replicates with similar kinetics and to equivalent levels as wild type HCMV 
(45). As pp28 transcription requires prior viral DNA replication, inhibiting the HCMV lytic cycle at 
any step prior to viral DNA replication (e.g. entry, uncoating, immediate early and early gene 
expression, etc.), will result in decreased pp28-GFP expression. 
Figure 4 - Analysis of potential HCMV antivirals. (A) Schematic of method.  Fibroblasts were treated 
with infected with pp28-GFP at an MOI of 1 in a 96 well plate format. Cells were treated with 7 
concentrations of each drug ranging from 10 µM to 2.4 nM at the time of infection. Cells were harvested 
at 96 hours after infection, and the GFP fluorescence of each well was determined using a Guava HTS 
flow cytometer. The change in GFP fluorescence at each dose of drug was used to calculate the 50% 
inhibitory concentration (IC50). (B) Fibroblasts were infected as in A, and treated with a range of 
concentrations of PAA, a well-characterized inhibitor of viral DNA replication. The IC50 was determined 
as in A. The observed IC50 value and previously reported IC50 are shown. (C) Graph showing the IC50 
data for drugs that significantly inhibited pp28-GFP fluorescence. (D) The dose of each drug that resulted 
in 50% cell death (LD50) was determined using the LDH release assay. Toxicity data is shown for drugs 
that inhibit pp28-GFP fluorescence. TG003 is included in graphs C and D as an example of a drug with 
no effect on pp28-GFP fluorescence or cell viability. The graphs show the mean and standard deviation of 
at least two experiments. 
100 
 
To test the applicability of this assay, we examined the effect of a known inhibitor of 
HCMV DNA replication, phosphonoacetic acid (PAA)(66, 67), on pp28-GFP expression. Primary 
human fibroblasts were infected with the pp28-GFP virus and treated with a range of 
concentrations of PAA at the time of infection. At 96 hours after infection, pp28-GFP 
fluorescence was measured using a 96 well flow cytometer. The percent inhibition of pp28-GFP 
fluorescence at each concentration was used to calculate the 50% inhibitory concentration 
(IC50). PAA decreased the fluorescence of pp28-GFP infected cells, and the observed IC50 value 
of 26.8 µg/ml closely matched the previously reported IC50 of 20 µg/ml (Fig. 4B and (66)). These 
data confirm that the pp28-GFP expression assay closely recapitulates inhibition of HCMV 
replication as determined by traditional molecular techniques.  
We next used the pp28-GFP assay to measure the potential antiviral activity of specific 
kinase inhibitors. The inhibitors were selected based on three criteria. First, we selected kinases 
increased in at least one time point after HCMV infection, as detected by MIB-MS. From this list 
we chose kinase inhibitors that had been tested in humans or were currently in clinical trials. A 
few additional kinase inhibitors were selected based on preclinical data suggesting their 
potential entry into clinical trials. The list of the 13 kinase inhibitors tested are shown in Table 1.  
These compounds were examined in the pp28-GFP assay for their ability to inhibit HCMV 
replication.  
Inhibitors of Kinases Identified by MIB-MS Have Antiviral Activity 
Nine of these inhibitors had little or no effect on pp28-GFP expression, suggesting that 
their kinase targets are not critical for virus replication. However four compounds significantly 
decreased pp28-GFP expression (Fig. 4C). The bromodomain and extraterminal (BET) proteins 
BRD2, BRD3 and BRD4 are known to bind kinase inhibitors (68) and were detected by MIB-MS 
after HCMV infection.  While not a kinase inhibitor, OTX015 binds and inhibits the BRD2, BRD3 
and BRD4 proteins (69-71). Consistent with a role for BRD2 in HCMV replication, OTX015 
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inhibited HCMV replication with an IC50 of 8.5 µM, although some toxicity was observed in 
uninfected cells.  
Drug Name Target(s) Clinical Stage IC50 LD50 
OTSSP167 MELK Phase 1/2 5.4nM 98nM 
Dinaciclib CDK1, 2, 5, 9 Phase 3 20nM >10µM 
OTX015 BRD2,3,4 Phase 1 8.4µM >10µM 
LY2603618 Chk1   10µM >10µM 
Tivantinib c-Met Phase 3 >10µM >10µM 
Alisertib  AURKA Phase 3 >10µM >10µM 
Saracatinib  c-Src, v-Abl, lyn Phase 1/2 >10µM >10µM 
BMS-777607 c-Met, Axl, Ron, TYRO3 Phase 1/2 >10µM >10µM 
Sotrastaurin PKC (pan) Phase 1/2 >10µM >10µM 
TG003 CLK1,2,4   >10µM >10µM 
SBI-0206965 ULK1/2   >10µM >10µM 
PF-03814735 AURKA, AURKB Flt1, FAK, TrkA Phase 1 N.D. 1.7µM 
#2026 MERTK   N.D. 1.2µM 
MRT67307 IKK(epsilon), TBK1   N.D. 1.1µM 
Table 1 - Kinase Inhibitors Tested for HCMV Inhibition. List of kinase inhibitors and their target(s). The 
stage of clinical testing is listed for those drugs currently in clinical trials. Inhibition of HCMV replication 
(IC50 values) was determined using the pp28-GFP assay (N.D. = drug does not reach 50% inhibition at 
concentrations tested). Cellular toxicity (LD50 values) was determined by LDH assay in uninfected 
primary human fibroblasts. 
 
The Chk1 kinase plays a central role in the DNA damage response, which is induced by 
HCMV infection and required for efficient virus replication (72). Incubation with the Chk1 inhibitor 
LY2603618 inhibited HCMV replication with an IC50 of ~10 µM. Dinaciclib, a CDK1,2,5,9 
inhibitor in clinical testing for the treatment of solid tumors (73), also inhibited pp28-GFP 
expression with an IC50 of 20 nM with limited toxicity to uninfected cells (Fig. 4C,D, Table 1). We 
confirmed the specificity of dinaciclib by showing that dinaciclib specifically prevented the 
binding of CDKs to MIB beads (Fig. S4, Tables S7 and S8)  
MELK is believed to play a critical role in cell cycle regulation, and HCMV specifically 
modulates the cell cycle to support replication. OTSSP167 was discovered as a potent MELK 
inhibitor and was the first commercially available MELK inhibitor.  While the specificity of 
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OTSSP167 is uncertain, it is currently in phase I/II clinical trials for the treatment of solid tumors 
and leukemias, is well tolerated and bioavailable in vivo (74). OTSSP167 decreased pp28-GFP 
fluorescence with an IC50 of < 5.4 nM which was >18 times lower than the toxic dose observed 
for fibroblasts (Fig. 4C,D, Table 1). These results suggest that compounds that inhibit MELK, 
select CDKs, Chk1, and the BRD family of proteins may have potential as antiviral drugs. In 
addition these data demonstrate the utility of MIB-MS kinome profiling to identify specific kinase 
inhibitors currently used in humans that could be repurposed to treat HCMV disease. 
The OTSSP167 is a potent inhibitor of HCMV replication. Dinaciclib and OTSSP167 
exhibited IC50 concentrations significantly lower than the IC50 of the current frontline HCMV 
antiviral gancyclovir (approx. 1.7 µM (75)). Based on the low IC50 value of OTSSP167, we further 
characterized the effect of OTSSP167 on the HCMV lytic cycle. We began by confirming the 
antiviral efficacy of OTSSP167 on the production of infectious wild type HCMV. Infected cells 
were treated with a range of OTSSP167 concentrations at the time of infection, and the 
abundance of cell-free HCMV in culture supernatants at 96 hours after infection was measured 
by the TCID50 assay. OTSSP167 inhibited the production of infectious virus in a dose-
dependent manner (Fig. 5A), further confirming that decreased pp28-GFP expression correlates 
with decreased HCMV replication. We next measured the effect of OTSSP167 at its IC90 (20 
nM, as determined by the pp28-GFP assay) on virus replication over a single cycle of virus 
growth. OTSSP167 was added at the time of infection, and replenished every 48 hours. 
Importantly this concentration of drug was not toxic to uninfected cells at 48 hours after 
treatment (data not shown). Infectious cell-free virus was first detected in untreated cell 
supernatants at 72 hours after infection, however no virus was observed in OTSSP167-treated 
cells at this time point (Fig. 5B). The amount of cell free virus produced by untreated cells 
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increased at 96 and 120 hours after infection, however virus yield in OTSSP167-treated cells 
was reduced by > 2 orders of magnitude at these later times.  
Figure 5 - OTSSP167 inhibits HCMV infection. (A) Primary fibroblasts were infected with HCMV and 
treated with varying concentrations of OTSSP167 at the time the inoculum was removed. The amount of 
virus in cell free supernatants was quantified by the TCID50 assay at 96 hours after infection. (B) Cells 
were treated with 20 nM OTSSP167 at the time of infection with HCMV (MOI = 1), and cell free virus was 
quantified as in A at the indicated times after infection. (C) Cells were infected as B, and harvested at the 
indicated times. Viral protein expression was measured by Western blot. Tubulin protein expression was 
used as a loading control. The results are representative of three independent experiments. (D) Cells 
were infected with HCMV at an MOI of 0.05, and treated either OTSSP167 (20 nM) or PAA (200 µg/ml) 
when the inoculum was removed. Intracellular viral DNA abundance was measured by qPCR at 96 hours 
after infection. (E) Cells were infected as in C. The abundance of the indicated viral transcripts was 
measured by qRT-PCR. All experiments were performed at least three times. The graphs in A, B, D and E 
show the mean and standard error of three independent experiments. 
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To better define the step in replication blocked by OTSSP167, we measured the 
expression of representative HCMV immediate early (IE1), early (pUL44) and late (pp28) 
proteins in OTSSP167-treated infected cells (Fig. 5C). IE1 protein levels were slightly reduced 
at 6 hours after infection in OTSSP167-treated cells, but recovered to similar levels observed in 
untreated cells by 24 hours after infection and remained constant thereafter. In contrast, the 
expression of the early protein UL44 and late protein pp28 was reduced and delayed in 
OTSSP167-treated cells compared to untreated cells. As expression of pUL44 is required for 
viral DNA accumulation, we next examined the levels of viral DNA in OTSSP167-treated cells 
(Fig. 5D). We found that viral DNA accumulated to lower levels in OTSSP167-treated cells 
compared to controls. The levels of HCMV proteins correlated with the abundance of viral 
transcripts; IE1 mRNA levels were similar in treated and untreated cells, while OTSSP167 
reduced the accumulation of UL44 and pp28 (UL99) mRNAs (Fig. 5E). Together these data 
confirm that OTSSP167 inhibits the HCMV lytic cycle at low nanomolar concentrations that are 
not toxic to uninfected cells. In addition, these results confirm the accuracy of the pp28-GFP 
assay, and demonstrate the utility of kinome profiling for identifying drugs that may be 
repurposed as novel antivirals. 
Discussion 
In this study we sought to apply MIB-MS kinome profiling to define changes in the host 
kinome during HCMV infection. Our ultimate goal was to use this methodology to identify kinase 
inhibitors that could potentially be repurposed as novel HCMV antivirals.  While other studies 
have approached the impact of HCMV infection on the proteome more broadly(76, 77), our studies 
were specifically focused on characterizing the kinome. The results of this study identified global 
changes in the kinome after infection with either the lab-adapted AD169 strain or the clinical 
strain TB40E. Both strains induced surprisingly similar changes to the kinome, suggesting that 
both lab-adapted and clinical strains modify host signaling pathways in a similar manner. 
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 Changes in cellular kinase activity induced by HCMV infection have previously been 
identified on a case-by-case basis using traditional molecular virology approaches. Although 
useful, the vast number of cellular kinases prohibits a comprehensive analysis of the kinome in 
response to infection using standard techniques. Using MIB-MS kinome profiling, we were able 
to measure the effect of infection on >250 cellular kinases in a single sample.(28-30) This provided 
a global view of kinome reprogramming in HCMV infected cells, and identified cellular signaling 
pathways that were significantly affected by HCMV infection. Many of the kinome changes 
observed matched previous reports, confirming that MIB-MS profiling accurately identifies 
changes in kinase expression/ abundance during HCMV infection.(9, 21, 78) Importantly, we 
identified perturbations in several signaling pathways that have not previously been examined 
during infection, highlighting the utility of kinome profiling for identifying novel kinases/ signaling 
pathways that may play critical roles in HCMV replication. 
Our results also confirmed previously reported changes to cellular signaling pathways 
during infection(21, 22, 78-82), and identified several new pathways manipulated by HCMV.  This 
included multiple receptor kinases, some that were upregulated and many that were 
downregulated after infection.   We validated several of the changes by Western blotting in 
particular the decreased expression of the Eph receptor (EphA2, B4) tyrosine kinases.   
Membrane bound ephrins bind their cognate Eph receptors on neighboring cells to induce 
bidirectional signaling events that affect cell adhesion and growth.(83) The decreased expression 
of multiple Eph receptors in infected cells suggests that HCMV might limit ephrin mediated cell-
to-cell communication. Interesting, the study of Weekes et al. also detected significant down-
regulation of Eph proteins including EphB2 after HCMV infection.(77)  Down-regulation of this 
and/or other Eph proteins may be involved in immune evasion as suggested.  Conversely we 
found that a specific subset of ephrins continue to be expressed during infection. Given the 
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variety of functions ephrins play in cell biology (59), our results warrant additional studies to 
understand the role of ephrin signaling during HCMV infection. 
Similarly, infection decreased the amount of TGFreceptor subunits recovered with 
MIBs beads. This likely reflects a decrease in TGF receptor kinase activity, as the expression 
of the TGF receptor remains constant during infection, however infected cells fail to induce 
SMAD phosphorylation in response to TGFtreatment. The mechanism of TGF receptor 
inhibition is currently unclear, as is the underlying biological significance of its inhibition in 
primary human fibroblasts. However inhibition of TGF signaling might play an important role in 
HCMV replication in other cell types. HCMV induces an M1 macrophage-like phenotype in 
infected monocytes, which promotes virus replication.(84) Since TGF signaling promotes M2 
macrophage differentiation (85), blocking TGF receptor signaling could drive infected monocytes 
to differentiate into M1 macrophages, potentially promoting HCMV replication and spread in 
infected hosts. 
  We also identified multiple kinases whose quantification after MIB-MS was increased 
after infection.  These kinases may be crucial for increased replication and/or host cell survival. 
For example MELK is believed to be important for increased cell proliferation and survival in 
cancer.(53) Previous studies found that MELK regulates cell cycle progression, and HCMV 
specifically modifies the cell cycle to support virus replication. This suggests that MELK 
activation promotes HCMV replication and early gene expression by modulating the cell cycle.  
The temporal increase in MELK detected by MIB-MS was confirmed by Western blotting.  
Moreover, this change was consistent with the temporal increase and decrease in the MELK 
substrate eIF4B.(86)  Whether MELK phosphorylation of this protein affects its stability remains to 
be determined.   
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We also detected an increase in a number of CDKs, including CDK9 after HCMV 
infection.  Consistent with previous studies that CDK inhibitors inhibit viral early gene 
expression, DNA accumulation and late gene expression (81, 82), we found that dinaciclib, a broad 
CDK inhibitor, potently inhibits HCMV replication. These results warrant further investigation of 
cell cycle inhibitors as HCMV antivirals. 
Using our newly developed assay to quantify virus replication, we tested inhibitors 
against the induced kinases as potential antivirals. While applied on a small scale, the potential 
for this assay to be used in high-throughput screens is evident from our studies.  Based on our 
kinome profiling results, and focusing on drugs in clinical use or development, we identified 
three kinase inhibitors that significantly decreased HCMV replication. The fact that 3 of only 13 
tested drugs inhibited HCMV replication (Table 1) suggests that a more extensive analysis 
would likely identify additional kinase inhibitors that limit virus replication.  
The potential for HCMV-induced kinases to serve as targets for antiviral drugs was 
highlighted by our finding that the reported MELK inhibitor OTSSP167, potently decreased 
HCMV replication by limiting early gene transcription and viral DNA accumulation.  Additional 
studies revealed that OTSSP167 inhibited the production of infectious progeny virus at non-toxic 
concentrations in a dose-dependent manner by inhibiting HCMV early protein expression and 
viral DNA accumulation. Importantly OTSSP167 inhibited HCMV replication at a non-toxic dose 
that is clinically achievable in humans.  Since OTSSP167 has already been evaluated for safety 
and efficacy in humans, these data suggest a potential novel use as an HCMV antiviral. 
Currently the mechanism by which OTSSP167 inhibits early gene transcription is unknown.  
While a recent study questioned the specificity of OTSSP167 and showed that it could inhibit 
additional kinases including the Aurora kinase (87), our experiments with the Aurora inhibitor 
Alisertib failed to recapitulate the effects of OTSSP167, suggesting that inhibition of Aurora 
alone was insufficient to block viral replication.  Additional studies are necessary to determine if 
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the antiviral effects of OTSSP167 is through inhibition of MELK or other kinases.  Despite 
concerns about its specificity, OTSSP167 demonstrated the greatest potency and lowest toxicity 
of the compounds tested herein. 
Together these data demonstrate the utility of kinome profiling for identifying changes in 
cellular kinase activity and/or expression during HCMV infection. These data also show that 
defining HCMV-induced kinome reprogramming is a powerful approach for identifying drugs in 
clinical use or development that may be repurposed as novel HCMV antivirals.  Future studies 
to identify cell-type specific changes in kinase activity in response to HCMV infection may reveal 
additional cellular kinases that could also be targeted to limit HCMV disease.  Moreover, this 
approach may be useful for identifying common changes to cellular signaling pathways in 
response to infection with additional viruses, potentially allowing for the development of broad 
spectrum antiviral drugs.  Ultimately this approach could save millions of dollars and many years 
of testing compared to the traditional antiviral drug development process. 
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Chapter 5: Discussion 
Summary of Chapters 
Due to the importance of MIE protein expression in regulating the HCMV replicative 
cycle, I sought to better understand the regulation of MIE gene expression during infection. 
While transcriptional regulation of MIE genes has been long-studied, RNA-Seq data from our 
lab suggested the existence of additional MIE transcripts. Using 5’ RACE, a previous student, 
Dr. Ben Ziehr, identified multiple transcription start sites (TSSs) for the MIE mRNA. In Chapter 
2, I characterized the novel MIE transcripts. I found that each of the novel MIE transcripts 
encode full length IE1 and IE2 proteins, but differ in their 5’ untranslated regions (5’UTRs). Each 
MIE mRNA associated with polyribosomes in infected cells, suggesting that each MIE mRNA 
isoform contributes to IE1 and IE2 protein expression. Genomic regions surrounding each 
transcription start site had promoter activity, but not enhancer activity, as indicated by the 
direction specific activation of an exogenous reporter. The novel MIE mRNAs differed in their 
temporal patterns of expression, suggesting that each promoter contributes to dynamic 
regulation of MIE gene expression throughout infection. We found that recombinant viruses 
lacking two of the novel MIE promoters exhibited delayed viral protein expression and 
decreased virus replication compared to WT viruses. These results show that additional 
promoters contribute to transcriptional regulation of full-length MIE protein expression 
throughout infection.  
In addition to finding novel mechanisms regulating MIE transcription, I also found that 
translational regulation plays a significant role in modulating MIE protein levels. In Chapter 3, I 
determined the role of the canonical MIE 5’UTR on mRNA translation efficiency in transfected 
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cells, and the requirement for the MIE 5’UTR in IE1 and IE2 protein expression during infection. 
I found that the MIE 5’UTR enhances the translation of a reporter gene in transfected cells, but 
not in a cell-free system. Furthermore, I found that replacing the MIE 5’UTR with an 
unstructured sequence of the same length decreased the translation efficiency of the IE1 and 
IE2 mRNAs during infection, thus reducing IE1 and IE2 protein levels and attenuating virus 
replication. These results show that IE1 and IE2 protein expression is regulated at the level of 
translational, and identify the MIE 5’UTR as a critical determinant of HCMV replication. 
Lastly I also provided new insights into cellular pathways that are modulated by HCMV 
infection to identify potential targets for antiviral drugs. Using the MIB/MS kinome profiling 
approach we measured HCMV-induced changes to over 240 kinases throughout infection. The 
kinome changes we observed corroborated the dysregulation of signaling pathways that have 
been previously reported. In addition we identified novel changes to cellular pathways caused 
by HCMV infection. Furthermore, with guidance from the kinome profiling data we identified 
three compounds that could potentially be repurposed as antivirals against HCMV. 
Role of Alternative MIE Promoters During HCMV Lytic Replication 
The use of alternative promoters within the MIE genomic region is not entirely unique. In 
fact, two alternative promoters, expressed with L gene kinetics, have been identified in intron D 
and internal to the exon 5 coding sequence of the MIE gene. Transcription initiating from these 
promoters produces two unspliced exon-5 only RNAs that are translated into the IE2-60kDa and 
IE2-40kDa protein isoforms.(1-4) The truncated 60- and 40-kDa protein isoforms lack the N-
terminal domain required for promoter transactivation but retain the ability to repress 
transcription from the MIEP. The IE2-60kDa and IE2-40kDa proteins are not essential for HCMV 
replication but their expression is necessary for the efficient production of virions at late times of 
infection.(5-7)  
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However, the promoters we identified in Chapter 2 differ from the late IE2 promoters 
described above. Each of the promoters I identified drives the expression of transcripts 
encoding the full length IE1-72kDa and IE2-86kDa proteins. All but one of the alternative MIE 
transcripts (UTR70) are spliced to the exon 2 splice acceptor site, which is located 17bp 5’ of 
the translation start site. The UTR70 transcript initiates just 5’ of the exon 2 splice acceptor site, 
and thus contains the translation start site as the other MIE transcripts. Nevertheless all of the 
novel primary MIE transcripts isoforms could be alternatively spliced into IE1 and IE2 mRNAs.  
I demonstrated that two of the alternative MIE promoters, UTR378 and UTR70, are 
necessary for efficient viral replication. These promoters are located in the first intron (intron A) 
of the previously described MIE transcript, thus they are referred to them here as “the intronic 
promoters”. I found that the intronic promoters were required for efficient IE1 and IE2 mRNA 
and protein expression, as deletion of either the UTR378 promoter or the entirety of intron A 
significantly decreased and delayed the accumulation of both IE1 and IE2 mRNAs and protein. 
The decrease in MIE protein expression after infection with the recombinant viruses resulted in 
delayed expression of E and L viral proteins, decreased viral DNA replication, and diminished 
virus production. Interestingly, I found that one of the novel MIE promoters was expressed with 
IE kinetics, as transcription from the UTR378 promoter occurs in the absence of de novo viral 
protein synthesis. While the UTR378 mRNA is expressed as an IE transcript, it is ~5-fold less 
abundant than the canonical UTR136 mRNA. This result correlates with the weaker promoter 
activity for the UTR378 promoter as compared to the MIEP that we observed in our reporter 
assays, and may also explain why this transcript has not been previously observed. These 
results show that both the MIEP and UTR378 promoter drive MIE gene expression during the 
immediately early phase of infection.  
Transcripts arising from the alternative promoters reach maximal levels at late times of 
infection, while the MIEP has maximal activity at IE times after infection. One potential 
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explanation for these different kinetics is that the very strong MIEP effectively sequesters the 
transcription machinery from the alternative MIE promoters at IE times of infection. Later in 
infection the IE2-86kDa protein suppresses MIEP activity, thereby eliminating competition for 
the transcription machinery and allowing transcription from the alternative MIE promoters. 
Consistent with this hypothesis, I found that the MIEP has >100-fold higher promoter activity 
than the alternative promoters in transfection assays. In cells transfected with the genomic MIE 
locus, I found that IE1 and IE2 transcripts were solely derived from the MIEP despite the 
presence of the alternative promoters. However deleting the core promoter region of the MIEP 
resulted in activation of the UTR378 and UTR70 promoters. These results suggest that 
suppression of the MIEP by the IE2 protein allows for the alternative MIE promoters to recruit 
RNA Pol II. However my results do not exclude the possibility that additional viral proteins 
and/or cellular changes that occur during infection are also involved in regulating transcription 
from the alternative MIE promoters. 
Consistent with a role for other viral proteins in the activation of transcription from the 
alternative promoters, I found that accumulation of the UTR487 mRNA requires viral DNA 
replication; UTR487 mRNA abundance is significantly decreased in the presence of 
phosphonoacetic acid (PAA), an inhibitor of HCMV DNA replication. Thus the UTR487 promoter 
is expressed with either leaky late or true late kinetics. The promoters of true late HCMV genes 
contain a non-canonical TATA box, TATT, which is recognized by a complex of viral proteins 
including pUL79, pUL87, pUL91, pUL92, and pUL95.(8-11) This complex forms a late promoter-
specific transcription complex that recruits RNA Pol II to the TATT sequence. Both the UTR487 
and UTR378 promoters have TATT elements ~30bp upstream of the transcription start sites 
that could play a role in activating these promoters at late times of infection. Future experiments 
with recombinant viruses that mutate the TATT element in the alternative promoters could 
discern if they are important for the late accumulation of the UTR378 and UTR487 mRNAs. 
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Our experiments suggest the UTR487 promoter contributes to MIE gene expression at late 
times of infection. However previous studies with recombinant viruses lacking the MIE distal 
enhancer, where the UTR487 promoter is also removed, show that the genomic region 
surrounding the UTR487 promoter is necessary for efficient MIE gene expression at IE times of 
infection. As minimal UTR487 mRNA is transcribed by 6 h.p.i., the loss of transcription from the 
UTR487 promoter cannot account for the decreased MIE mRNA and protein expression 
observed in the recombinant viruses lacking the MIE distal enhancer. Together our results and 
previous findings suggest that the UTR487 genomic region functions as an enhancer at IE times 
to facilitate transcription from the MIEP, but acts as a promoter at later times. This may in part 
allow for the increased expression of the IE2 mRNA as infection progresses.  
The findings in Chapter 2 force us to re-consider the current paradigm that a single, strong 
promoter (the MIEP) drives expression of a single primary transcript that is alternatively spliced 
into the mature IE1 and IE2 mRNAs. Instead our data supports a revised model for 
transcriptional control of the MIE genes, where multiple promoters drive expression of multiple 
primary transcript isoforms encoding full length IE1 and IE2 proteins. While the MIEP is the 
predominant site of transcription at IE times of infection, alternative MIE promoters with different 
kinetic expression patterns contribute to MIE gene expression throughout infection to maintain 
steady-state levels of IE1 protein and increasing levels of IE2 protein at late times of infection. 
What is the function of IE1 and IE2 proteins at late times of Infection? 
 While my data identifies additional MIE transcripts and promoters, my results do not 
provide insight into why the continued expression of IE1-72kDa or IE2-86kDa is necessary at 
late times of infection. The requirement for IE2-86kDa protein expression (and IE1-72kDa in 
some contexts) for progression into the E and L phases of viral replication has hindered the 
ability to use traditional approaches (e.g. IE2 deletion viruses) to discern their roles at late times 
of infection. One approach to determine the importance of late MIE protein expression would be 
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to generate recombinant viruses that fuse a destabilization domain (DD) to the MIE proteins. 
The L106P mutant form of FKBP12 is a DD that is rapidly degraded in mammalian cells in the 
absence of its highly specific Shield1 ligand.(12) To determine the role of both IE1-72kDa and 
IE2-86kDa during late times of infection the DD could be fused to the shared amino terminus of 
the IE1 and IE2 proteins. Treating infected cells with Shield1 during IE and E times of infection 
would allow for IE1 and IE2 expression, and thus the progression of infection through the E and 
L stages. Removing Shield1 at late times after infection would result in rapid degradation of both 
proteins, allowing us to determine what role, if any, the IE1 and IE2 proteins have in the late 
stage of replication. Further, the N-terminal DD fusion should not affect the expression of late 
IE2-isoforms (IE2-60kDa and IE2-40kDa) that are necessary for efficient virion production. A 
caveat of this approach is that it would not determine the individual roles of IE1-72kDa and IE2-
86kDa proteins at late times of infection.  
To determine the individual requirement for IE1-72kDa during late times of infection 
recombinant viruses with the DD fused to the C-terminus of the IE1 protein encoded by exon 4 
as outlined above. However defining the role of IE2-86kDa at late times after infection will 
require some additional considerations. Fusion of the DD to the C-terminus of IE2 (encoded by 
exon 5) would disrupt expression of the IE2-86kDa protein as well as the late IE2-40kDa and 
IE2-60kDa proteins, thus preventing an evaluation of the importance of IE2-86kDa. To 
circumvent this problem, cell-lines that express the IE2 40kDa and 60kDa could be used in 
combination with the exon 5-DD recombinant viruses. Expression of the late IE2 isoforms at IE 
or E times of infection would likely be detrimental to viral replication as they both contain the crs 
binding domain that negatively autoregulates the MIEP.(5-7) Therefore an inducible promoter, 
such as the Tet-On promoter, could be used to control expression of the late IE2 isoforms.(13) 
Experiments that measure late gene expression, viral DNA synthesis, and/or virion production 
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could be used in the above systems to determine if the recombinant viruses are defective 
compared to the WT.  
Are alternative promoters important for reactivation from latency? 
Alternate promoter usage is common mechanism among mammalian genes to provide for 
cell-type or tissue-specific gene expression.(14-17) Thus the presence of multiple promoters for 
the MIE genes is not so unusual. MIEP activity varies in different cell types, suggesting a 
potential cell-type specific role for the alternative MIE promoters.(18-26) Of particular note is the 
fact that the MIEP is not active in myeloid cells, which are sites of HCMV latency.(27-31) Thus, I 
hypothesize that the alternative promoters express MIE transcripts during latency where MIEP 
activity is repressed. Consistent with this hypothesis, two latency associated transcripts were 
identified in in granulocyte-macrophage progenitor cells that initiate in the MIE distal 
enhancer.(32) These transcripts correspond to the UTR406 and UTR487 transcript start sites we 
identified during lytic infection. The latent MIE transcripts were alternatively spliced to both exon 
4 and exon 5, similar to our findings. However no MIE protein products were observed in 
granulocyte-macrophages, and their role in latent infection was not defined. 
Robust expression of MIE proteins is required for reaction from latency and the onset of lytic 
infection.(27, 33-39) During lytic replication tegument proteins facilitate the initial burst of MIE gene 
expression. However tegument proteins are not present in latently infected myeloid cells, and 
the MIEP is not active.(29, 32, 40) I hypothesize that the alternative MIE promoters are required for 
re-expression of IE1 and IE2 during reactivation from latency. To test the hypothesis that the 
alternative MIE transcripts are important for HCMV reactivation, recombinant viruses lacking 
each of the alternative promoters could be tested in a latency cell culture system to determine if 
they reactivate less efficiently than WT virus. An alternative approach would be to measure 
reactivation efficiency in latently infected cells expressing shRNAs that target the alternative 
MIE transcripts. The use of shRNAs would eliminate the possibility that the regions surrounding 
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the alternative TSSs is important for enhancing expression from the MIEP during reactivation 
from latency.   
Does alternative promoter usage regulate alternative splicing of MIE primary transcript? 
In Chapter 2, we show that transcripts initiating from alternative promoters can be 
spliced into both IE1 and IE2 mRNAs. However we observe that IE1 transcript abundance 
closely correlates with the abundance of the previously recognized MIE transcript throughout 
the course of infection. In contrast, IE2 transcript abundance correlates with the abundance of 
the novel MIE 5’ UTRs, and increases throughout the course of infection after relatively low 
levels early in infection. These observations lead me to hypothesize that the promoters driving 
MIE transcription may influence alternative splicing of the primary MIE transcript. The methods I 
used in Chapter 2 to show that each promoter gives rise to mature IE1 and IE2 transcripts were 
not quantitative, and thus do not identify a preference for a given primary transcript to splice to 
exon 4 (IE1) or exon 5 (IE2). However long-read next generation sequencing platforms could be 
used to address this problem. I propose using PAC-Bio Iso-Seq to sequence full-length MIE 
cDNAs from infected cells. PAC-Bio Iso-Seq can be used to identify transcripts up to 10kb in 
length, from 5’ UTR to the polyadenylation signal within targeted genes.(41) The measurement of 
all MIE transcript isoforms would enable us to determine if alternative promoter usage 
influences splicing to downstream exons. Furthermore this technique would allow us to discern 
the expression patterns for the full complement of MIE transcript that we have identified, which 
was not possible to measure by qPCR due to technical constraints.  
Do alternative promoters enable efficient translation of MIE mRNAs during cell stress?  
One interesting aspect of the UTR378 and UTR487 MIE transcripts is that each contains 
upstream ORFs (uORFs) in their 5’UTRs, which are not present in the 5’UTR of the UTR136 
mRNA. uORFs can regulate translation in two ways. Under normal conditions, scanning 
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translation initiation complexes recognize the start codon of uORFs within the 5’UTR before 
reaching the start codon of the coding determinant sequence. Thus uORFs typically inhibit 
translation of the downstream coding sequence.(42, 43) However during cell stress the presence 
of a uORF in the 5’UTR can enhance translation. Stresses that inactivate the eIF2 translation 
initiation factor, such as limiting nutrient availability or the presence of viral double stranded 
RNA, lead to a global inhibition of protein synthesis. However in these conditions the presence 
of a 5’UTR uORF can serve to enhance translation through an unknown mechanism.(44, 45) Thus 
the presence of uORFs in the 5’UTR of the alternative MIE transcripts could allow for efficient 
IE1 and IE2 protein expression under conditions that limit the translation of most mRNAs. As 
IE1 and IE2 expression is required to establish lytic infection, the ability to translate the IE1 and 
IE2 mRNAs may be critical upon infection of stressed cells. Further, cell stress reactivates latent 
HCMV to lytic replication. If the alternative MIE promoters drive transcription of the IE1 and IE2 
mRNAs during reactivation, uORFs in the 5’UTRs of the alternative MIE transcripts could allow 
for the translation of the IE1 and IE2 mRNAs in the presence of the cellular stress that initiated 
reactivation.  
To determine if 5’UTR uORFs regulate the translation of the alternative MIE transcripts, 
we could in vitro transcribe reporter mRNAs with the different UTR sequences, and test their 
ability to be translated in a cell-free translation system with and without the induction of stress. If 
the alternative MIE transcripts are translated in the presence of stress, we could further mutate 
the uORF start codon to determine if the uORF was required for stress resistant translation. The 
choice of cell-free system is important in these experiments as we did not see similar results 
between our transfection assays and the rabbit reticulocyte lysates when determining the 
translation efficiency of the canonical MIE 5’ UTR and synthetic sequences in Chapter 3. 
Instead, translation extracts could be generated from Hela cells or HCMV-infected fibroblasts to 
measure the translation efficiency of the reporters either in the absence or presence of other 
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viral proteins, respectively. Stress can be replicated in the cellular extracts by either adding 
poly-IC to inactivate eIF2, or by creating translation extracts from HCMV-infected cells at late 
times of infection when increased levels of eIF2α are naturally observed.(46, 47) In addition, the 
translation efficiency of the alternative MIE mRNAs can be determined during infection by 
measuring the association of MIE transcript isoforms with polyribosomes by qRT-PCR at late 
times of infection.  
5’ UTR Post-Transcriptional Regulation of MIE mRNAs 
Viral protein synthesis is absolutely necessary for HCMV replication, but HCMV does not 
inhibit host protein synthesis.(48, 49) Continued host protein synthesis during infection forces viral 
mRNAs to compete with host mRNAs for access to ribosomes and suggests that a viral 
mechanism has likely evolved to ensure efficient translation of viral mRNAs.(50, 51) As the 5’ UTR 
of mRNAs is known to play a role in translation regulation(52), we hypothesized that the 
canonical 5’ UTR shared between the IE1 and IE2 mRNAs may be important for regulating their 
translation efficiency. We also compared the canonical MIE 5’ UTR sequence across laboratory 
and clinical stains of HCMV (AD169, Towne, Toledo, Merlin, HAN20, and TB40/E). We found 
that the MIE 5’ UTR is 100% conserved across all HCMV strains, further suggesting it may be 
an important post-transcriptional regulatory element for the expression of MIE proteins.  
In Chapter 3 we demonstrate that replacement of the canonical 5’ UTR of MIE mRNAs 
with a synthetic sequence of trinucleotide repeats (CAA) of the same length delayed replication 
in recombinant viruses compared to a wild-type control. The defect in recombinant virus 
replication results from delayed synthesis of MIE proteins that subsequently delays E and L viral 
gene expression and virion production. Importantly no defects were observed in the 
accumulation of either IE1 or IE2 mRNAs in the recombinant viruses suggesting that the defect 
in MIE protein accumulation was due to decreased mRNA translation. Furthermore, we 
confirmed that recombinant IE1 and IE2 mRNAs are less efficiently translated during infection 
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by demonstrating their decreased association with polyribosomes compared to WT controls. 
These experiments demonstrate that the MIE 5’ UTR is a crucial regulator of MIE mRNA 
translation and required for efficient viral replication.  
 The 5’ UTR recombinant viruses used in Chapter 3 provide little information as to how 
the MIE 5’ UTR impacts translation other than to rule out 5’ UTR length as the cause of 
decreased translation efficiency. One hypothesis is that regulatory RNA-binding proteins (RBPs) 
bind to the 5’ UTR at either primary sequence elements or secondary structures and facilitate an 
interaction between the mRNA and translation machinery. Host and/or viral RBPs may play a 
role in binding the 5’ UTR as we demonstrate that the MIE 5’ UTR enhanced translation 
efficiency of a reporter protein outside the context of infection. To identify RBPs that interact 
with the MIE 5’ UTR I would use an RNA affinity pulldown protocol coupled with mass 
spectrometry.(53) In particular, RNA of the MIE 5’UTR can be in vitro transcribed and biotinylated 
to capture RBPs from cell lysates. Mass spectrometry can be used to identify the proteins 
bound to the MIE 5’ UTR. Any RBP-MIE 5’UTR interactions identified by mass spectrometry can 
be confirmed by immunoblotting for the specific protein in RNA affinity capture experiments as 
well as qRT-PCR for the MIE 5’ UTR from RNA isolated after immunoprecipitation of the protein 
from cell lysates. RNA affinity capture and immunoblotting can also be used with progressively 
smaller MIE 5’ UTR sequences to map the RNA sequence required for interaction with the RBP. 
Alternatively, photoactivatable ribonucleoside-enhanced UV cross-linking and 
immunoprecipitation (PAR-CLIP) could be used to map the RNA sequence that interacts with 
the RBP by including 4-thiouridine during the in vitro transcription of MIE 5‘ UTR.(54) After RBP 
identification and RBP-RNA interaction mapping, the effect of the RNA-binding protein on MIE 
mRNA translation and viral replication can be determined. Examples of such experiments 
include knockdown/out of the RBP in cells prior to MIE gene expression or infection, expression 
of RBP lacking its functional motif(s), and/or generation of recombinant viruses that mutate the 
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specific sequence/structure bound by the RBP. Regardless of the approach, measurements of 
MIE protein synthesis and MIE mRNA association with polyribosomes will be crucial to 
demonstrate that defects in viral replication are a result of decreased translation efficiency. 
MIB/MS Kinome Profiling of HCMV-Infected Cells and Drug Repurposing 
Changes in cellular kinase activity induced by HCMV infection have previously been 
identified on a case-by-case basis using traditional molecular virology approaches. Although 
useful, the vast number of cellular kinases prohibits a comprehensive analysis of the kinome in 
response to infection using standard techniques. Thus in Chapter 4, we used MIB-MS kinome 
profiling to measure the effect of infection on >240 cellular kinases in a single sample.(62) This 
provided a global view of kinome reprogramming in HCMV infected cells, and identified cellular 
signaling pathways that were significantly affected by HCMV infection.  
Many of the kinome changes observed matched previous reports, such as increased 
abundance of AMPK, p70 S6 kinase, Aurora kinase A and PI3-K.(55-61) In addition, we performed 
bioinformatics analysis on our kinome data to identify signaling pathways that were altered 
during HCMV infection. Consistent with previous studies, our data showed increased 
abundance/activity of kinases in the AMPK, mTOR and MAPK/ERK signaling pathways. 
Furthermore our data also showed decreased abundance/activity of kinases in the NFkB and 
PDGFR pathways that is consistent with previous reports that these pathways are inhibited 
during HCMV infection. These findings confirm that MIB-MS profiling can accurately identify 
changes in the abundance/activity of specific kinases and broad cellular signaling pathways 
known to be important for HCMV replication.  
Our MIB-MS results also identified several new kinases/signaling pathways manipulated 
by HCMV. We confirmed by Western blotting that Eph receptor tyrosine kinase (EphA2, B4) and 
maternal embryonic leucine zipper kinase (MELK) expression was decreased and increased, 
respectively, during HCMV infection. We also show that TGFβ receptor kinase activity is 
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inhibited during HCMV infection, as TGFβ treatment failed to induce phosphorylation of its 
downstream target SMAD, despite constant expression of the TGFβ receptor. Together these 
data demonstrate the utility of kinome profiling for identifying changes in cellular kinase 
expression and/or activity that may play critical roles in HCMV replication. Future experiments 
should focus on identifying the specific mechanisms and viral proteins responsible for inducing 
these changes in kinase expression/activity. 
In addition, we developed a GFP-based assay to quantify virus replication and screen 
inhibitors against induced kinases for antiviral activity. With a focus on kinase inhibitors currently 
being investigated in clinical trials, we identified several compounds that significantly decreased 
HCMV replication. In particular, we found that the MELK inhibitor, OTSSP167, inhibited HCMV 
replication by limiting viral early gene expression and viral DNA accumulation. Our data shows 
that defining HCMV-induced kinome reprogramming is a powerful approach for identifying drugs 
in clinical use or development that may be repurposed as novel HCMV antivirals. Future studies 
to identify cell-type specific changes in kinase activity in response to HCMV infection may reveal 
additional cellular kinases that could also be targeted to limit HCMV disease. Moreover, this 
approach may be useful for identifying common changes to cellular signaling pathways in 
response to infection with additional viruses, potentially allowing for the development of broad 
spectrum antiviral drugs. Ultimately this approach could save millions of dollars and many years 
of testing compared to the traditional antiviral drug development process. 
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